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ABSTRACT 
 
Asymmetric Hydrogenations of Chiral Acyclic Alkenes for Important Chiron Syntheses. 
(May 2011) 
Ye Zhu, B.S., Nanjing University, People’s Republic of China; 
 M.S., Nanjing University, People’s Republic of China 
Chair of Advisory Committee: Dr. Kevin Burgess 
 
Hydrogenation of "largely unfunctionalized" alkenes has been an active area of 
research for about a decade.  Many catalysts have been prepared but we noticed that 
comparatively few substrates have been studied and none of these hydrogenations 
provided useful chirons for the organic synthesis area.  That motivated us to investigate 
asymmetric hydrogenations of chiral acyclic alkenes, which are seldom used for 
hydrogenations and usually the reactions are fully substrate controlled.   It emerged that 
such reactions could provide a concise entry points into chirons that can be used to 
prepare many natural products.   
Asymmetric hydrogenations of functionalized, but not coordinatively 
functionalized, alkenes have been used to prepare several chirons for syntheses of 
polyketide natural products using our N,carbene Crabtree’s catalyst analog.  Starting 
from optically active starting materials (eg Roche esters, lactic acid, glyceraldehyde 
dimethyl ketals, amino acids), highly optically active chiral alkenes can be made in 
several steps with high yield.  With the iridium catalyzed asymmetric hydrogenations, 
chiral ethers, 1,3-hydroxymethyl chiron, α-methyl-β-hydroxy-γ-methyl chiron, α-methyl-
γ-alkyl-γ-amino acid can be obtained with high stereoselectivities.  With those well-
developed methodologies, (-)-dihydromyoporone, (-)-spongidepsin, (-)-invictolide have 
been prepared with high efficiency. 
Not like the vinyl acetate, which can be hydrogenated quite well with many Rh 
catalysts, the alkyl vinyl ether does not have a coordination functional group nearby, 
hence it is a difficult substrate for asymmetric hydrogenation and there are relatively few 
 iv 
 
reports.  Also the simple alkyl enol ether is quite acid sensitive and the Pfatlz’s type N,P-
Ir catalysts cannot hydrogenate the simple alkyl enol ethers well under the standard 
hydrogenation conditions.  We explored many alkyl enol ethers and found some of them 
can be hydrogenated efficiently (50 bar H2, 1 mol % N,carbene-Ir catalyst, 25 °C) with 
high enantioselectivities (up to 98% ee).  This study led us to suspect that more protons 
were produced when N,P-Ir catalyst precursors were used relative to the corresponding 
carbene catalyst since the former only gave complex mixture when being used.  DFT 
calculations and several other experiments supported this postulation.   
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CHAPTER I 
INTRODUCTION 
  
1.1 Chiral iridium homogeneous hydrogenation catalysts  
Transition metal catalyzed homogeneous enantioselective hydrogenations 
emerged in the 1960s.1,2  Since then numerous chiral hydrogenation catalysts have been 
synthesized and many functionalized substrates can be hydrogenated in good 
enantiomeric excess and yields.3-6  This breakthrough is largely due to the findings that 
good hydrogenation stereoselectivity might result from C2-symmetric diphosphine  
ligands such as DIOP7 and DIPAMP8.  Since that time, numerous other phosphorus 
ligands have been introduced,3 and hence have considerably expanded the scope of 
enantioselective hydrogenations. 
 
O
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H
H
PPh2
PPh2
(-)-DIOP
P P
Ph o-An
o-An Ph
(R,R)-DIPAMP
+
PCy3
Ir
N
PF6
-
Crabtree's catalyst  
 
Review of the extensive and fundamentally important research on Rh-, Ir-, Ru-
diphosphine complexes3-6 may create the impression that stereoselective hydrogenations 
of alkenes is a solved problem.  In fact, metal diphosphine complexes do not 
hydrogenate tri- or tetra-substituted alkenes at useful rates unless the substrate has one or 
more coordinating functional groups (CFGs) to anchor the substrate to the metal so 
facilitating catalysis.9,10  Asymmetric hydrogenations mediated by Rh-, Ir-, Ru-
diphosphine complexes are largely restricted to substrates with CFGs, typically amides, 
carboxylic acids, and alcohols, disposed in the correct orientation.  
____________ 
This dissertation follows the style of Journal of Organic Chemistry.  
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Figure 1.1. Examples of iridium complexes with oxazoline derived N,P ligands. 
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It takes other types of catalyst to hydrogenate alkenes that do not have CFGs, and 
the most useful are the ones based on Crabtree’s catalyst, ie N,P-lr complexes.   In 1998, 
Pfaltz, et al, reported the first chiral analogues of Crabtree’s catalyst.11  For a wide range 
of unfunctionalized olefins, excellent enantioselectivities could be achieved with these 
complexes.  During this research, tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (BArF-) 
was found to be a much better counterion than hexafluorophosphate (PF6-).  Iridium 
complexes with this bulky, apolar, and extremely weakly coordinating anion did not 
suffer from deactivation, and full conversion could be routinely obtained with catalyst 
loadings as low as 0.02 mol %.12  In addition, the BArF salts proved to be much less 
sensitive to moisture than the corresponding hexafluorophosphates.  This success has 
inspired a lot of research into chiral N,P-ligands for enantioselective hydrogenations.  
The largest and most successful group of chiral analogues of the Crabtree’s catalyst are 
iridium complexes with oxazoline derived N,P-ligands13-21 (Figure 1.1).  
 
Scheme 1.1. Synthesis of iridium catalyst bearing NHC-oxazoline ligand. 
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As N-heterocyclic carbenes (NHCs) are frequently regarded as the mimics of 
phosphines, they are suitable components for the construction of N,carbene-analogues of 
Pfaltz’s catalyst.  In 2001, our group reported the first highly effective N,carbene-Ir 
catalyst for the asymmetric hydrogenation of trisubstituted unfunctionalized alkenes.22,23 
The NHC-oxazoline bidentate ligand is derived from an imidazolium salt, which is 
easily handled, robust, and air-stable.  This salt is obtained from an oxazoline 
electrophile and an imidazole.  The catalyst 1 can be made from the salt by reacting with 
an iridium precursor and exchanging the anion of the complex formed with tetra-(3,5-
ditrifluoromethylphenyl)borate (BARF-).23 Both the (R)-1 and (S)-1 can be made 
through the same routes, but starting from enantiomers of dimethyl aspartate, both of 
which are commercial available (Scheme 1.1). My dissertation research throughout my 
Ph.D studies has been related to the applications of catalyst 1. 
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Figure 1.2. Iridium catalyzed hydrogenation pathways via DFT calculations. 
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Contrary to the case for rhodium catalysts, the mechanism(s) of action of chiral 
Crabtree’s catalyst (or chiral analogs) has not been experimentally proven.  Recently 
though our group24,25 and others26 have collected relevant kinetic and spectroscopic data, 
because of the challenges associated with multiple highly fluxional intermediates in a 
catalytic cycle that turns over rapidly, an convincing conclusion for the most possible 
mechanism still can not be made.  This is unfortunate because Crabtree’s catalyst 
analogs may evolve to the stage where they are more important than Wilkinson’s 
catalyst derivatives.  We24,27-29 and others30 used high level DFT calculations to study the 
hydrogenations by chiral Crabtree catalyst analogs, and reached very similar 
conclusions.  Basically, the metal undergoes not one but two oxidative additions of 
hydrogen oxidizing the Ir(1+) to a seven-coordinate Ir(5+) tetrahydride. This complex is 
in a fast equilibrium with two isomers of Ir(3+) dihydrogen dihydrides, which is 
important because it allows some flexibilities for the following migratory insertion and 
reductive elimination steps before rate limiting transfer of hydrogen to the coordinated 
alkene (Figure 1.2).  This explains why only Crabtree’s catalyst, and not Wilkinson’s, 
hydrogenates tri- and tetra-substituted alkenes at a significant rate: the metal center is 
more electrophilic (Ir(5+) vs Rh(3+)) and less hindered (the iridium is seven-coordinate 
and the four hydride ligands are small).  Also hydrogenations with these Ir complexes 
are not particularly sensitive to oxygen, as expected for high oxidation state Ir 
intermediates.  Involvement of Ir(5+) tetrahydride intermediates also explains why the 
catalytic cycle is so hard to follow spectroscopically because these tetrahydrides are in 
rapid, dynamic equilibrium with dihydrido-dihydrogen complexes. 
 
 
1.2 Asymmetric hydrogenations with chiral iridium catalysts 
1.2.1    Enantioselective hydrogenations  
Pfaltz’s success in stereoselectively hydrogenating unfunctionalized olefins 
inspired many efforts to design other iridium complexes for this purpose.  Developments 
in this field have been the subject of several reviews.31-35  Actually at one time, 
 6 
hydrogenation of alkenes with no functional groups (only alkyl substituents) was 
considered to be a “holy grail” in asymmetric hydrogenations,36 but in 2005 our group 
reviewed the area and reached a different conclusion.31  Research on chiral analogs of 
Crabtree’s catalyst had produced literally hundreds of N,P-ligands, but had applied them 
to less than ca 20 simple alkene substrates (Figure 1.3).  Asymmetric hydrogenation 
products are most useful if they can be used as chiral building blocks, chirons.  This 
requires such chirons have at least one functional group (FG) for modification.  Alkenes 
that have only alkyl substituents give alkanes on hydrogenation, and these are not useful 
chirons.  
 
Ph
Ph
MeO
Cl
Ph
Ph OH Ph OAc Ph
CO2Et
MeO MeO
Et
Ph
Et
Ph
MeO
MeO  
Figure 1.3. Most frequently studied hydrogenation substrates. 
 
There are a huge number of trisubstituted alkenes with FGs that are generally not 
thought of as coordinating, ie not CFGs, so these alkenes are not hydrogenated at any 
significant rate by Wilkinson’s catalyst analogs.  However hydrogenations of these 
substrates could give useful chirons if hydrogenated with high enantioselectivities (eg 
using chiral analogs of Crabtree’s catalyst).  This category encompasses a far broader 
array of substrates than those that have only CFGs, and asymmetric hydrogenations of 
these alkenes are wide open for development.  Indeed, recently iridium catalysts have  
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been applied to the hydrogenation of olefins with non-coordinating functional groups, 
including vinyl phosphonates,37-40 vinyl fluorides,41,42 CF3-substituted olefins,43 vinyl 
silanes,44 enol phosphinate esters,45,46  enol ethers,13,47 vinyl boronates,48 enamines,49-51 
and even heteroaromatic rings.4  Excellent yields and enantioselectivities have been 
observed in many of these reactions (Figure 1.4). 
R P(O)Ph2
N
S
N
Ph
P
Ph2
Ir
+
BArF
-
1 mol% Ir*(I), 50 bar H2
25 oC, 12 h R
1 P(O)Ph2
R = Ph, Ar, Alkyl >99% conv.
up to 99% ee
vinyl phosphine 
oxide
P Ar
EtO
O
EtO
1 mol% Ir*(I), 50 bar H2
25 oC, 12 h
P Ar
EtO
O
EtO
vinyl phosphonate up to >99% conv.
up to >99% ee
P R
EtO
O
EtO
1 mol% Ir*(I), 50 bar H2
25 oC, 24 h
P R
EtO
O
EtO
vinyl phosphonate up to >99% conv.
up to >99% ee
EtO2C EtO2C
Ir*(I)
Ph
F
OH
1 mol% Ir*(I), 50 bar H2
40 oC, 72 h
Ph
F
OH
97% conv.
99% ee  
S
N
Ph
P
Ph2
Ir
+
BArF
-
Ir*(II)
F3C
R'
1 mol% Ir*(II), 100 bar H2
25 oC, 72 h
F3C
R'
up to 99% conv.
up to 96% ee
R R
TMS
R'
1 mol% Ir*(II), 30 bar H2
25 oC, 12 h
TMS
R'
up to 99% conv.
up to 98% ee
R R
 
Figure 1.4. Iridium catalyzed enantioselective hydrogenation of alkenes with non-coordinating 
functional groups. 
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N
P
Ir
BArF-
0.5 mol% Ir*(III), 50 bar H2
25 oC, 12 h
up to 99% conv.
up to 99% ee
R2
OP(O)R2R
1
R2
OP(O)R2R
1
O
N
iPr
+
(o-Tol)2
Ir*(III)  
R2O
R1 O
OR3
50 bar H2
1 mol% (S)-1
CH2Cl2
25 oC,  48 h
R1
OR2 O
OR3
85% to 99% conv.
up to 88% ee
R2O
R1 OR3
50 bar H2 
1mol% (S)-1
1 eq. K2CO3, CH2Cl2
 25 oC, 12 h
R1
OR2 OR3
>99 % conv.
up to 98% ee
iPr
iPr
N
O
Ir
N
N
(COD)
(S)-1
BArF
-
 
6 atm H2 
1mol% Ir*(IV)
0.5 eq. Cs2CO3
MeOH, 40 oC
+
R1
OR2
COOH N
O
P
Ir(COD)
ArAr
R
BArF
-
R1
OR2
COOH
88% to 98% yield
up to 99.8% ee
Ir*(IV)  
1 atm H2 
[Ir(COD)Cl]2/Lignad
5 mol% I2
THF, 25 oC, 12 h
>90% yield
up to 97% ee
N
R1
R2
O
O
P N
Ph
Ph
Ligand
N
R1
R2
 
50 bar H2 
1 mol% Ir*(III)
CH2Cl2, 25 
oC
R1
Bpin
R2
64% to 98% yield
up to 98% ee
R1
Bpin
R2
 
Figure 1.4. continued. 
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1.2.2    Diastereoselective hydrogenations  
In enantioselective hydrogenation, stereochemical control is performed through 
the selection of one diastereomeric intermediate composed of a prochiral (achiral) 
substrate and a chiral metal complex.  In the hydrogenation of compounds with a 
stereogenic center, by selecting the catalyst, diastereoselective hydrogenation can induce 
excellent stereoselectivity via double stereo-differentiation (matched pair).52  By linking 
the steric factor of the stereogenic center of substrates with the chiral inducing ability of 
properly designed ligands, homogeneous diastereoselective hydrogenation can attain 
high level of stereoselectivities for optically active compounds with several stereogenic 
centers. 
4 atm H2, 1 mol% Cat.
MeOH, 25 oC
CO2Me
OH
CO2Me
OH
Rh(OAc)2((S)-binap)       >23:1.0
Rh(OAc)2((R)-binap)       >23:1.0
anti:synCat.
 
1 atm H2, 0.2 mol% Cat.
MeOH, 25 oC
Ru(OAc)2((S)-tol-binap)       99.9:0.1
Ru(OAc)2((R)-tol-binap)          22:78
anti:synCat.
OH
NH
TBSO
O
HH
OH
NH
TBSO
O
HH
 
3 bar H2, 0.23 mol% Cat.
MeOH, 25 oC
[Rh((S,S)-dipamp)]+          80:20
[Rh((R,R)-dipamp)]+         20:80
anti:synCat.
CO2
tBu
NHBocO
CbzN
CO2
tBu
NHBocO
CbzN
 
Figure 1.5. Chiral transition-metal catalyst catalyzed diastereoselective hydrogenations of allylic 
alcohols. 
 
Research into directed hydrogenations for acyclic stereocontrol peaked in the 
1980s.53  Much of that work involved 1,1-disubstituted alkenes that are sterically non-
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congested and easy to hydrogenate.  Those reactions were mostly substrate-controlled, 
so it was not possible to obtain both diastereoisomers of the hydrogenation product by 
varying the catalyst chirality alone54-56 (Figure 1.5).  Examples involving trisubstituted 
alkenes are rarer, and tend to feature homoallylic alcohols.57  In these cases high 
diastereoselectivities are possible because simultaneous coordination of the metal to the 
hydroxyl and alkene gives rigid, chair-like intermediates.58  However, those reactions 
were also mostly substrate controlled (Figure 1.6).  Despite recent huge success of chiral 
iridium catalysts on the asymmetric hydrogenation of olefins with non-coordinating 
functional groups, few investigations of acyclic stereocontrol have focused on optically 
active analogs of Crabtree’s catalyst.  This is a significant gap in the literature because of 
the well-known matching and mismatch effects.52  
 
1000 psi H2, 1 mol% Cat.
CH2Cl2, 25 
oC
[Rh((S,S)-Et-Duphos)]+          95:5
[Rh((R,R)-Et-Duphos)]+         40:60
anti:synCat.
OTBDPS
EtO2C
OH
OTBDPS
EtO2C
OH
 
1000 psi H2, 1 mol% Cat.
CH2Cl2, 25 
oC
[Rh((+)-BINAP)]+               3:97
[Rh((-)-BINAP)]+               8:92
anti:synCat.
Et OBz
TBSO
OH
Et OBz
TBSO
OH
 
1000 psi H2, 1 mol% Cat.
CH2Cl2, 25 
oC
[Rh((+)-BINAP)]+               2:98
[Rh((-)-BINAP)]+             33:67
anti:synCat.
Et
CO2Me
Me
OH
Et
CO2Me
Me
OH
 
Figure 1.6. Chiral transition-metal catalyst catalyzed diastereoselective hydrogenations of 
homoallylic alcohols. 
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1.3       Conclusion 
Chiral analogues of Crabtree’s catalyst have emerged as a new class of highly 
efficient catalysts for asymmetric hydrogenation, which are largely complementary to 
rhodium- and ruthenium-diphosphine catalysts.  Many substrates that used to be very 
difficult to hydrogenate can now be hydrogenated with excellent enantioselectivities.  
Recently, the iridium catalysts have also been applied to substrates with more exotic 
non-coordinating functional groups.  Many valuable chirons can be obtained with high 
optical purities.  However, even excellent yields and enantioselectivities have been 
observed in some of the reactions, there remain considerable opportunities to optimize 
the reaction scope and the hydrogenation stereoselectivities.  Specifically, many of the 
reactions are very substrate dependent and good enantioselectivities can only be 
achieved for certain alkenes.  Also the hydrogenation of some other types of alkenes, 
like nitro alkenes, cyanide alkenes, etc., have never been reported.  These challenging 
substrates want the development of more powerful chiral iridium catalysts. 
 
R1
NO2
R1
CN
R1
SO2Ar
R1
X
X= Cl, Br, I
R1
SR3
R2 R2 R2 R2 R
2
 
One logical “global strategy” to evolve catalytic methodology for organic 
synthesis would be to first develop highly efficient reactions, then enantioselective 
transformations involving chiral catalysts, and finally diastereoselective transformations 
with chiral starting materials and chiral catalysts.  Since the seminal work of Carbtree 
about the iridium catalyzed hydrogenation of unfounctionalized alkenes, the first and 
second stages of this logical “global strategy” have been successfully reached.  
However, none of the research on using chiral analogs of Crabtree’s catalysts has 
systematically studied chiral substrates in which the chiral center is close enough to 
influence the stereochemical outcome.  My Ph.D. research is mainly about the highly 
diastereoselective hydrogenations of chiral alkenes with the N,carbene-Ir catalyst 1. 
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CHAPTER II 
ASYMMETRIC HYDROGENATION APPROACHES TO VALUABLE 
ACYCLIC 1,3-HYDROXYMETHYL CHIRONS* 
 
2.1       Introduction  
 Carbon chains bearing 1,3,5…n polymethyl groups are ubiquitous in natural 
products.  Recently, effective solutions for a flexible, stereocontrolled synthesis of such 
arrays have been achieved by many organic research groups.59,60   Carbon chains bearing  
 
 
Figure 2.1. 1,3-Hydroxymethyl fragments in polyketide natural products. 
 
_____________ 
*Reprinted in part with permission from “Asymmetric Hydrogenation Approaches to 
Valuable, Acyclic 1,3-Hydroxymethyl Chirons”, Ye Zhu, Kevin Burgess, J. Am. Chem. 
Soc., 2008, 130,  8894-8895. Copyright 2008 American Chemical Society. 
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1,3-hydroxymethyl fragments, although less common, are also frequently encountered 
(Figure 2.1),61-66 but synthetic methodologies to obtain these fragments are far from 
refined; older methods usually feature C-C bond formation reactions like asymmetric 
zinc addition64,67 or allylation68 to chiral aldehydes.  These methods either have very 
limited reaction scopes (only Me2Zn and Et2Zn can be used) or need use excess of 
expensive chiral reagents.  Recently Furstner et al reported a potential solution to this 
problem.69  Starting from commercial available Roche ester,  chiral allylic alcohol can be 
made in five steps.  Sharpless asymmetric epoxidation, followed by highly regioselective 
ring opening gave the 1,3-hydroxymethyl chiron with very good diastereoselectivity 
(Scheme 2.1).  Since both enantiomers of the Roche ester and diethyl tartarate are 
commercial available, so ideally all the four diastereomers can be obtained via this route. 
 
Scheme 2.1. One recent example for the synthesis of 1,3-hydroxymethyl chiron. 
 
HO OMe
O
5 steps
TBSO OH
 (+)-DET, Ti(OiPr)2, 
tBuOOH
 4 A MS, CH2Cl2, -20 
oC
60%  
 
TBSO OH
O
68%, 93% de
(i) DIBAL-H, toluene, -40 oC
(ii) tBuOH quench, -60 oC to 25 oC
TBSO OH
78%
OH
 
 
Research into directed hydrogenations for acyclic stereocontrol peaked in the 
1980s.53  Much of that work involved 1,1-disubstituted alkenes that are sterically non-
congested and easy to hydrogenate.  Examples involving trisubstituted alkenes are rarer, 
and tend to feature homoallylic alcohols.57  In these cases high diastereoselectivities are 
possible because simultaneous coordination of the metal to the hydroxyl and alkene 
gives rigid, chair-like intermediates.  However, there are relatively few examples of 
useful acyclic stereocontrol in hydrogenations of trisubstituted alkenes that are allylic 
alcohols, or where no alcohol at all is present.  There is a good reason for this.  Most of 
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the work on directed hydrogenations has featured rhodium and iridium catalysts of the 
type MP2 where P2 is a chelating diphosphine ligand, and these do not hydrogenate 
trisubstituted alkenes at a significant rate if a directing group is not present.  This is not 
so, however, for Crabtree’s catalyst70-73 and analogs of the Ir-N,P type (N,P = sp2-N 
ligand and phosphine); they can hydrogenate trisubstituted and even tetrasubstituted 
alkenes where there are no apparent directing groups.31  Few investigations of acyclic 
stereocontrol, however, have focused on Crabtree’s catalyst,58,74 and in those the 
stereoselectivities obtained were poor.   Even fewer studies on acyclic stereocontrol have 
featured optically active analogs of this catalyst; indeed, the first of these complexes was 
not reported until 1998.11  This is a significant gap in the literature because it is well 
known that chiral catalysts can constructively couple with substrate biases (matching 
effects).52  
Nearly all the substrates studied before 2005 in hydrogenations mediated by 
chiral analogs of Crabtree’s catalyst give relatively simple, uninteresting products.31  To 
access more sophisticated chirons, our group launched a program to study 
hydrogenations of dienes and polyenes,24,25,75 and Pfaltz et al recently reported reduction 
of a 1,5,9-triene to give (R,R,R)-tocopherol.76 The latter work stands out as a 
synthetically very useful application of chiral Crabtree’s catalyst analogs.  However, 
although it is formally a diastereoselective synthesis, the pre-existing chiral center in the 
substrate was too far away from the nearest alkene to affect the face selectivity.  In 2007, 
our group reported a systematic study of the asymmetric hydrogenations of chiral 
substrates in which the chiral center is close enough to influence the stereochemical 
outcome.  This study resulted a highly practical methodology for the 1,3,5…n 
polymethyl fragment synthesis77 (Figure 2.2).  This route is competitive with the other 
state-of-art methods, in terms of catalyst loading, stereoselectivities, and atom economy.  
It proved that the chiral analogues of Crabtree’s catalyst, unlike diphosphine systems for 
the same substrates, could exert strong influences for the diastereoselectivities.28,77,78  In 
other words, catalyst control usually dominated in these hydrogenation reactions.  
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protecting  and functional groups , P and FG,
 varied for optimization of stereoselectivities
FG
PO
(S)-Cat
(R)-Cat
50 bar H2
FG
PO
FG
PO
anti
syn
 
 
Figure 2.2. Asymmetric hydrogenation routes to 1,3-dimethyl chirons. 
 
        Inspired by the above discoveries, an interesting idea rose.  We thought that 
changing the allylic methyl substitutent to an alcohol substitutent would provide another 
very interesting type of substrates for the hydrogenation.  The catalyst might also work 
well for the hydrogenations of this new type of alkenes.  All the substrates featured in 
the last project were derived from Roche’s ester.  However, several other readily 
available natural starting materials could be used to generate related alkenes in a similar 
way (Figure 2.3).  In this chapter, the studies about the asymmetric hydrogenations 
mediated by complex 1 to afford the “internal” and “terminal” chirons A and B found in 
many natural products and useful derivatives will be described.79 
 
OH OP1
P2O
FG O
O
OH
O
O
OH
internal
A
 
 
OH OP1
FG
OH
O
OEt
OH
O
OMe
terminal
B
 
 
Figure 2.3. Asymmetric hydrogenation routes to 1,3-hydroxymethyl chirons. 
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2.2 Results and discussions 
2.2.1 Syntheses of the internal fragments  
Syntheses of substrates to prepare the internal fragments A began with glycidol 
acetonide (conveniently available as either enantiomer).80  Hence alkene 3-8 were 
prepared straightforward (Scheme 2.2).    Only alkene 5, 6, 8 were hydrogenated and the 
hydrogenation data were shown in Table 2.1.  The alkene 5 did not give high 
selectivities with both enantiomers of the catalyst, but excellent data were obtained for 6 
and 8.   
 
Scheme 2.2. Routes to alkene substrates for syntheses of internal chiron A.  
 
O
O
OH
(i) (COCl)2, Et3N, DMSO
CH2Cl2, -78 
oC, 10 min
Ph3P
O
OMe
(ii)
PhMe, 60 oC, 16 h
O
O
O
OMe
3  90%, >97% ee2
TsOH, MeOH
 25 oC, 24 h
 
 
4  84%
OH
O
OMeHO
1.1 eq TBDPSCl
 imidazole
CH2Cl2
 25 oC, 1 h
OH
O
OMeTBDPSO
5  93%
DIBAL, CH2Cl2
 -30 oC, 4 h
 
 
 
     
OH
OHTBDPSO
6  86%  
 
 
4
2.5 eq TBDPSCl
 imidazole
CH2Cl2, 25 
oC, 4 h TBDPSO
O
OMeTBDPSO
7  95%
HF Py
THF/Py
 0 oC, 8 h TBDPSO
O
OMeHO
8  77% conv., 92%  
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Table 2.1. Hydrogenation of internal hydrogenation substrates. 
OP1
P2O
FG
50 atm H2, 1 mol % Ir*
CH2Cl2, 25 
oC, 4 h OP1
P2O
FG
>99% conv.
syn or anti  
Entry Substrate P1 P2 FG Ir* (cat) syn:antia,b 
       
1 5 H TBDPS CO2Me (S)-1 1.0:3.3 
2 5 H TBDPS CO2Me (R)-1 1.0:2.3 
3 6 H TBDPS CH2OH (S)-1 14:1.0 
4 6 H TBDPS CH2OH (R)-1 1.0:24 
5 8 TBDPS H CO2Me (S)-1 17:1.0 
6 8 TBDPS H CO2Me (R)-1 19:1.0 
a absolute chemistry was determined by comparison of the optical rotation value with reported 
one.  b the diasterisomer ratio were measured by GC. 
 
 
Formation of the syn product 9 is an excellent reaction because this lactone is 
crystalline and it can be recrystallized from the crude material without column 
chromatography (Figure 2.4.a).  In both reactions, the diastereoselectivity is extremely 
high.  A chair-like intermediate can be used to rationalize preferential formation of the 
product 9, so this is a typical directed hydrogenation of a homoallylic alcohol via 
substrate control (Figure 2.4.c).  Formation of 10, however, is catalyst controlled.  In 
that case there is a substrate vector based on conformers preferred by 1,3-allylic strain 
considerations, and possibly some directing effect from the allylic alcohols; however, 
these two factors modulate, but do not overcome, the catalyst vector (Figure 2.4.b and 
2.4.d). 
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>99% conv.
50 bar H2
1 mol % 1
CH2Cl2
25 °C, 4 h
a
HO
TBDPSO
OMe
O
8
partial
lactonization
>99% conv.
TsOH, CH2Cl2
25 °C, 1 h
O
O
OTBDPS
9  
(R)-1
syn:anti
  crude: 19:1.0 
purified: 40:1.0
75% isolated
(S)-1
syn:anti
  crude: 17:1.0 
not purified
 
TBDPSO
OH
OH
6
b
TBDPSO
OH
OH
10
>99% conv.
50 bar H2, 1 mol % 1
CH2Cl2, 25 °C, 4 h
 
 (R)-1
syn:anti  
crude: 1.0:24
purified: 1.0:56
  84% isolated
 (S)-1
syn:anti  
crude: 14:1.0
not purified
 
HO
Me
HOTBDPSO
large
protecting
groups favor
attack from the 
underside
1
3
1,3-allylic 
strain
O
[Ir]+
Me
CO2Me
TBDPSO
H
H
H
substrate control
hydroxyl
directed
c
OH
(R)-1
d
catalyst control  
Figure 2.4. Preparation of: a a syn-type A chiron; and, b an anti-type A chiron. All ratios quoted 
are from GC.  c Directed hydrogenation model gives substrate control; and, d catalyst control 
dominates where the substrate conformation is only held by 1,3-allylic strain. 
 
2.2.2 Syntheses of the terminal fragments 
A similar approach was used to obtain optically pure syn and anti-isomers 
corresponding to the terminal fragment B, except that lactic acid was the starting 
material.   Starting from commercial available (S)-lactic acid, enantiomeric pure 12 can 
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be made via silyl protection, reduction, and Wittig olefination sequence.  Starting from 
this key intermediate, seven relevant substrates were prepared with high yields (Scheme 
2.3).  The hydrogenation data were listed in Table 2.2.  Hydrogenations of 12, 13, 15, 16 
did not provide good diastereoselectivities, but excellent data were obtained for 14, 17 
and 18. 
   
Scheme 2.3. Routes to alkene substrates for the syntheses of terminal chiron B.  
 
OH
O
OEt
TBDPSCl
 imidazole
CH2Cl2
25 oC, 1 h
OTBDPS
O
OEt
11  100%
(i) DIBAL-H, CH2Cl2
 -78 oC, 4 h
Ph3P
O
OMe
(ii)
CH2Cl2, 25 
oC, 16 h
TBDPSO
O
OMe
12  92%, >99% ee
 
TBDPSO
O
OMe
12
DIBAL-H
 CH2Cl2
25 o C, 1 hTBDPSO
OH
14  82%
TBAF, THF
25 oC, 1 h OH
O
OMe
13  67%  
 
TBDPSO
OH
14
TBAF, THF, 40 oC, 4 h
OH
OH
15  71%  
TBDPSCl
 imidazole, CH2Cl2
 25 oC, 2 h
TBDPSO
OTBDPS
16  96%
(i) Ac2O, Et3N, DMAP
           CH2Cl2, 25 
o C, 30 min
       (ii) TBAF, THF
           40 oC, 4 h
OH
OAc
17  87%
TBDPSCl
 imidazole, CH2Cl2
 0 oC, 2 h
OH
OTBDPS
18  74%  
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Table 2.2.  Hydrogenation of terminal hydrogenation substrates. 
OP1
FG
50 atm H2, 1 mol % Ir*
CH2Cl2, 25 
oC, 4 h OP1
FG
>99% conv.
syn or anti  
 
Entry Substrate P1 FG Ir* (cat) syn:antia,b 
      
1 12 TBDPS CO2Me 
(S)-1 
(R)-1 
3.0:1.0 
2.4:1.0 
2 13 H CO2Me 
(S)-1 
(R)-1 
1.0:12 
1.0:2.0 
3 14 TBDPS CH2OH 
(S)-1 
(R)-1 
38:1.0 
1.0:1.1 
4 15 H CH2OH 
(S)-1 
(R)-1 
3.2:1.0 
1.0:8.2 
5 16c TBDPS CH2OTBDPS 
(S)-1 
(R)-1 
7.7:1.0 
8.5:1.0 
6 17 H CH2OAc 
(S)-1 
(R)-1 
1.0:8.6 
1.0:57 
7 18 H CH2OTBDPS 
(S)-1 
(R)-1 
1.0:7.3 
1.0:55 
a absolute chemistry was determined by comparison with the true sample.  b the diasterisomer 
ratio were measured by GC.  c after 24h only ~30% conv. (seeing from 1H NMR). 
 
 
Catalyst control dominated for substrate 14 and the optimal stereoselectivity was 
obtained when the 1,3-allylic strain vector from the substrate matched with the preferred 
approach of the catalyst (Figure 2.5.c).  Hydrogenations of 17 and 18 were substrate 
controlled.  In these two examples the alkene is quite hindered.  The simplest 
explanation for the observed selectivity is in terms of directed attack resulting from 
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coordination to the allylic alcohol.  This could occur via oxygen coordinating with 
iridium, or via hydrogen bonding from an iridium hydride to the allylic alcohol oxygen 
(Figure 2.5.d).81,82  The latter is possible since recent observations from our group 
indicate the iridium complex is slightly acidic.27,47  
 
TBDPSO
OH
14
a
50 bar H2,1 mol % 1
CH2Cl2, 25 °C, 4 h
>99% conv.
TBDPSO
OH
19  
 (S)-1
syn:anti  
crude: 38:1.0
purified: 78:1.0
  68% isolated
 (R)-1
syn:anti  
crude: 1.0:1.1
not purified
 
OH
OTBDPS
18
b
50 bar H2,1 mol % 1
CH2Cl2, 25 °C, 4 h
>99% conv.
OH
OTBDPS
20  
 (S)-1
syn:anti  
crude: 1.0:55
purified: >99% de
 80% isolated
 (R)-1
syn:anti  
crude: 1.0:7.3
not purified
 
catalyst control
substrate
control
TBDPSO
Me
H
disfavors
attack from  
underside
1
3
1,3-allylic 
strain
c
OH
dL-1
14
HO
Me
H
1
3
1,3-allylic 
strain
OTBDPS
[Ir]
H
H
(R)-1
hydroxyl 
directed
18  
Figure 2.5.  Preparation of type B chirons: a a syn-form; and, b anti-form.  All ratios quoted are 
from GC.  c Catalyst control dominates where the substrate conformation is only held by 1,3-
allylic strain; and, d substrate control prevails for substrate 18. 
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2.2.3 Relative and absolute configuration determination 
2.2.3.1 For the internal chiron A 
TBDPSO
OH
OH
6
TBDPSO
OH
OH
10
>99% conv.
50 bar H2, 1 mol % 1
CH2Cl2, 25 °C, 4 h
(2.1)
 (R)-1
syn:anti  
crude: 1.0:24
purified: 1.0:56
  84% isolated
 (S)-1
syn:anti  
crude: 14:1.0
not purified
 
The alkene 6 was made from enantiomer enriched (R)-(-)-glycerol acetonide 
(98% ee).  So the absolute stereochemistry was determined by the chirality from the 
starting material.  Hydrogenation of 6 with (R)-1 provided the anti-isomer of chiron A 
with high diastereoselectivity (syn:anti, dr 1.0:24) (reaction 2.1).  The product 10 was a 
known compound with reported optical rotation value.83  The optical rotation value for 
compound 10 obtained from this hydrogenation work was quite close to the reported 
one.  On the other hand, compound 10’, the syn diastereoisomer of 10, was also a known 
compound with reported 13C NMR and optical rotation value.84  Both the 13C NMR and 
optical rotation value of 10’ are significantly different from those data obtained from 10.    
 
TBDPSO
OH
OH
TBDPSO
OH
OH
[!]21D = +8.8 (c 1.1, CHCl3)  (from this work)
[!]25D = +4.1 (c 1.1, CHCl3)  (reported)
[!]25D = -19.1 (c 0.68, CH2Cl2)  (reported)
10
10'  
 
Alkene 8 was hydrogenated with Pd/C to afford a mixture of two 
diastereoisomers.  The crude products were reduced by DIBAL-H and the silyl-
protecting group was removed by TBAF.  The crude triols were further converted to the 
corresponding triacetate, which was directly used for gas chromatography (reaction 2.2).  
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The GC gave a pair of well-separated peaks corresponding to the syn and anti 
diastereoisomers (Figure 2.6). 
 
HO OMe
O
TBDPSO
20 bar H2
10 mol% Pd/C
MeOH, 25 oC, 8 h
HO OMe
O
TBDPSO
(i) DIBAL-H
(ii) TBAF, THF
(iii) Ac2O, Et3N
AcO OAc
AcO
syn:anti
1.6:1.0
(2.2)
8
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Figure 2.6.  GC separation of modified hydrogenation products from Pd/C catalyzed 
hydrogenation of 8. 
 
Alkene 6 was hydrogenated efficiently with either (S)-1 or (R)-1.  The 
hydrogenation product was modified similarly as above.  The crude triacetate was also 
checked by the gas chromatography under the same condition to determine the 
diastereoisomer ratio.  As we already mentioned above, the hydrogenation of alkene 6 
with (R)-1 would provide the anti-isomer as the major product, so based on the gas 
chromatography the diastereoisomer ratio was 24:1.0 in favor of the anti-isomer.  
Meanwhile it was clear that the (S)-1 provided the syn-isomer for the hydrogenation with 
a diastereoisomer ratio 14:1.0 (Figure 2.7 and 2.8). 
 24 
TBDPSO OH
HO
50 bar H2
1 mol% (S)-1
CH2Cl2, 25 
oC, 4 h
(i) TBAF, THF
(ii) Ac2O, Et3N
AcO OAc
AcO
syn:anti
14:1.0
(2.3)
6
TBDPSO OH
HO
 
m in45 46 47 48 49 50 51 52 53 54
Norm.
2.5
5
7.5
10
12.5
15
17.5
20
22.5
 FID1 A ,  (ZHU\SIG10664.D)
  A
re
a:
 3
00
.7
94
 4
8
.1
9
0
  A
re
a:
 2
1.
13
82
 4
9
.0
3
1
 
Figure 2.7.  GC separation of modified hydrogenation products from (S)-1 catalyzed 
hydrogenation of 6. 
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Figure 2.8.  GC separation of modified hydrogenation products from (R)-1 catalyzed 
hydrogenation of 6. 
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Based on the 1H NMR, hydrogenation of alkene 8 with (S)-1 and (R)-1 favored 
the same diastereomer of the hydrogenation product (reaction 2.5).  The relative 
stereochemistry of the product and the diastereoisomer ratio were determined in the 
following way.  First the alkene 8 was hydrogenated using either (S)-1 or (R)-1 to give a 
mixture of two diastereomers.  These were reduced to the diol (DIBAL), the silyl 
protecting group was removed (TBAF), and the resulting triol was converted to 
triacetate.  The two diastereomers were then separated via GC (same condition as 
above).  The anti-isomer of 9, ie compound 10, is a known compound so the GC peak 
corresponding to the syn-isomer was the other peak.  From the GC, it is clear that both 
(S)-1 and (R)-1 provided the syn-isomer of the hydrogenation product.  For the (S)-1 the 
diastereoisomer ratio was 17:1.0 (Figure 2.9); for the (R)-1 the diastereoisomer ratio was 
19:1.0 (Figure 2.10). 
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Figure 2.9.  GC separation of modified hydrogenation products from (S)-1 catalyzed 
hydrogenation of 8. 
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Figure 2.10.  GC separation of modified hydrogenation products from (R)-1 catalyzed 
hydrogenation of 8. 
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2.2.3.2 For the terminal chiron B 
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Figure 2.11.  GC separation of modified hydrogenation products from Rh/Al2O3 catalyzed 
hydrogenation of chiral lactone.  
 
The authentic anti-isomer of chiron B was made via reported literature 
procedures (reaction 2.8).62  The syn-dimethyl lactone was reduced to diol (DIBAL), and 
the resulting diol was converted to the trimethylsilyl ether.  The two diastereomers were 
then separated via GC and the major peak corresponded to the anti-isomer (Figure 2.11).  
The derivative of product 19 gave the different major peak as the authentic compound, 
which corresponds to the syn-isomer (Figure 2.12).  The derivative of product 20 gave 
the same major peak as the authentic compound, which corresponds to the anti-isomer 
(Figure 2.13).   
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Figure 2.12.  GC separation of modified hydrogenation products from (S)-1 catalyzed 
hydrogenation of 14.  
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Figure 2.13.  GC separation of modified hydrogenation products from (R)-1 catalyzed 
hydrogenation of 18.  
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2.2.4 Total synthesis of (-)-dihydromyporone 
        (-)-Dihydromyoporone is a stress metabolite of the furanoterpenoid type, isolated 
from slices of the root of sweet potato.85  A synthesis (-)-dihydromyoporone 2186,87 was 
performed to illustrate α-hydroxyacids other than lactic could be used to build terminal 
1,3-hydroxymethyl chirons.  Thus the allylic alcohol 22 was prepared from 
commercially available (R)-2-hydroxy-4-methylpentanoic acid C via a series of standard 
steps.  The Wittig reaction provided the desired E-enoate with contamination of small 
amount of Z-isomer.  After reduction (DIBAL), the pure E-allylic alcohol 22 can be 
obtained with high yield (Scheme 2.4). 
 
Scheme 2.4.  Synthesis of olefin substrate 22 for the total synthesis of (-)-dihydromyoporone. 
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Hydrogenation of 22 under the standard conditions gave the crude alcohol in 
excellent diastereoselectivity.  The isobutyl-for-methyl substitution that connects Figure 
2.5.a with the hydrogenation in Figure 2.14.a had no adverse effect on the 
stereoselectivity.   After flash chromatography, the desired product was isolated in high 
yield, and the diastereomeric impurity was hardly perceptible by GC.  Interestingly, the 
hydrogenation of 23, the Z-isomer of 22, gave a even higher selectivity for the anti-
isomer of 24 (syn:anti, dr  1.0:60) (Figure 2.14.b).   
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Figure 2.14.  a Preparation of total synthesis precursor 24 (isolated in 84 % yield and a 170:1.00 
syn:anti ratio after one chromatographic separation);  b hydrogenation of Z-allylic alcohol 23; c 
1,3-allylic strain model. d model for substrate 23; Conversion >99 % throughout.  All ratios 
quoted are from GC. 
 
From the hydrogenation product 24, the final product (-)-dihydromyoporone 21 
can be obtained via formation of the iodide 26, homologation with sulfoxide 27, 
reduction, then deprotection.  The 1H NMR, 13C NMR, optical rotation value, HRMS 
data of the synthetic compound all agreed well with the reported data. 
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Scheme 2.5. Total synthesis of (-)-dihydromyoporone. 
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2.3 Conclusions 
 This chapter attempts to convey several key points.  First, constructive matching 
of chiral Crabtree’s catalyst analogs with stereochemical vectors from substrates can 
afford high diastereoselectivities, even in cases where Ir- or Rh-diphosphine complexes 
would probably give poor conversions and/or selectivities.  We have previously 
observed catalyst control dominating hydrogenation of some substrates leading to 
deoxypolyketides.28,77,78   The fact that this is not uniformly so here enhances the scope 
of the approach; mechanistic complementarities enabled all stereoisomers of the 
ubiquitous chiral fragments A and B to be made.   
         Using the newly developed methodology, (-)-dihydromyoporone was 
synthesized efficiently.  This not only demonstrated that this methodology is highly 
practical, but also proved that methyl substitutent is not necessary for the terminal 
chirons (can also be iso-butyl etc.).  To the best of our knowledge, this is the first 
method that can give all the diastereoisomers of chiron A and B with high selectivities.   
We are looking forward to seeing the wide application of this methodology in organic 
chemistry.  
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CHAPTER III 
AN ASYMMETRIC HYDROGENATION ROUTE TO (-)-SPONGIDEPSIN* 
 
3.1 Introduction  
(-)-Spongidepsin 28 is a natural product isolated recently from a Spongia sp. 
sponge collected off the Vanuatu Islands, Australia, by Riccio and co-workers.88  Its 
cytotoxic and antiproliferative activities against J774.A1, WEHI-164, and HEK-293 
cancer cell lines are accompanied by an unprecedented structure.  The genus Spongia is 
a well-known source of diterpenoid and polyketide natural products, such as 
epispongiadiol and spongistatin, respectively.  However, 28 reflects a distinct biogenetic 
origin that combines amino acid and ketide motifs within a 13-membered macrocycle.  
The ketide domain is comprised of a 9-hydroxy-2,4,7-trimethyltetradeca-14-ynoic acid, 
while the amino acid was established as (S)-N-methylphenylalanine by Marfey analysis 
of the acidic hydrosylate of 28.88,89  The absolute configurations of the other four 
stereogenic centers were determined by total synthesis.90-93 
Besides the amino acid-derived chirality, there are four stereogenic centers in 
spongidepsin.  Table 3.1 outlines the origin of these chiral centers in the four previous 
total syntheses of this molecule.  As the data shown here, most of the previous syntheses 
focused on C-C bond formation reactions, which often involve chiral auxiliaries.  In two 
of these syntheses, enzyme-mediated resolutions were used to generate 1,3-dimethyl 
chirons.  For most of these key reactions, the diastereoselectivities were not very good,  
so alternative methods were sought to increase synthetic efficiency and expose 
opportunities for analogs syntheses.     
 
 
 
 
______________ 
*Reprinted in part with permission from “An Asymmetric Hydrogenation Route to (-)-
Spongidepsin”, Ye Zhu, Aurore Loudet, and Kevin Burgess, Org. Lett., 2010, 12,  4392-
4395. Copyright 2010 American Chemical Society. 
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Table 3.1.  Comparison of previous syntheses of spongidepsin. 
 
O
N
O
Ph
Ofrom amino
acid
1
2
34  
 
 chiral centers 
 1 2 3 4 
Forsyth91 enzyme resolutiona hydroboration 
(1.0:1.0) 
epoxide opening 
Ghosh92 enzyme resolution Evan’s alkylation 
(98:2.0) 
bromo-lactonization 
(19:1.0) 
Cossy90 Roche ester crotyl-stannylation 
(87:13) 
asymmetric alkylation 
(85:15) 
SmI2-mediated 
(85:15) 
Negishi93 ZACAb (82 
% ee) 
ZACA (5.5:1.0) ZACA (3.5:1.0) allyl-boration (not 
specified) 
a Stereoselectivities are not indicated for kinetic resolution steps since they are conversion 
dependent.  bZACA is zirconium-mediated asymmetric carboalumination.  There are also two 
“formal” syntheses of spongidepsin.94,95 
 
Our group has been using chiral analogs of Crabtree’s catalyst in syntheses of 
some pivotal chirons for preparations of natural products, particularly in the polyketide 
series.  This chapter describes how those methods were applied to the preparation of  (-)-
spongidepsin 28 and some close analogs of this structure. 
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3.2 Results and discussions 
3.2.1 Syntheses of the 1,3-hydroxymethyl chiron  
Figure 3.1 illustrates the target molecule containing chirons 29 and 30 that we 
proposed could be made via stereoselective hydrogenations.  To obtain compound 29, a 
Sharpless kinetic resolution96,97 of the allylic alcohol 31 was used (Scheme 3.1).  
Acylation, oxidative cleavage, reaction with a stabilized Wittig reagent, then hydride 
reduction gave the allylic diol 32. 
                       
O
N
O
Ph
O
HO
O
N
O
Ph
O
28  
OH
HO
HO
O
+
29 30  
Figure 3.1.  Retrosynthesis of 28 highlighting the chirons from stereoselective hydrogenations. 
 
 
Previous studies from our group have shown that catalyst control tends to prevail 
in hydrogenations of acyclic chiral substrates28,77-79,98,99 using catalysts like our carbene 
complex 1.  However, manipulation of the alkene component in these reactions provides 
a means to optimize the “substrate-vector” such that it matches52 the catalyst influence to 
maximize stereoselectivity.  This can be done by interchanging ester and alcohol 
functionalities, altering protecting groups, or changing the alkene geometry.  In the case 
of 1,3-hydroxymethyl chirons, we have shown that an alkene with similar functionality, 
protection, and geometry relative to 33 was hydrogenated with high stereoselectivity.79 
The reduction of 33 to 34 occurred with similar high selectivity.  Chiron 29 was then 
generated from 34 via routine oxidation, reduction, and Wittig homologation steps. 
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Scheme 3.1.  Synthesis of the 1,3- hydroxymethyl chiron 29. 
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3.2.2 Syntheses of the 1,3-dimethyl chiron  
Scheme 3.2 oulines how the second pivotal chiron, 30, was obtained.   Starting 
from the Roche ester, Z-allylic alcohol 36 can be made in 4 steps with an 83% overall 
yield. Hydrogenation of 36 reiterates one of the several reactions we have used to 
prepare 1,3-dimethyl chirons.28,77,78  This reaction is catalyst controlled, but there is a 
significant “substrate vector”, and the Z-allylic alcohol was used to optimize this.  Crude 
material formed in this step had a 34:1.0 syn:anti diastereomeric ratio, and 93 % yield of 
120:1.0 syn:anti product was obtained after one chromatography.  The sequence of 
Swern oxidation, Wittig reaction, silyl deprotection, and alcohol oxidation shown here 
converting the alcohol 37 to the acid 30 were straightforward transformations. 
 
Scheme 3.2.  Synthesis of the 1,3-dimethyl chiron 30. 
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3.2.3 Coupling of the fragments and completion of the total synthesis 
To complete our synthesis of (-)-spongidepsin 28, chiron 29 was coupled with 
the appropriate protected N-methyl amino acid to give the ester 39 (after removal of the  
 
Scheme 3.3.  Completion of the synthesis of 28. 
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Boc group).  This was then coupled with chiron 30 to form the α,ω-diene 40.  Ring 
closing metathesis with the “second generation” Grubbs catalyst100,101 gave the 
macrocycle 41 after simultaneous O-deprotection and alkene hydrogenation.   The final 
steps in the synthesis were oxidation and generation of the alkyne group (Scheme 3.3). 
1H and 13C NMR spectra of the synthetic product 28 compared closely with those 
reported in previous syntheses. 90-93   
 
Scheme 3.4.  Syntheses of the derivatives of (-)-spongidepsin. 
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As far as we are aware, nothing has been reported on structure activity 
relationships for spongidepsin.  Consequently, several intermediates in Scheme 3.3 were 
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diverted to form analogs of the target material for testing.  Thus compounds 42 and 43 
were also prepared.   Starting from intermediate 40, after ring closing metathesis, instead 
of reducing the internal double bond, the PMB protecting group was removed with 
DDQ.  The resulting primary alcohol was then transformed to the alkyne 42, which was 
an unsaturated derivative of the natural product 28.  Compound 43 could be 
conveniently obtained via reduction of 42 (Scheme 3.4).  Motives for making these 
particular compounds were to test the effects of increased conformational rigidity in the 
macrolide, and the effects of saturating the side chain on the cytotoxicity.  
 
Scheme 3.5.  Syntheses of the dimers of (-)-spongidepsin. 
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The cellular target for spongidepsin is unknown.  Consequently, we also decided 
to prepare two bivalent molecules consisting of two macrolide fragments joined by a 
flexible linker via a “click reaction” (Scheme 3.5).102,103  These analogs were designed to 
probe if this modification would have significant effects on the molecular cytotoxicities; 
if it did, this might implicate a homodimeric binding partner. 
 
Table 3.2.   In vitro antiproliferative activity of 28 and derivatives 42, 43, 45, and 46. 
compound IC50 (mM)a 
28 5.68 (0.66)b 
42 8.27 
43 7.32 
45 non cytotoxic 
46 non cytotoxic 
6-mercaptopurine 7.45 (0.007)b 
a Assay run for 72 h in EMEM + 2% FBS at 37 °C using human embryonic kidney cells 
(HEK-293).;  b Literature data.88  IC50 values were measured three times and averaged. 
 
With the help from a postdoc researcher, Aurore Loudet, Compounds 28, 42, 43, 
45, and 46 were tested in an antiproliferative assay on human embryonic kidney (HEK-
293) cells (Figure 3.2), and the IC50 values measured are indicated in Table 3.2 relative 
to 6-mercaptopurine (control cytotoxic compound).  These assays were reproduced 
several times; in our hands the cytotoxicity of compound 28 and of 6-mercaptopurine 
were both significantly less (one and three orders of magnitude, respectively) than 
reported previously.88  However, the IC50 of 6-mercaptopurine reported in reference 88 
is about 100x less than in three other literature reports.104-106  Further, the relative 
cytotoxicity of the target compound 28 and 6-mercaptopurine is almost the same.  We 
cannot account for these discrepancies; nevertheless, it is possible to confidently 
compare the relative cytotoxicities of 6-mercaptopurine, 28, and its analogs in our 
assays. 
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Figure 3.2. Antiproliferative assay for the natural product 28 and the new derivatives 42, 43, 45, 
and 46 in MTT assays featuring human embryonic kidney cells (HEK-293). 
 
 
Figure 3.2 indicates that the new monomer derivatives 42 and 43 show little 
effect up until 2 mM concentrations, after which they are significantly cytotoxic, just as 
the natural product is.  Consequently, reduction of the alkyne side-chain, or 
incorporation of an alkene in the macrolide has no significant effect.  Surprisingly, the 
bivalent molecules 45 and 46 do not show significant cytotoxicities in the same 
concentration range.  Compound 28 and the new derivatives were also tested on human 
pancreatic carcinoma cells (Panc-1); the IC50 values for the monomers 28, 42, 43 were in 
the same range, and the dimers were also non-cytotoxic (Figure 3.3).  Together, these 
data indicate incorporation of a large substituent on the alkyl chain almost completely 
eliminates the cytotoxic effect, there was no positive effect from these bivalent analogs. 
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Figure 3.3. Antiproliferative assay for the natural product 28 and the new derivatives 42, 43, 45, 
and 46 in MTT assays featuring human pancreatic carcinoma cells (Panc-1).  Assay were run for 
3 days at 37 °C in PFHM-II medium (protein and serum free medium). 
 
 
3.3 Conclusions 
Asymmetric hydrogenations via chiral analogs of Crabtree’s catalyst are viable 
for synthesis of spongidepsin.  The results presented here offered some major advantages 
over previous syntheses.  Previous studies from our group indicate all stereoisomers of 
chirons like 29 and 30 can be made via such methods.  We infer from this that 
stereoisomers of this natural product could be made via similar approaches.   The results 
presented here indicate that practical syntheses of other analog types are also possible.  
We hope this study can alert synthetic organic chemists to the importance of asymmetric 
hydrogenations of largely unfunctionalized alkenes in acyclic stereocontrol.  We also 
hope that in the immediate future researchers may use some of the routes to privileged 
chirons that shown here. 
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CHAPTER IV 
IRIDIUM-CATALYZED ASYMMETRIC HYDROGENATION OF VINYL 
ETHERS* 
 
4.1 Introduction  
 Early interest in the asymmetric hydrogenation of vinyl ethers aimed to find 
suitable alternatives to the asymmetric hydrogenation of ketones.107-110  However, the 
hydrogenation of vinyl ethers is not merely a substitute for ketone hydrogenation.  
Rather, it can lead to products that are difficult or impossible to access directly from the 
hydrogenation of ketones, such as chiral cyclic ethers.  Additionally, some vinyl ethers 
can also be converted to products other than alcohols.  Finally, selective asymmetric 
hydrogenation of vinyl ether forms a protected chiral alcohol that can be deprotected at 
any later point in a synthesis. 
In our view, alkenes for asymmetric hydrogenations can be divided into three 
categories.31 At one extreme, there are “coordinatively-functionalized alkenes”, that 
have proximal directing groups that are likely to bind transition-metals in a catalytic 
cycle.  Alkenes with only alkyl substitutents are at another extreme; they are completely 
unfunctionalized.  Intermediate between these extremes are “non-coordinatively 
functionalized alkenes”.  These have a proximal functional group that does not 
coordinate to transition-metal catalysts and direct stereofacial modifications.  There are 
more non-coordinative functional groups than coordinative ones, so this intermediate 
category is the largest.  It also contains an abundance of precursors to useful chirons for 
organic syntheses. 
 
 
__________________ 
*Reprinted in part with permission from “Carbene-Metal Hydrides Can Be Much Less 
Acidic Than Phosphine-Metal Hydrides: Significance in Hydrogenations”, Ye Zhu, 
Yubo Fan, and Kevin Burgess, J. Am. Chem. Soc., 2010, 132, 6249-6253. Copyright 
2010 American Chemical Society.  The pre-peer reviewed version of the following 
article “Iridium-Catalyzed Asymmetric Hydrogenation of Vinyl Ethers”, Ye Zhu, and 
Kevin Burgess, Adv. Synth. Catal., 2008, 350, 979-983.  
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Asymmetric hydrogenations of enol ethers illustrate the viewpoint outlined 
above.  Enol acetates D have a coordinative-functional group: the carbonyl of the 
acetate, that can transiently bind to a metal center.  Consequently, the literature contains 
many examples of asymmetric hydrogenations of enol acetates, and most of them are 
quite successful.111-122  α-Aryloxy or α-alkoxy α,β-unsaturated carboxylic acid E also 
has a coordinative-functional group, the carboxyl anion under the basic condition.  
Recently there are several literature reports about the successful asymmetric 
hydrogenation of this type of enol ethers too (up to 99.8 ee %).123-126  Conversely, 
alkylated-, and silylated-enol ethers, F and G are, by our definition, non-coordinatively 
functionalized.  There are relatively few reports of asymmetric hydrogenations of these, 
and the enantioselectivities observed have not reached levels that are practical for 
general application in organic syntheses (alkylated enol ethers,127-129 silylated enol 
ethers,130 furans129,131). 
Ph
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Pfaltz’s realization11 that phosphine oxazoline ligands could be used to form 
chiral analogs of Crabtree’s catalyst73 has inspired many researchers.  Following his 
lead, Andersson and co-workers investigated chiral N,P-ligated iridium complexes in 
asymmetric hydrogenations of the silyl- and methyl-enol ethers H and I, but complex 
mixtures were obtained using four different catalysts.  Subsequently, their study evolved 
into an investigation of the successful hydrogenations of the enol phosphinates J with 
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catalyst K.46  Our group was also studying enol ethers as substrates at the time when this 
research was published.   This chapter describes our research results about this study.  
During this study, we realized that it is quite interesting that catalyst K does not work for 
the simple alkyl enol ethers but the structure similar 1 does.  A hydride intermediate 
acidity difference theory was proposed for this phenomenon based on DFT calculations 
and some experiment results.  This chapter will also talked about these studies in detail.   
 
 
4.2 Asymmetric hydrogenation of vinyl ethers 
4.2.1 Syntheses of the vinyl ethers  
 
R2
O O
OR1
(RO)3CH, H2SO4 (cat.)
25 oC, 36 h RO
O
OR1
R2
(4.1)
 
 
MeO
O
OEt
47a 74%a
MeO
O
OMe
47b 65%
EtO
O
OEt
47c 60%
O
OMe
MeO
47d 65%  
 
MeO
O
OtBu
47e 50%
MeO
O
N
47f 41%
MeO
O
OH
47g 65%
MeO
O
47h 74%
OMe
 
a. 1 eq. CaCl2 was used. 
Figure 4.1. Synthesis of vinyl ether ester and its’ relative derivatives. 
 
The vinyl ether esters can be made from acetoacetate and orthoformate by using 
catalytic amount of H2SO4.132  Usually to avoid the ester scrambling, the R1 group in the 
acetoacetate and the R group in orthoformate should be same (for example 47b, 47c, and 
47d).   However, by adding anhydrous CaCl2, this scrambling can be suppressed since 
the by-product MeOH can be trapped by the CaCl2 (47a was obtained with 74% yield).   
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Starting from the 47b, a series of derivatives can be made via Wenireb amide formation 
(47f), ester hydrolysis (47g), and ester formation (47e) (Figure 4.1). 
 
RO
O
OR1
R2
(4.2)
DIBAL-H, CH2Cl2, 0 
oC, 1 h
RO OH
R2
 
 
MeO OH
48a 88%
MeO OH
nBu
48b 80%
EtO OH
48c 51%
OH
MeO
48d 78%  
 
MeO OTBDPS
48e 75%
MeO OAc
48f 72%  
Figure 4.2. Synthesis of vinyl ether alcohols and its’ relative derivatives. 
 
With these vinyl ether esters in hand, the vinyl ether alcohols can be easily made 
by reducing the ester functional groups with DIBAL-H.   The vinyl ether alcohols are 
much more acid sensitive than the vinyl ether esters.   Flash chromatography with silica 
gel (with or without Et3N) and reduced pressure distillation both gave decomposed 
products.   Finally it was found that flash chromatography with the basic Al2O3 can 
afford the desired product with good isolated yield and purity (Figure 4.2). 
 
 
4.2.2 Asymmetric hydrogenation of the vinyl ethers  
 
(4.3)
Ph
OMe 35 bar H2, 1 mol% (S)-1
CH2Cl2, 25 
oC, 24 h Ph
OMe
100 % conv.
29 % ee
I
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Reaction 4.3 shows the first hydrogenation of an enol ether studied in our 
laboratories.  1-Methoxy-1-phenylethene (I) was reduced exclusively to the product 
using the carbene oxazoline catalyst (S)-1.  The low enantioselectivity observed for this 
particular substrate was not a concern because there are many routes to chiral aryl(1-
hydroxyethyl) compounds.  On the other hand, the high conversion to one single product 
obtained with the carbene-oxazoline catalyst 1 contrasted with the poor results reported 
for similar N,P-ligands, and provided motivation to investigate substrate scope. 
 
Table 4.1. Optimization of hydrogenation conditions for substrate 47a. 
MeO
O
OEt
H2, 1 mol% (S)-1
 CH2Cl2 MeO
O
OEt
47a  
Entry Temp. 
(oC) 
Pressure 
(bar) 
Time 
(h) 
Conv.a 
(%) 
Eeb 
(%) 
1 25 5 24 <5 5 
2 25 50 24 81 78 
3 25 100 24 82 79 
4 25 50 48 >99 78 
5 50 50 12 95 73 
6 -20 50 12 30 83 
7 25 50 12 95 77c 
8 25 50 12 68 83d 
a Determined by 1H NMR;  b Determined via chiral GC;  c Catalyst loading, 5 mol %;  d Catalyst 
loading, 0.2 mol %. 
 
The enol ether 47a, available from the corresponding ketoester and 
trimethylorthoformate, was selected as a substrate for further studies and optimization of 
reaction conditions (Table 4.1).  Hydrogen pressures greater than 5 bar were shown to be 
necessary, but increasing from 50 to 100 bar had no productive effect (entries 1 – 3).  
Complete conversion was observed when the reaction time was extended to 48 from 24 
h (entry 4).  At 50 °C the reaction proceeded faster but the enantioselectivity decreased 
(entry 5).  Conversely, a slightly higher enantioselectivity was observed at -20 °C but the 
conversion was poor (entry 6).  Entries 7 and 8 show that a slightly higher 
enantioselectivity was observed at a lower catalyst loading, but the conversion was less 
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reflecting a slower reaction rate.  On the basis of these observations, the conditions used 
in entry 4 were selected for application to different substrates. 
 
Table 4.2. Asymmetric hydrogenation of vinyl ether esters. 
        
R2O
R1 O
OR3
50 bar H2, 1 mol% (S)-1
CH2Cl2, 25 
oC,  48 h R
2O
R1 O
OR3
47 49  
47 Conv.  (%)a Ee (%)b 49c 
MeO
O
OEt
47a  
>99 78 O
OEt
OMe
49a  
MeO
O
OMe
47b  
85 60 O
OMe
OMe
49b  
EtO
O
OEt
47c  
>99 66 O
OEt
OEt
49c  
O
OMe
MeO
47d  
15 ndd O
OMe
MeO
49d  
MeO
O
OtBu
47e  
>99 88 O
OtBu
OMe
49e  
MeO
O
N
47f
OMe
 
90 90 O
N
OMe
49f
OMe
 
MeO
O
OH
47g  
>99 63 O
OH
OMe
49g  
MeO
O
Ph
47h  
<5 nde nd 
a Determined by 1H NMR;  b Determined via analysis on a chiral GC column;  c Stereochemical 
assignments via reduction of the hydrogenation products to primary alcohol then comparison 
with authentic samples;  d Assignment of the absolute configuration of the product was not made;  
e E/Z isomerization occurs during the reaction and most of the starting material remains. 
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Table 4.2 shows hydrogenations of similar substrates 47a – h at 48 h reaction 
time.  High conversions could be achieved for esters 47a – c where the substituents are 
not large, but the iso-propyl substituted enol ether 47d gave only 15 % conversion in the 
first 48 h of the reaction. When the size of the ester group in this series was increased to 
tert-butyl as in substrate 47e, the enantiomeric excess increased significantly.  The N-
methoxy amide 47f was a good substrate for this reaction; it gave a high conversion and 
the best enantiomeric excess in the series.  However, the enantioselectivity for the 
corresponding acid 47g was significantly diminished.  Finally, the phenyl ketone 47h 
was not hydrogenated quickly under these conditions and E/Z-isomerization of the 
alkene was observed.  
DIBAL reduction of the ester 47c gave the allylic alcohol 48b.  However, when 
this was hydrogenated under the conditions specified in Table 4.2 (and Table 4.3, entry 
1), the ketone 51 was formed in preference to the desired ether 50b.  One explanation for 
this by-product is protonation of the hydroxyl group, elimination to an enone, then 
hydrogenation.  Indeed, entries 2 – 4 in Table 4.3 show that progressively higher 
amounts of anhydrous potassium carbonate enhance the chemoselectivity of the reaction 
in favor of the hydrogenation product 50b, and the ee values throughout were excellent.  
It was also observed that when 4Å molecular sieves were used (and no potassium 
carbonate), then 50b could also be the major product (data not shown).   
 
Table 4.3. Optimization of the hydrogenation conditions to avoid ketone formation. 
EtO
OH
50 bar H2 
1 mol%  (S)-1
K2CO3, CH2Cl2
 25 oC, 12 h
OEt OH
+
O
Et
48b 50b 51
>99 % conv.
>98 % ee  
Entry K2CO3 (mol %) 50b:51a 
1 0 30:70 
2 20 67:33 
3 30 83:17 
4 50 >99:1.0 
a Determined by 1H NMR. 
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Table 4.4. Asymmetric hydrogenation of vinyl ether alcohols. 
R2O
R1 OR3
50 bar H2 
1 mol% (S)-1
1 eq. K2CO3, CH2Cl2
 25 oC, 12 h
R1
OR2 OR3
48 50
>99 % conv.  
48 Ee (%)a 50b 
MeO
48a
OH
 
96 OMe
50a
OH
 
EtO
48b
OH
 
98 OEt
50b
OH
 
MeO
nBu
48c
OH
 
93 
nBu
OMe
50c
OH
 
iPr
OMe
48d
OH
 
91 
iPr
OMe
50d
OH
 
MeO
48e
OTBDPS
 
89c OMe
50e
OTBDPS
 
MeO
48f
OAc
 
92c OMe
50f
OAc
 
a  Determined via analysis on a chiral GC column;  b Stereochemical assignments were made via 
comparison with authentic samples;  c  K2CO3 was not required in this case. 
 
The observations outlined above led us to broaden the substrate scope to include 
those shown in Table 4.4.  Substrates 48a and 48b have methyl-to-ethyl relationships, 
and this change did not significantly alter the enantioselectivities observed.  The 
enantioselectivity reduced only very slightly when the alkene methyl-substituent was 
replaced with an n-butyl group as in substrate 48c.  Substrate 48d has a Z-
stereochemistry and a more bulky substituent (iPr).  For this compound the 
enantioselectivity observed was also high, and the catalyst approached the alkene from 
the same face effectively giving an inverted stereochemistry because the alkene 
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geometry was reversed.  Hydrogenation of substrate 48e compared with the 
corresponding alcohol 48a indicates that the catalyst approaches the alkene from the 
same direction for the silylated substraste, and high enantiomeric selectivity is 
maintained.  Similarly the acetate 48f was hydrogenated with good enantioselectivity 
and from the same face.  Potassium carbonate was not required to obtain high 
conversions with the protected alcohols 48e and 48f.  Conversions were very high 
throughout this series and the reaction was faster than for the corresponding esters 
shown in Table 4.2. 
 
MeO
50 bar H2 
1 mol% (S)-1
1 eq. K2CO3, CH2Cl2
 25 oC, 24 h
OMe
48a
2.0 mmol
50a
88 % isolated
96 % ee
OH OH
(4.4)
 
 
Finally, reaction 4.4 was performed on a slightly larger scale than those shown in 
Table 4.4.  The product of this reaction 50a was isolated in high yield via column 
chromatography. 
 
 
4.2.3 Absolute configuration determinations  
The absolute stereochemistry of the hydrogenation products was determined via 
comparison with the known compounds that were made via the asymmetric 
hydrogenation of acetoacetate with Noyori’s type catalyst.  The R type chiral ethers can 
be made through the route shown in Scheme 4.1.  By comparing the GC retention time 
of these prepared ethers with the products from iridium catalyzed hydrogenation of vinyl 
ethers, it is clear that hydrogenations with (S)-1 provided S type chiral ethers for the 50a, 
50c, 50e, and 50f.   For (Z)-vinyl ether alcohol 48d, (S)-1 provided R type chiral ether 
50d. 
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Scheme 4.1.  Synthesis enantiomer enriched chiral ethers. 
R
O
OMe
O [((R)-BINAP)RuBr2]2(acetone)
23 bar H2, 50 
oC, 48 h R
(R)
OH
OMe
O
MeOTf, CH2Cl2
25 oC, 24 h
NtBu tBu  
      
R (R)
OMe
OMe
O DIBAL-H, CH2Cl2, 25 
oC, 1 h
R (R)
OMe
OH
R=Me, iPr, nBu  
 
Starting from commercial available (R)-1,3-butanediol, the enantiomeric 
enriched ether ent-50b can be synthesized through route shown in Scheme 4.2.  By 
comparing the GC retention time of ent-50b with hydrogenation product, the 
stereochemistry of 50b can be determined to be S. 
 
Scheme 4.2.  Synthesis enantiomer enriched ent-50b. 
(R)
OH
OH
TBDPSCl, imidazole
CH2Cl2, 25 
oC, 1 h
(R)
OH
OTBDPS
NaH, EtI, HMPA
THF, reflux, 24 h  
 
            
(R)
OEt
OTBDPS
TBAF, THF, 25 oC, 1 h
(R)
OEt
OH
ent-50b  
 
Finally, the stereochemistry of the 49a-g can be determined by reducing to the 
alcohols, and then compared with the geometry already known chiral alcohols 50a-f via 
GC.  
 
4.3 Metal hydrides acidity studies 
4.3.1 Background  
Transition-metal hydrides are ubiquitous in catalysis.133  They are frequently 
formed as intermediates even in cases where the catalyst precursor does not contain a M-
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H bond, and they may also be formed en route to catalyst deactivation.  The reactivity of 
transition-metal hydrides is widely variable.  Different coordination modes are open to 
hydride (and dihydrogen) ligands, they may dissociate to donate hydrides or protons, and 
they can participate in hydrogen bonding.81,134  In some cases the importance of metal 
hydrides in catalysis is obvious.  In most Heck couplings,135 for instance, transtion-metal 
hydrides reductively eliminate acidic molecules, hence it is necessary to add a base to 
avoid complications that would be caused by accumulation of acid.  In the rhodium 
catalyzed hydrogen-mediated reductive aldol coupling reaction, addition of base is also 
necessary to suppress the undesired 1,4-reduction pathways.136 In other cases, basic 
additives have equally profound effects but the underlying reasons may be obscure.  For 
instance, some asymmetric homogenous hydrogenation reactions give significantly 
better enantioselectivities in the presence of base for non-evident137 or undefined138 
reasons.  Acidities of transition-metal hydrides139 therefore must also account for some 
obscure ligand effects;140 in other words, ligands complexed to metal centers influence 
the acidities of transition metal hydrides, and this in turn can impact catalysis.  
Despite the considerations outlined above, there is a tendency to regard 
homogeneous catalytic alkene hydrogenations as pH neutral because the starting 
materials, dihydrogen and alkene, are not acidic.  Some hydrogenations may be 
described as “ionic”107,108,141,142 because heterolytic cleavage of hydrogen occurs; 
however, to the best of our knowledge, there are few reports that have commented on 
how activation of hydrogen with transition metal catalysts impacts the pH of the medium 
in catalytic transformations.  Matsuda and co-workers reported that allylic alcohols 
could be substituted by various nucleophiles when treated with [Ir(cod)(PPh3)2]PF6 that 
had been  activated by H2.  They suggested that the reaction proceeded via activation of 
the alcohol to give an allylic cation that was subsequently attacked by the nucleophile to 
give the final product.  In control experiment, Matsuda observed similar reactivity using 
a catalytic amount of CF3SO3H instead of the iridium catalyst.143  In both Andersson144 
and Pfaltz’s145 asymmetric hydrogenation work, they found that their Ir-N,P catalysts are 
not suitable for some very acid sensitive substrates.  In some of Krische’s rhodium 
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catalyzed hydrogen-mediated C-C bond formation reactions, base was found to be 
necessary for high yields of the desired coupling products.136,146 
The research study presented here further demonstrates that catalytic 
hydrogenation reactions need not be intrinsically neutral, and this can be extremely 
significant to the products formed.  Specifically, we draw attention to iridium-mediated 
hydrogenations of alkenes by analogs of Crabtree’s catalyst [(COD)Ir(PCy3)(py)]+ as a 
situation in which significant concentrations of protons may be generated.  Further, the 
outcome of these hydrogenation reactions can be affected by the acidities of catalytic 
intermediates. 
 
4.3.2 DFT calculations about the pKa’s of the metal hydride intermediates  
Direct experimental evidence for the mechanism of hydrogenations by Crabtree’s 
catalyst analogs is unavailable, and difficult to obtain via kinetic or spectroscopic 
methods.24,26,147   However, calculations first by Andersson30 on a simplified system with 
an N,P-ligand set, then from our laboratories24,29 on the carbene-oxazoline complex 1 
converge on very similar preferred reaction pathways.  This involves loss of the COD 
ligand, and complexation with the alkene substrate and two molecules of dihydrogen.  
The rate-limiting step in the catalytic cycle is transformation of this tetrahydride L into 
the s-alkyl species M (Figure 4.3).  
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Figure 4.3.  Postulated turnover limiting step in hydrogenations with Crabtree catalyst and 
analogs. 
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This mechanism involves alternation between iridium(III) and (V) oxidation 
states.  It indicates why Crabtree’s catalyst analogs are able to hydrogenate 
“coordinatively unfunctionalized” tri- and tetra-substituted alkenes whereas rhodium 
complexes like Wilkinson’s catalyst do not.   Specifically, the positively charged and 
higher oxidation state Ir-complexes are more electrophilic than neutral, and lower 
oxidation state Rh-complexes, so they have more affinity to the π-electron density of 
alkene substrates.  Moreover, the small steric demands of a tetrahydride ligand set 
facilitate coordination of alkenes with three or four substituents that are intrinsically 
hindered.  Finally, hydrogenations with these Ir-complexes are not particularly sensitive 
to oxygen, as expected for high oxidation state Ir-intermediates.   Involvement of 
intermediates L also explains why the catalytic cycle is so hard to follow 
spectroscopically because these tetrahydrides are in a rapid, dynamic equilibrium with 
dihydrido-dihydrogen complexes.24,29 
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Figure 4.4. Postulate for acidities of a the P-Ir-H complexes relative to b carbene-Ir-H systems.  
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Figure 4.4 contrasts the factors driving dissociation of protons from the 
iridium(V) intermediates L (shown in abbreviated form) where the ligating group X is 
either a phosphine or an N-heterocyclic carbene intermediate.   In both cases, an 
iridium(III) species forms, ie the metal is reduced as its electron density increases.   We 
postulate that this dissociation is easier when X is a P-ligand than a carbene because P-
ligands are: (i) inferior σ-donors hence are less able to stabilize Ir(V);148 and, (ii) 
superior π-acceptors thus better able to stabilize Ir(III).  Consequently, Crabtree’s 
catalyst and P-ligated derivatives should be more acidic than the corresponding 
carbenes. 
 
Table 4.5.  pKa values for transition metal hydrides. 
 complex pKa  
  MeCN CH2Cl2 
  exp calca ΔpKab ΔpKab 
1 [HNi(dmpe)2]+ 24.4±0.2 21.7 11.9 13.4 
2 [HPt(dmpe)2]+ 31.1 32.3 22.5 24.0 
3 [HNi(dppe)2]+ 14.7±0.3 13.8 4.0 5.5 
4 [HPt(dppe)2]+ 22.2 24.6 14.8 16.3 
5 N - 11.3 1.5 1.4 
6 O - 9.8 0 0 
7 P - 11.5 1.7 1.8 
8 Q - 17.4 7.6 7.4 
9 R - 36.1 26.3 30.0 
a Experimental pKa of Ni and Pt complexes as references, and all have a standard deviation of 
+ 2.2; b calculated relative pKa and set the catalyst intermediate O as reference. 
 
Dr. Yubo Fan helped us to use density functional theory (TPSS functional)149 to 
calculate acidity differences for the key metal hydride complexes involved in 
hydrogenations with Crabtree’s catalyst analogs,  These data were then compared to 
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reference systems to estimate absolute pKa values.150  Almost all reliable experimental 
pKa’s for metal hydrides in the literature are measured in acetonitrile, so the calculated 
pKa’s were first obtained by simulating reactions in this medium.  
In validation work, calculations were performed for several metal hydrides for 
which pKa’s have been measured in MeCN (Table 4.5, entries 1 – 4).  The calculated pKa 
differences were then related to absolute pKa values using the literature experimental 
data for each of the other three metal hydride controls, then averaged to give the data 
shown in Table 4.5, entries 1 – 4.  These numbers are consistent with the experimental 
data with a maximum deviation of 2.7 for entry l, which concerns a complex of pKa 21.7.  
This close agreement for the control complexes indicates a high degree of confidence for 
application of the same technique to calculate acidities for the key intermediates in 
hydrogenations by Crabtree’s catalyst analogs. 
Calculated data for the hydrogenation intermediates are shown in Table 4.5, 
entries 5 – 9.  Considering first the data in MeCN, Crabtree’s catalyst N was calculated 
to be less acidic than the P-oxazoline complex O, so the latter was used as a “bottom-
line reference”.  The N,P-ligands in O and P are alike, hence these complexes would be 
expected to have similar acidities, and the calculations are consistent with this.  
Moreover, higher acidity for the diphenylphosphinite complex O relative to P was also 
predicted because the diphenylphosphine in P is a superior σ-donor, better able to 
stabilize Ir(V); again, the calculations support this (Figure 4.5). 
The most important comparison in Table 4.5 is between the data for the N,P-
complexes O/P, and the corresponding carbene Q.  Hydrides O and P were calculated to 
be 7.6 to 5.9 pKa units more acidic than the carbene intermediate Q, as predicted from 
the concepts outlined in Figure 4.4.  A 7.6 pKa difference is similar to the acidity 
difference between formic acid and tBuOH.   
Finally, it is interesting to compare intermediates from Crabtree’s and 
Wilkinson’s catalysts.  The hydrogenation intermediate R from Wilkinson’s catalyst was 
far less acidic than that from any of the iridium complexes.  It was 26.3 pKa units less 
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acidic than O and 24.8 pKa units less acidic than the tetrahydride N from Crabtree’s 
catalyst. 
All the calculations discussed so far are for acetonitrile solvent, but 
hydrogenation reactions with Crabtree’s catalyst analogs are generally run in 
dichloromethane.  No pKa data for useful control metal hydrides in dichloromethane has 
been published; hence calculated pKa values in that medium cannot be related to 
absolute values.  However, pKa differences between the complexes are accessible, and 
that data is shown in the right hand column of Table 4.5., relative to the intermediate that 
was calculated to be the most acidic, ie the diphenylphosphinite oxazoline O.   The 
calculated acidity differences for complexes N – R in dichloromethane (right hand 
column) are very similar to those for acetonitrile (penultimate column).  This indicates 
that the differences in pKa values for the complexes are preserved, no matter how the 
absolute pKa values vary between these two solvents. 
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Figure 4.5.  Relative acidities of putative intermediates in hydrogenations. 
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4.3.3. Experimental evidences for the acidity difference  
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It was a study on enol ether substrates that originally led us to suspect that more 
protons were produced when N,P-Ir-catalyst precursors were used relative the 
corresponding carbene catalyst.  Specifically, Andersson et al had noted45,46 that alkyl 
enol ethers gave complex mixtures when hydrogenated using one of their N,P-iridium 
catalysts, but we observed the same reaction gave only the expected hydrogenation 
products when our N,carbene-iridium catalyst 1 was used.47    
In the present work we expanded the scope of our studies to include catalyst 
precursors 1, 52 and 53 in hydrogenation of the acid-sensitive enol ether I.  We predicted 
these catalyst precursors would give progressively more acidic intermediates in 
hydrogenations.  This assertion was based on the assumption that the carbene ligand is a 
better σ-donor than either of the P-ligands and, of those, the PCy2 system has superior σ-
donating properties.148,151-153   The degree of backbonding to these ligands is likely to be 
minor, and to follow the opposite trend.154-156  Figure 4.6 shows 1H NMR spectra of 
crude materials isolated from these reactions.  The desired product 54, and almost 
nothing else, was formed when the carbene complex 1 was used.  The 
dicyclohexylphosphinite complex 52 gave much less of the desired ether product 54 and 
relatively more byproducts.  At the other extreme, the diphenylphosphinite complex 53 
gave less than 5% of 54 (ie almost none by NMR), and mostly undesired impurities. 
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Figure 4.6.  Hydrogenation of the acid sensitive enol ether I with complexes 1, 52, 53 give 
progressively less of the anticipated ether product 54.  
 
The byproducts shown in Figure 4.6 could not be conveniently isolated and 
characterized.  However, hydrogenation of the enol ether 55 gives mainly two products: 
56, from direct addition of hydrogen, and 57 via acid-mediated rearrangement and 
hydrogenation.47  This reaction only gave the direct hydrogenation product 56 if a base, 
eg K2CO3, was added.47  Complete conversion and almost quantitative yields were 
achieved using all the three catalyst precursors 1, 52 and 53 in these reactions.  Product 
ratios obtained (1H NMR) when 55 was hydrogenated using catalysts 1, 52 and 53 are 
shown below (reaction 4.5).  More of the acid-derived byproduct 57 was formed from 
the dicyclohexylphosphinite complex 52 than from the carbene, and most accumulated 
when the diphenylphosphinite complex 53 was used as the catalyst precursor.  Thus the 
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amount of direct hydrogenation product follows the order 1 > 52 > 53, ie the amount of 
56 decreases as the anticipated acidities of the predicted intermediates increase. 
 
(4.5)
MeO OH MeO OH
50 bar H2
1 mol % Ir*
CH2Cl2
25 oC, 12 h
1.0 K2CO3
>99% conv.
OTBDPS OTBDPS
O
OTBDPS
+
55 56 57
1 52 53
99:1.0 6.7:1.0 1.3:1.056:57  
 
 
A second set of evidence for the acidity effects comes from deuterium labeling 
studies.  Several years ago we observed addition of deuterium to alkenes gave some 
label incorporation at sites other than those corresponding to direct addition.23  In the 
light of the data presented above, we postulated that abnormal D-incorporation arises via 
addition of D+ to the alkene, loss of H+ to give isomerism, then addition of D2 (Scheme 
4.3).  Table 4.6 shows experiments designed to test this hypothesis by using complexes 1 
and 53.  According to this hypothesis, 53 should generate more protons in the 
hydrogenation reactions and give more “abnormal” deuteration.   Comparing entries 1 
with 2, and 4 with 5, for substrate 58 indicates levels of abnormal deuterium 
incorporation (in red) were greater without K2CO3 (indicating acidic conditions favor 
abnormal D-incorporation), and that the N,carbene-catalyst 1 (entries 1 and 2) gave 
significantly less abnormal incorporation than the N,P-catalyst 53 (entries 4 and 5).   
This is consistent with less generation of acid from the hydrogenation reactions 
involving the carbene 1 relative to the N,P-complex 53. 
 
Scheme 4.3.  Rationale for the deuterium scrambling. 
 
Ar
D
+
Ar
D
- H
+
Ar
D
D2
Ar
D
D
D
 
 62 
Table 4.6. Deuteration of styrene derivatives.a 
20 bar D2, 1 mol % Ir*
CH2Cl2, 25 °C,  20 h
alkene alkane
 
 catalyst/ad
ditive 
58
Ar
 59
Ar
 
1 1/ 
 
none 
Ar
D(1.00)
(0.21) D
D (0.97)
D(0.02)
 
Ar
D (0.09)
(1.00)D
D (1.00)
 
2 1/ 
1.0 eq 
K2CO3 
Ar
D (1.00)
(0.11) D
D (0.91)
 
Ar
D (1.00)
(0.99) D
D (0.10)  
3 1/ 
0.015 eq 61 
- 
Ar
D (0.34)
(1.00) D
D (0.92)
 
4 53/ 
 
none 
Ar
D (0.54)
(1.00) D
D (0.52)
D(0.04)
 
Ar
D (0.39)
(0.93)D
D (1.00)
 
5 53/ 
1.0 eq 
K2CO3 
Ar
D (1.00)
(0.62) D
D (0.87)
D(0.04)
 
Ar
D (1.00)
(0.93) D
D (0.41)  
6 3/ 
0.5 eq 
60 
- 
Ar
D (0.80)
(1.00) D
D (0.08)  
a Relative to the maximum, 1.00, with the results of indirect addition shown in red, determined 
by 2H NMR of the crude deuteration products. 
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The same trends observed for deuteration of substrate 58 were seen for 59 except 
that addition of K2CO3 did not significantly change the levels of abnormal deuterium 
incorporation.  However, the levels were decreased when a stronger base, proton sponge 
60, was added to the deuteration mediated by catalyst 53 (compare entry 4 – 6).  
Conversely, when the acid 61 was added instead, the levels of abnormal deuteration 
increased (compare entry 1 - 3). 
 
Ar iPr
50 bar H2, 1.0 mol % Ir*
CH2Cl2, 25 °C,  4 h
> 99% conv.
Ar iPr
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after reaction
62  
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w/ methyl
red
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w/ methyl
red
a b c d
 N,carbene catalyst
control for
acidic
conditions
 t = 4 h
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Figure 4.7.  Hydrogenation with catalyst 1: a methyl red with Et3N in CH2Cl2 (control for base); 
b without indicator (after 4 h); c with methyl red added after 5 min; and, d with methyl red 
added after 4 h. Hydrogenation with catalyst 53: e methyl red with acid 61 in CH2Cl2 (control for 
acid); f without indicator (after 4 h); g with methyl red added after 5 min; and, h with methyl red 
added after 4 h.   
 
Perhaps the most dramatic illustration of pH in the hydrogenation reactions came 
from simple experiments using substrate 62 and the acid-base indicator “methyl red” 
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(orange under basic conditions, and red in acid) (Figure 4.7).  Methyl red was added: (i) 
5 min after the hydrogenation reaction began; and, to another sample, (ii) after the 
reaction was completed (4 h).  Control experiments demonstrate methyl red gives a red 
coloration under acidic conditions in this environment (frame e).  Hydrogenation using 
the carbene catalyst 1 (frames c and d) and the N,P-system 53 (frames g and h) show the 
latter is clearly more acidic.   Frames c and g suggest acidic intermediates formed after 
only 5 min in the reaction. 
We suspect that proton concentrations in hydrogenation reactions are particularly 
important for tetrasubstituted alkenes substrates like 63.157  High levels of abnormal 
deuteration were observed for the catalyst precursors that are most likely to generate 
acid, ie 52 and 53 (Figure 4.8).  Further, carbene 1 did not hydrogenate these same 
tetrasubstituted alkenes.  This could be because of steric factors.  However, if acid was 
generated and the alkene isomerized to a 1,1-disubstituted form then complex 1 should 
reduce this material.   Consequently, it is possible that the carbene complex 1 simply 
generates less acid than 52 and 53, hence the reaction does not proceed in the former 
case. 
 
Ar Ar
(1.00) D
D (0.92)2 mol % 52, 20 bar D2
 
CH2Cl2, 25 °C,  24 h D (0.79)
Ar
(1.00) D
D (0.79)
2 mol % 53
20 bar D2, CH2Cl2, 25 °C,  24 h
D (0.68)
2 mol % 1, 50 bar H2
CH2Cl2, 25 °C,  24 h <5 % conversion
63
 
Figure 4.8.  Abnormal deuterium distributions for the tetrasubstituted alkene 63 were less for the 
catalyst precursor 52 than with 53 whereas minimal conversion was obtained when the carbene 1 
was used. 
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4.4      Conclusions  
The data presented here demonstrated that our Ir-N,carbene catalyst 1 is a highly 
efficient catalyst for the enantioselective hydrogenation of simple unfunctionalized alkyl 
vinyl ethers.  Hydrogenation of substrates 47 and 48 both provide access to the terminal 
fragment S in more complex molecules.  That small motif is common in natural products 
and their analogs; consequently, hydrogenation of these substrates, particularly 48, can 
be regarded as a route to this privileged chiron. 
 
OH ester or alcohol
facilitates
attachment
S  
 
The data presented here also shows that hydrogenations of alkenes using chiral 
analogs of Crabtree’s catalyst can be sensitive to protons generated by the catalytic 
intermediates.  Further, the carbene catalyst precursor 1 is less inclined to generate 
protons than the N,P-systems 52 and 53 (in that order).  We also have shown that the 
acidities of catalytic intermediates in hydrogenation reactions may impact the product 
distributions for acid-sensitive substrates, like enol ethers.  For some other alkenes, acid-
mediated isomerization might compete with direct addition of hydrogen in ways that is 
not apparent until deuterium labeling is used.  Asymmetric hydrogenations of 
tetrasubstituted alkenes, for instance, are especially vulnerable to this complication 
because the direct addition of hydrogen is relatively slow due to steric effects, while 
protonations are fast because they give carbocations that are both benzylic and 
trisubstituted.  It will be interesting to see how acidities of M-H bonds in hydrogenations 
can impact other acid-sensitive substrates.  Acidities of metal hydride intermediates are 
important in many transition metal catalyzed reactions; in some cases, dramatically 
altered catalytic behavior on phosphine-to-carbene ligand substitution will be indicative 
of this. 
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CHAPTER V 
ASYMMETRIC HYDROGENATION APPROACHES TO α-METHYL-γ-
ALKYL γ-AMINO ACIDS 
 
5.1 Introduction  
γ-Amino acids include some important biologically active compounds in the 
central nervous system (CNS) of mammals.  Over the last few years, significant interest 
in the stereoselective synthesis of γ-amino acids has been shown.  Practical application 
of linear and cyclic chiral γ-amino in the synthesis of α,β- and β,γ-hybrid peptides acids 
has also been reported.  These clearly demonstrate the theoretical interest and the 
practical importance of γ-amino acids.158-165 
γ-aminobutyric acid (GABA) 64 is the major inhibitory neurotransmitter in the 
CNS of mammals.  It exerts its physiological action through interaction with three 
receptor subtypes: termed GABAA, GABAB, and GABAC.  The GABAA and GABAC 
receptors are ligand-gated ion channels permeable to anions and convey fast synaptic 
transmission, whereas GABAB is a G-protein coupled receptor, which modulates the 
synaptic transmission through intracellular effector systems.166 
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GABA   64
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H2N
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Cl
 
Figure 5.1. Structures of GABA derivatives that are commercialized drugs.  
 
GABA deficiency is associated with several important neurological disorders 
such as Huntington’s and Parkinson’s disease, epilepsy, and other psychiatric disorders, 
such as anxiety and pain.  However, oral or intravenous administration of GABA is 
inefficient due to its low lipophilicity, and its poor ability to cross the blood–brain 
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barrier (BBB).  Consequently, the synthesis of more lipophilic GABA derivatives that 
have better permeability to the BBB is an area of interest.  Such considerations had also 
led to pharmaceutical compounds (Figure 5.1). 
 
Scheme 5.1. Mn-mediated addition of functionalized iodide to hydrazone. 
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In contrast to α- and β-amino acids, general synthetic methods to supply γ-amino 
acids are comparatively underdeveloped.167,168  Previous strategies for synthesis of α-
methyl-γ-alkyl-γ-amino acids have exploited Pd/C catalyzed hydrogenations,169,170 
alkylation of enolates of N-substituted γ-amino acids171 or pyrrolidinones,172 
regioselective N-tosylaziridine opening,173 asymmetric aldol reaction followed by 
removal of the secondary hydroxy group,174 and zirconium catalyzed diastereoselective 
intramolecular ester transfer reaction of N-alkenylcarbamate derivatives.175  Most of 
these methods provided the desired products with low stereoselectivities.  Also these 
reactions were not very practical in terms of the availability of the starting materials, the 
reaction yields and the difficulty of separation of the desired of diastereoisomer from the 
product mixture.   To the best of our knowledge, the most general methods to date for 
preparing the α-methyl-γ-alkyl γ-amino acids were reported by Friestad, which used the 
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Mn-mediated coupling of functionalized iodides and hydrazones (Scheme 5.1).176,177 
Since both enantiomers of N-amionoxazolidione 68 are commercially available, and also 
both enantiomers of alkyl bromide 69 are conveniently available, so all the four 
diastereoisomers can be obtained via this route.  More importantly, both the α- 
substituents and the γ-substitutents can be easily modified using different aldehydes and 
bromoalcohols in this reaction.  The only drawback for this methodology is that the 
reaction involves the use of excess Mn and In metals; this is undesired for 
pharmaceutical industries. 
 
Scheme 5.2.  An asymmetric hydrogenation route to α-methyl-γ-alkyl amino acids. 
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Inspired by successful syntheses of 1,3-dimethyl chirons and 1,3-hydroxymethyl 
chirons, we realized new ground could be broken not only by being able to synthesize 
this important chirons via our iridium catalyzed asymmetric hydrogenations but also 
being able to incorporate pharmacologically active side-chains (not just Me, Et, etc).  
Stereoselectivities in reductions of substrates 74 could derive from the catalyst, and from 
the substrate.  Largely inconsequential groups like the protecting groups P and FG can 
be varied to increase “substrate vectors” to enhance stereoselectivities in the desired 
direction (Scheme 5.2; both hands of the catalyst are available). 
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The hydrogenated products have somewhat more conformational constraints than 
compounds like GABA, Preggabalin and Vigabattrin because of the presence of the 
methyl group; this is useful because stereochemistries can then be varied to access 
preferred binding conformations.  Amino acid derived side chains R will be selected 
from those presented above.  An iso-leucine side chain is desirable because the chiral 
center in this provides an indicator for racemization at any stage in the procedure.  The 
phenylalanine, glutamine, and valine side-chains are found in some pharmaceutically 
active α-alkyl-γ-alkyl-γ-amino acids that we have found in the literature (Figure 5.2).  
Side chains from tryptophan and tyrosine are included because these are two of the most 
common side-chains found at “hot-spots” for protein-protein interactions and are known 
to be interesting pharmacophores.178 
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Figure 5.2.  Examples of pharmaceutically active α-methyl-γ-alkyl-γ-amino acids. 
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5.2 Results and discussions  
5.2.1    Hydrogenation studies 
Dr. Amber Schaefer, who is a postdoc researcher in our group, initiated this 
research project.  Starting from various protected amino acids 76, Weinreb amides 77 
can be obtained with high yields in one step.179  The amides 77 was reduced to aldehyde 
with LAH at 0 oC, and without purification the aldehydes were directly converted to the 
alkenes 78 under the standard Wittig conditions.  Thus enantiomeric pure allylic amines 
78 can be obtained in three steps with high yields (Scheme 5.3). 
 
Scheme 5.3. Synthesis of chiral allylic amines. 
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R
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O
R
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(i) HOBt, EDC
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N
MeO (i) LAH, Et2O
0 oC, 1 h
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(ii)
CH2Cl2, 25 
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76 77 78  85-90%
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With these alkene substrates in hand, Dr. Schaefer tried several hydrogenation 
reactions with our Ir-N,carbene catalyst 1, and the results are shown in  Figure 5.3.  As 
can be seen here, four amino acids with different side chains and four different 
protecting groups for the amine have been used.   However, none of these alkene 
substrates gave satisfactory results and the diastereoselectivities for these reactions are 
poor.     
Even though the preliminary results from Dr. Schaefer did not show good 
diastereoselectivities in the hydrogenation reactions, some lessons can be learned from 
those studies.  First, most of the substrates she tried can be hydrogenated well with 
catalyst 1.  The protected amine will not poison the catalyst.  Second, all the substrates 
that have been tried are α,β-unsaturated esters.  It occurred to us that this type of alkenes 
might not be suited to hydrogenation in terms of diastereoselectivity.  Last, Dr. Schaefer 
had tried several different alkene substrates with four different side chains.  She found 
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the stereoselectivities for those substrates were similar.  My role in this project was to 
identify a suitable substrate class for both syn- and anti-diastereoisomers. 
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Figure 5.3.  Preliminary results for the hydrogenation of chiral allylic amines. 
 
Our 1,3-hydroxymethyl chirons synthesis project found that good 
diastereoselectivities for syn and anti terminal isomers can be achieved in the 
hydrogenation of substrates 14 and 18.  Allylic amines 79 and 80 are structurally similar, 
so we hypothesized they might provide better stereoselectivities than those substrates 
tried by Dr. Schaefer. 
TBDPSO
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OTBDPS
18
TBDPSNH
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Starting from alkene 78a, the DIBAL reduction afforded the allylic alcohol 81 
with 88% yield.  Protecting the hydroxy group with TBDPSCl and removing the Boc 
protecting group afforded alkene 82 and 83.  Staring from the same intermediate 81, the 
amino alcohol 84 can be synthesized.  Without further purification, 84 was treated with 
1.1 eq. TBDPSCl and after 1 h a mixture of two different allylic amines were obtained.  
Interestingly, the amino protected product 85 was the major product  (Scheme 5.4). 
 
Scheme 5.4. Syntheses of modified chiral allylic amines. 
 
NHBoc
CO2Me
DIBAL-H, CH2Cl2
-30 oC, 2 h
NHBoc
OH
78a
NHBoc
OP
82  93%81  88%
TBDPSCl
imidazole
CH2Cl2
25 oC, 1 h
TFA, CH2Cl2
25 oC, 3 h
NH2
OP
83  68%
TFA, CH2Cl2
25 oC, 3 h
NH2
OH
TBDPSCl
imidazole
CH2Cl2
25 oC, 1 h
NHTBDPS
OH
NH2
OTBDPS
85  75%
83  25%
P= TBDPS
84
 
 
With these allylic amines in hand, a series of hydrogenations were undertaken.   
Changing the functional group from ester to allylic alcohol did not improve the 
diastereoselectivity dramatically (compare 78a to 81, Figure 5.4).   However, protecting 
the free hydroxy group of 81 with a bulky TBDPS protecting group significantly 
improved the diastereoselectivity when the (S)-1 was used (alkene 82).  The alkene 83, 
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which originally was thought to give a good diastereoselectivity for the anti-isomer, was 
not hydrogenated at all under the general hydrogenation conditions.  Adding base did not 
improve the conversion.  This is not very surprising because the strong coordinating 
ability of the free amine might kill the catalyst during the catalytic cycles.  On the 
contrary, the alkene 85, which was thought to be a good substrate for the syn-isomer, did 
provide an excellent diastereoselectivity when the (S)-1 was used (dr >19:1.0).  
However, the highest conversion was only 60% when 1 mol% catalyst was used.  
Elevated hydrogen pressure (100 bar) and reaction temperature (60 oC) did not improve 
the conversion.  When 5 mol% of (S)-1 was used, 100% conversion was obtained and 
the stereoselectivity was still very good (dr >19:1.0) (Figure 5.4). 
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Figure 5.4. Hydrogenation results for the first cycle of modified chiral allylic amines. 
 
 
Considering the diastereoselectivity improvement from 81 to 82, we realized that 
a bulky hydroxy protecting group would be beneficial for the reaction.  Thus we did not 
change anything about this part in subsequent substrate structure modifications.  Based 
on the Rh catalyzed hydrogenation of enamide reactions, we thought the carbonyl from 
the Boc protecting group might be a directing functional group for the hydrogenations.  
However, the bulky tert-butyl group possibly would hamper this coordination.  As a 
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consequence, we became interested in smaller protecting groups than Boc that also has a 
coordinating carbonyl group, e.g. CF3CO-, CH3CO-, HCO- (Scheme 5.5). 
 
Scheme 5.5. Syntheses of modified chiral allylic amines 86-88. 
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The hydrogenation results of the newly synthesized alkene substrates supported 
our hypothesis.  Hydrogenation of alkene 86 provided an excellent stereoselectivity 
when (S)-1 was used, although 4 mol% catalyst was needed for 100% conversion.  
When the amine-protecting group was changed to CH3CO- (alkene 88), high 
diastereoselectivity was obtained and catalyst loading was also reduced to 2 mol%.  For 
the alkene 87, the stereoselectivity was not very good for both enantiomers of the 
catalyst.  Since the alkene 87 was a mixture of the amide rotamers, it is not very 
surprising that the diastereoselectivity was moderate (Figure 5.5). 
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Figure 5.5. Hydrogenation results for the second cycle of modified chiral allylic amines. 
 
 
Despite all kinds of efforts, all the previous hydrogenations afforded the 1,3-syn 
isomers as the major isomer for the α-methyl-γ-alkyl-γ-amino acids.  However, our 
previous experience for the hydrogenation reactions indicated the 1,3-anti isomers might  
 
Scheme 5.6. Syntheses of Z-chiral allylic amines. 
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accessable by changing the geometry of the alkenes.  Thus starting from intermediate 77, 
the Z-allylic amine 91 was synthesized in 6 steps with a 36% yield (Scheme 5.6).  In the 
 76 
event the hydrogenation of 91 provided the 1,3-anti isomer with an excellent 
diastereoselectivity when the (S)-1 was used (reaction 5.4).  
 
50 bar H2,  2 mol% 1
CH2Cl2, 25
 oC, 24 h
NHCOCH3
(5.4)
OTBDPS
100% conv.
(S)-1 >19:1.0
(R)-1 2.3:1.0
1,3-anti
NHCOCH3
TBDPSO
91
 
 
 
5.2.2 Relative and absolute configuration determination 
All the chiral allylic amines were synthesized from natural amino acids.  Hence 
the absolute stereochemistries are governed by the chirality from the starting materials.  
Alcohol 92 was a known compound with reported 1H NMR.180 By comparing the 1H 
NMR, we can tell that the hydrogenation product of 81 has the same relative 
stereochemistry as 92.  Further, from the hydrogenation product of 81, enantiomeric 
enriched compound 93-96 can be obtained in one or several steps.  By comparing the 1H 
NMR of these compounds with our hydrogenation products, all the relative and absolute 
stereochemistries of the hydrogenation products were determined.  
 
NHBoc
OH
NHBoc
OTBDPS
NHTBDPS
OH
9492 93  
NHCOCF3
OTBDPS
NHCOCH3
OTBDPS
95 96  
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5.3 Conclusions 
In summary, we have developed a new entry to α-methyl-γ-alkyl γ-amino acids 
via iridium catalyzed asymmetric hydrogenation of chiral allylic amines.  Both anti- and 
syn-isomers can be obtained with high diastereoisomeric purities.  The study shown here 
only demonstrated the development progress for the successful production of the allylic 
amines from phenylalanine.  However, based on these studies, other allylic amines that 
have different side chains should also be suitable substrates for the hydrogenations.  
Considering the importance the γ-amino acids, we are looking forward to seeing some 
applications of this stereoselective and environmentally benign method. 
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CHAPTER VI 
HIGHLY DIASTEREOSELECTIVE ROUTES TO α-METHYL-β-HYDROXYL-
γ-METHYL CHIRONS VIA IRIDIUM CATALYZED ASYMMETRIC 
HYDROGENATIONS 
 
6.1 Introduction  
The stereochemical complexity of polyketides presents formidable challenges for 
organic chemists.181-183 After the epochal total synthesis of erythromycin A (Figure 6.1) 
by Woodward, this inherent complexity has captured the imagination of synthetic 
chemists and the concise assembly of such complex system has been a key driver for the 
O
O O
O
OH
HO
OH
O
O
O
HO
OH
OMe
NMe2
erythromycin A
O
O
5
OH
OH
O
OH
OH
OHOMe
HO
OH
etnangien
O
O
(-)-invictolide
O O
OH
OH
HO
OH
dictyostatin
 
Figure 6.1. Polypropionate fragments in polyketide natural products. 
 
development of new methodologies.  A key structural feature in erythromycin A and 
polyketides in general, such as the macrolide antibiotics dictyostatin or etnangien, are 
the polypropionate fragments.  They are characterized by sequences of methyl-, 
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hydroxy-, and methyl- bearing stereogenic centers, enabling large numbers of possible 
stereochemical permutations.  Biosynthetically, these are derived by iterative 
condensations of propionyl subunits and subsequent reduction of the derived β-keto 
esters.  
 
OH
T  syn,syn
OH
U  syn,anti
OH
V  anti,syn
OH
W anti,anti  
 
Mimicking this biosynthetic pathway, aldol reactions between enolates derived 
from ethyl ketones and α-methylaldehyde are a conventional method for constructing 
such stereotriads.184-188  The reactions of crotylmetal reagents with α-methylaldehyde are 
an important alternative to aldol reactions and have been successfully used for the same 
purpose.189-192  In 1987, R. W. Hoffmann surveyed methodology under development for 
the synthesis of so-called stereotriads T-W.193  From that review, it was clear that many 
methods have been developed for the stereoselective synthesis of triads T-W.  However, 
of the four, W is the most difficult one to access by that time.  Also there has been no 
single strategy that allows the synthesis of all four triads with equal efficiency and 
stereoselectivity.  
 
Scheme 6.1. Aldol-type chirons from asymmetric hydrogenations of trisubstituted alkenes. 
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We have previously shown that iridium catalyzed asymmetric hydrogenations 
can provide aldol-type chirons with high conversions.99  These reactions are catalytic, 
high stereoselective, and afford both syn- and anti-aldol products (Scheme 6.1).  
Looking forward, we are interested in developing hydrogenations of trisubstituted 
alkenes to access stereochemical triads and higher homologs based on similar strategies.  
Specifically, starting from a suitable hydrogenation substrates, by choosing the right 
enantiomer of the catalyst and varying the protecting group on the hydroxy group, a 
good diastereoselectivity should be able to be obtained.  We are very ambitious on this 
research project and hoping we can obtain all the possible diastereoisomers T-W 
(Scheme 6.2).  
 
Scheme 6.2. Synthetic plans for the syntheses of stereotriads T-W. 
protecting group P also varied for optimization of stereoselectivity
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6.2 Results and discussions 
6.2.1 Syntheses of the hydrogenation substrates  
Syntheses of substrates to prepare the stereotriads T-W began with Roche ester.  
The key intermediate enone 97 can be made in three steps with high yield.  DIBAL-H  
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Scheme 6.3. Routes to alkene substrates for syntheses of triad T-W.  
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reduction of 97 at -78 oC afforded the key hydrogenation substrate 98 with 88% isolated 
yield.194  The newly generated hydroxy group had an anti relationship with the pre-
existing chiral methyl group.  The syn- to anti-diastereoisomer ratio for the crude 
product was 14:1.0, which can further increased to >99% de after purification with flash 
chromatography.  The preference for the anti-isomer in this reduction was presumably 
due to preferential reduction through a Felkin-Ann transition state.195  Deprotection of 
the silyl protecting group with TBAF at 25 oC provided another key hydrogenation 
substrate 99 with 92% yield (Scheme 6.3). 
In contrast, a near exclusive generation of the syn1,2-hydroxy, methyl isomer 
was observed when the free alcohol 100 was reduced under the reduction conditions 
exploited by Evans and co-workers.196 Thus, treatment of 100 with 
tetramethylammonium triacetoxyborohydride under the tailored reaction conditions that 
ensure hydroxyl exchange with the triacetoxyborohydride and subsequent intramolecular 
hydride delivery to the proximal carbonyl provided the desired syn-isomer 101 (85%, 
>19:1.0 syn:anti).  The diastereoisomer ratio can also be improved via the flash 
chromatography (>99% de).  With this intermediate, the alkene 102 and 103 can be 
easily synthesized via selective functional group protecting (Scheme 6.3). 
 
6.2.2 Syntheses of the stereotriad T-W via asymmetric hydrogenations 
Through the iridium catalyzed asymmetric diastereoselective hydrogenations, we 
were delighted to see that all the four diastereoisomers T-W can be obtained with high 
yields and diastereoisomer purities.  Hydrogenation of alkene 98 with (S)-Cat afforded 
the most challenging triad W with 84% isolated yield.  The syn to anti ratio for the crude 
product was 1.0:48, which was high enough for other possible homologations.  
Hydrogenation of alkene 99 with (R)-Cat afforded another triad V with 100% 
conversion.  The syn to anti ratio for the crude product was 21:1.0.  To help to remove 
the minor anti-isomer, the hydrogenation product diol was converted to an acetonide 
protected ketal, and the resulting triad V can be purified easily via flash chromatography, 
providing the triad V with 91% yield and >99% de (Figure 6.2). 
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Figure 6.2. Preparation of stereotriad T-W.  All ratios quoted are from chiral HPLC. 
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Figure 6.2. Continued. 
 
Very similarly, hydrogenation of alkene 102 with (S)-Cat afforded triad T with 
90% isolated yield.  The diastereoselectivity for this reaction was extremely high and 
only the syn-isomer was found in the crude hydrogenation product.  Hydrogenation of 
alkene 103 with (R)-Cat afforded triad U with 100% conversion.  The syn to anti ratio 
for the crude product was 1.0:18.  To help to remove the minor syn-isomer, the 
hydrogenation product acetate was reduced to an allylic alcohol, and the resulting triad 
U can be purified easily via flash chromatography, providing the triad U with 83% yield 
and >99% de (Figure 6.2). 
Throughout this study, all the hydrogenation reactions shown here were catalyst 
controlled, but “substrate vectors” (contributions to the diastereoselectivity by the 
substrate) were also significant.  The data shown here once again demonstrated that our 
chiral analog of Crabtree’s catalyst is almost uniquely suitable for asymmetric 
hydrogenation of coordinating unfunctionalized, trisubstituted alkenes. In most cases 
Cat usually can give catalyst control for hydrogenations of chiral alkenes.  
Hydrogenations of these relatively hindered substrates typically would not be induced at 
a significant rate using metal diphosphine complexes. Metal diphosphine complexes 
only hydrogenate these substrates well if there is a coordinating functional group, in 
which case substrate control is usually observed. 
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6.2.3 Relative and absolute configuration determination 
All the alkene substrates were made from enantiomer enriched (R)-Roche ester 
(98% ee).  So the absolute stereochemistry was determined by the chirality from the 
starting material.  Hydrogenation of 98 with (S)-Cat provided the triad 104 with high 
diastereoselectivity (syn:anti, dr 1.0:48) (Figure 6.2.a).  Starting from 104, an acetonide 
derivative 108 can be synthesized in two steps (Reaction 6.1).  108 was a known 
compound with reported 1H NMR and 13C NMR.197  Thus 104, the hydrogenation 
product of 98, was determined to be an anti,anti stereotriad W.  Hydrogenation of 99 
with (R)-Cat provided the triad 105 with high diastereoselectivity (syn:anti, dr 21:1.0) 
(Figure 6.2.b).  The isolated product 105 was also a known compound with reported 1H 
NMR and 13C NMR data.197  Hence 105 was determined to the the anti,syn stereotriad V 
undoubtedly. 
TBDPSO
OH
OBn
104
(i) TBAF, THF, 25 oC, 1 h
(ii) TsOH H2O, (MeO)2CMe2
CH2Cl2, 25 
oC, 1 h
O
OBn
O
108
(6.1)
 
 
Hydrogenation of 102 with (S)-Cat provided the triad 106 with high 
diastereoselectivity (syn:anti, dr >99:1.0) (Figure 6.2.c).  Starting from 106, the diol 109 
can be synthesized in one step (Reaction 6.2).  109 was a known compound with 
reported 1H NMR and 13C NMR data.198  Thus 106, the hydrogenation product of 102, 
was determined to be an syn,syn stereotriad T.  Hydrogenation of 103 with (R)-Cat 
provided the triad 107 with high diastereoselectivity (syn:anti, dr 1.0:18) (Figure 6.2.d).  
The 1H NMR and 13C NMR of the isolated product 107 was compared carefully with 
those of 106.197  Hence 107 was determined to the the syn,anti stereotriad U certainly. 
 
TBDPSO
OH
OBn
106
(i) TBAF, THF, 25 oC, 1 h
OH
OBn
OH
109
(6.2)
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6.2.4 Total syntheses of (-)-invictolide 
(-)-Invictolide was first isolated from the red imported fire ant queens as a queen 
recognition pheromone and its relative stereochemistry was proposed by Tumlinson and 
co-workers based on spectroscopic analysis and synthesis.199 The absolute 
stereochemistry of natural (-)-invictolide was established to have (3R, 5R, 6S, 1'R)-
configuration by Mori and co-worker in 1986,200 and both the levorotatory and the 
racemic forms of invictolide exhibit pheromone activity.199  Owing to its’ interesting 
structural feature having the δ-lactone moiety with four chiral centers and also to the 
biological activity, several syntheses have been appeared in the literature.199,201-205  
 
O
O
(-)-Invictolide
1
2
3
4 5
6
1'
 
 
Our group has been using chiral analogs of Crabtree’s catalyst in syntheses of 
some pivotal chirons for preparations of natural products, particularly in the polyketide 
series.  With the previous developed methodologies for the stereotriad synthesis, we 
were very interested in the stereoselective synthesis of (-)-invictolide.  In searching the 
structure of (-)-invictolide for retrosynthetic disconnections, we thought that the most 
straightforward way to achieve this goal was an exploitation of the triad V as a starting 
material, readily obtained from asymmetric hydrogenation.  The 3R-methyl group should 
also be able to be introduced with high selectivity by using the asymmetric 
hydrogenation methodology developed previously in our group28,77 (Scheme 6.4). 
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Scheme 6.4.  Retrosynthesis of (-)-invictolide. 
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Thus, the triad 105, readily accessible from hydrogenation of alkene 99, was 
subjected to the benzyl protecting group removal, Parikh-Doering oxidation,206 Wittig 
olefination to give the desired alkene 111 in 69% yield for three steps.  Reduction of 111 
and subsequent deprotection of the acetonide protecting group resulted diol 112 in 80% 
yield.  Treated with excess TBSCl generated the silyl ether 113 in 97% yield.  Highly 
selective removal of the primary hydroxy silyl protecting group of 113 on exposure to 
10% TsOH provided 114 in 86% yield.  The alcohol was subjected to Parikh-Doering 
oxidation,206 Wittig olefination again and gave the key alkene 115 in 96% yield for two 
steps.  Finally, (S)-Cat catalyzed asymmetric hydrogenation followed by silyl protecting 
group removal and simultaneous δ-lactone formation gave (-)-invictolide as a colorless 
oil in 90% yield for three steps (Scheme 6.5). 
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Scheme 6.5.  Total synthesis of (-)-invictolide. 
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 6.3 Conclusions 
 Once again, this chapter demonstrated several very important issues throughout 
the whole period of our asymmetric hydrogenation researches.  First, constructive 
matching of chiral Crabtree’s catalyst analogs with stereochemical vectors from 
substrates can afford high diastereoselectivities, even in cases where Ir- or Rh-
diphosphine complexes would probably give poor conversions and/or selectivities. 
Chiral analogs of Crabtree’s catalyst are almost uniquely suitable for asymmetric 
hydrogenation of coordinating unfunctionalized, trisubstituted alkenes.  In most cases 
our catalyst usually can give catalyst control for hydrogenations of chiral alkenes.  On 
the contrary, metal diphosphine complexes only hydrogenate these substrates well if 
there is a coordinating functional group, in which case substrate control is usually 
observed.  By choosing the right enantiomer of the catalyst and modifying the protecting 
group on the hydrogenation substrates, we are able to synthesize all the four stereotriads 
T-W with high diastereoselectivities and yields.  Mechanistic complementarities enabled 
all eight stereoisomers of the ubiquitous chiral methyl, hydroxy, methyl fragments to be 
made.  Compared to other traditional methods for synthesis of this type of chirons, 
methodologies shown here clearly demonstrate their high advantages in terms of 
economic efficiency, product universality, and environmental friendliness.   
Using the newly developed methodology, (-)-invictolide was synthesized 
efficiently.  Two key hydrogenation reactions have been applied to generate two chiral 
centers in the molecule.  This not only demonstrated that this new methodology is highly 
practical, but also proved that our previous developed methodology can be used in much 
more complex system.  To the best of our knowledge, this is the first catalytic method 
that can give all the diastereoisomers of stereotriads T-W with high stereoselectivities.   
We are looking forward to seeing the wide application of this methodology in future. 
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CHAPTER VII 
CONCLUSIONS AND OUTLOOK 
  
7.1 Conclusions 
7.1.1 New methodologies for the syntheses of privileged chirons 
Asymmetric hydrogenations of functionalized, but not coordinatively 
functionalized, alkenes have been used to prepare several chirons for syntheses of 
polyketide natural products using our N-carbene Crabtree’s catalyst analog (Figure 7.1).  
Most alkene substrates were made from optically active starting materials (eg Roche 
ester, lactic acid, glyceraldehyde dimethyl ketal) and the products were optically pure.  
High stereoselectivities generally were obtained, even before chromatography; this was 
possible by matching the stereochemical preference of the catalyst with that of the 
substrate (we call these “catalyst- and substrate-vectors”); the catalyst vector is nearly 
always dominant, but the substrate vector has influence.  Substrate vectors can be 
optimized by manipulating: (i) the functional group on the alkene (eg ester, 
hydroxymethyl, and alkoxymethyl); (ii) protecting groups; and, (iii) alkene geometry. 
Using chiral substrates that allow for these modifications via a rational approach has 
almost always enabled us to develop highly stereoselective reactions. 
Through our studies, we have shown that chiral analogs of Crabtree’s catalyst are 
almost uniquely suitable for asymmetric hydrogenation of coordinating 
unfunctionalized, trisubstituted alkenes.  Metal diphosphine complexes can only 
hydrogenate these substrates well if there is a coordinating functional group, in which 
case substrate control is usually observed.  We have successfully demonstrated the 
importance of chiral analogues of Crabtree’s catalyst in acyclic stereocontrolled 
diastereoselective hydrogenations.  Compared to other traditional methods for synthesis 
of these important chirons, methodologies shown here clearly demonstrate their high 
advantages in terms of economic efficiency, product universality, and environmental 
friendliness. 
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Figure 7.1. Chirons prepared via stereoselective hydrogenation. 
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The pivotal chirons shown in Figure 7.1 could be cornerstones of many 
convergent asymmetric syntheses.  Figure 7.2 depicts some natural products prepared so 
far to illustrate our hydrogenation approach to polyketide-derived natural products.  
Exercises like this clearly demonstrated to the natural products syntheses community 
that the methodology is practical.  
O
Oputative beetle pheromone
Org. Lett., 2007, 9, 1391
OH
iPr
O
O
(-)-dihydromyoporone
J. Am. Chem. Soc., 2008, 130, 8894
O
N
O
Ph
O
(-)-spongidepsin
Org. Lett., 2010, 12, 4392
(-)-invictolide
submitted
 
Figure 7.2. Some natural products prepared via hydrogenation reactions. 
  
   
7.1.2 Acidities of metal hydrides in catalysis 
H
Ir
H
C
H
N
+
HR
1
R3
Ph
R2
V
X  
The mechanism(s) of action of chiral Crabtree’s catalyst (or chiral analogs) has 
not been experimentally proven.  However, we24,27-29 and others30 used high level DFT 
calculations to study the hydrogenations by chiral Crabtree catalyst analogs, and reached 
very similar conclusions.  Basically, the metal undergoes not one but two oxidative 
additions of hydrogen oxidizing the Ir(1+) to a seven-coordinate Ir(5+) tetrahydride X 
(“C” here denotes carbene ligand) before rate limiting transfer of hydrogen to the 
coordinated alkene.  This explains why only Crabtree’s catalyst, and not Wilkinson’s, 
 93 
hydrogenates tri- and tetra-substituted alkenes at a significant rate: the metal center is 
more electrophilic {Ir(5+) vs Rh(3+)} and less hindered {the iridium is seven-coordinate 
and the four hydride ligands are small}.   This also explains the insensitivity of the 
iridium system to air and to oxidizing solvent, since Ir(3+) and Ir(5+) tend to be more 
stable than Ir(1+) both to air and to oxidants in general.  
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Figure 7.3. Ir-hydride intermediates in catalytic hydrogenations have markedly different 
acidities. 
  
While hydrogenating enol ether substrates, we realized that protons were being 
generated in the catalytic process.  Based on our proposed mechanism, we hypothesized 
that this was due to dissociation of a Ir(5+)-H bond to give Ir(3+) and a proton.47  
Further we suggested this is more prevalent for N,P-complexes than for N,carbene-
systems, for the reasons shown in Figure 7.3.  DFT calculations confirmed this, and 
estimated the difference for the key (ligand)Ir(5+)H4(alkene) X catalytic intermediates to 
be  stunning 7 pKa units.27  This accounts for several observations about the N,carbene-
system relative to N,P-catalysts, ie it is: (i) less likely to decompose acid-sensitive 
alkenes; (ii) less likely to cause acid-mediated double bond migration before 
hydrogenation (as shown via deuteration experiments); (iii) unable to hydrogenate 
tetrasubstituted alkenes, whereas N,P-catalysts are, probably because of issue (ii); and, 
(iv) unable to initiate a red-response in the acid-base indicator methyl red, whereas 
hydrogenations using the N,P-catalysts do this. These observations indicate the Ir 
carbene catalyst may be well suited to acid sensitive substrates. 
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7.2 Outlook 
7.2.1 Syntheses of other important chirons via asymmetric hydrogenations 
 Many polyketide-derived natural products contain acyclic 1,3-diol fragments.  
Existing methods for obtaining them207 are dominated by hydride reductions of 
carbonyls,208-210 hence our proposal to form the chiral centers via hydrogenation methods 
is interesting for its complementary chemoselectivity.  This work also further explores 
our recent findings that hydrogenations with N,P-Ir complexes generate acidic solutions, 
whereas our N,carbene-catalyst and hydrogen gives significantly less acidic solutions 
(by about 7 pKa units).27  For this reason, the carbene catalyst is more appropriate for 
enol ethers, 47 because N,P-Ir catalyst/H2 cause decomposition of these substrates. 
 
Scheme 7.1. Planned synthesis route to 1,3-diol and 1,3,5,…n-polyol chirons.  
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In preliminary studies, enol ether 117 was generated with high E-stereoselectivity 
(only one isomer observed by 1H NMR) via a known method.211  This was hydrogenated 
to the ether 118 with high stereoselectivity.  If it were critical to begin the synthesis with 
maximal optically purities, then similar substrates could be obtained via Noyori 
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reduction of β-ketoesters.212-214  Reduction of the ester functionality to an aldehyde, then 
homologation via Corey/Fuchs 215,216 gives an alkyne 119 to begin the iterative process 
as indicated.  We have tested the addition of several alcohols to alkynes via the PMe3 
mediated reaction, and they all worked.  Consequently, it would be easy to vary the 
alcohol protecting group in these schemes to maximize substrate vectors in the key 
asymmetric hydrogenation steps (Scheme 7.1). 
By analogy with the plans for skipped polyols Y, amino acid starting materials 
could be used to produce 1,3-amino alcohols.  To do this we propose to modify 
Seebach’s Arndt-Eistert approach to homologating amino acids,217 by using a thiol to 
quench the ketene intermediate.  This allows facile reduction of the thioesters 120 under 
mild conditions.218,219  Homologation of these substrates would be achieved in much the 
same way as above (Scheme 7.2). 
 
 Scheme 7.2. Planned synthesis route to 1,3-amino alcohol chirons. 
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Amino alcohols are common fragments in pharmaceuticals.168,209,210,220-234  The 
broader impact would be the methodology to obtain these fragments from a selection of 
amino acids.  Amino acid side-chains are excellent pharmacophores, all protein-protein 
interactions rely on them,235 so methods that allow diversification in medicinal chemistry 
beyond simple alkyl chains have merit. 
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Previously I have developed a good methodology for synthesis of 1,3-
hydroxymethyl chirons via iridium catalyzed asymmetric hydrogenations.  Through this 
route chiron A and B can be obtained with high yields and diastereoisomer purities 
(Figure 2.3).236  In this type of chirons, the chiral methyl substituent is directly connected 
with the functional groups.  Sometimes this will bring some extra steps for further 
homologations.  Actually literature searching has identified many natural products 
containing the 1,3-hydroxymethyl chirons like A’ and B’ that have one extra carbon 
between the methyl chiral center and the functional group (Figure 7.4).  Hence an 
alternative method for synthesis of the new type of 1,3-hydroxymethyl chirons is 
needed. 
 
O
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O
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Figure 7.4. Examples of natural products that contain the new type of 1,3-hydroxymethyl 
fragments A’ and B’. 
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Preliminary experiments indicate the acetate 124 is a good substrate for the 
hydrogenation.  Based on this result, I hypothesize that alkene 125 would be a very good 
substrate for the synthesis of the desired new type of 1,3-hydroxymethyl chirons.  By 
introducing a chiral acetate functional group, excellent diastereoselectivity is expected 
for the match case (Figure 7.5). 
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Figure 7.5. Proposed routes to the synthesis of new type of 1,3-hydroxymethyl chirons. 
 
The hydrogenation substrates shown above can be easily synthesized through 
titanium catalyzed asymmetric allylation reactions followed by cross metathesis 
reactions101.  The R- group can be alkyl, aromatic, heteroaromatic groups and protected 
alcohol can be tolerated in the reaction.  Generally, high yields and very good 
enantioselectivities can be obtained.237  The alcohol protecting group can be easily 
modified at the late stage, which can greatly facilitate the diastereoselectivity 
optimization process (Figure 7.6).  
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Figure 7.6. Alkene substrates synthesis for the new type of 1,3-hydroxymethyl chirons. 
 
 
The importance of enantiopure 1,2-amino alcohols in asymmetric synthesis is 
evident from their successful application as stereochemical control elements.238,239  
Chiral β-amino alcohols are also versatile synthons for the preparation of a wide range 
of biologically active natural and synthetic products such as unnatural amino acids239,240 
(Figure 7.7).  Recently, a series of chemical compounds containing the 1,2-amino 
alcohol fragments have been approved as HIV-1 protease inhibitors by FDA.241  
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Figure 7.7. Examples of natural products conatining 1,2-amino alcohol fragments. 
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Figure 7.8. Synthesis of 1,2-amino alcohols via iridium catalyzed hydrogenations. 
 
Figure 7.8 illustrates a route proposed to synthesize the chiral β-amino alcohols. 
The optical active propargylic alcohol can be synthesized from commercial available 
propane-1,3-diol in five step (54% overall yield, 97% ee).242  The alcohol 126 was 
treated with tosyl isocyanate in the presence of a catalytic amount of CuI and Et3N 
(THF, reflux) to produce the N-tosyl-4-(alkylidene)oxazolidin-2-one 127 (92%) as a 
single geometric isomer.243,244  By choosing the right enantiomer of the iridium catalyst 
and varying the protecting groups on both hydroxy groups, good diastereoselectivities 
for syn- and anti-isomers might be able to be achieved during the hydrogenation 
reactions.  After hydrolysis, the chiral β-amino alcohols could be obtained readily.  
Figure 7.9 shows an alternative approach to the chiral β-amino alcohols.  The 
optical active propargylic alcohol 128 can be synthesized from commercial available an 
alkyl propiolate and an alkyl aldehyde in one step.245,246  Treating the chiral alcohol 128 
with benzylamine at room temperature directly afforded the optically active 4-amion-
2(5H)-furanones 129 without any racemization.247  This is an interesting substrate for 
hydrogenation, which can directly provide 1,2-amino alcohol chirons.  Further, acyclic 
alkene substrates could also be obtained easily in one or two steps, which provides more 
chance to succeed in achieving good diastereoselectivities in the hydrogenation 
reactions.  
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Figure 7.9. Alternative route for synthesis of 1,2-amino alcohols via iridium catalyzed 
hydrogenations. 
 
 
7.2.2 Natural products total syntheses 
 During my Ph.D studies at Dr. Burgess’s group, our group has developed many 
good methodologies for the syntheses of highly important chiral building blocks.  My 
previous total synthesis for (-)-invictolide begins and ends with our hydrogenation 
methodology.  A similar approach could be applied to make alcohol 130, used in 
syntheses of the metabolite (+)-bourgeanic acid.248-250 This alternative target also 
contains 1,3-dimethyl/anti,syn-triad motifs.  10-Deoxymethynolide251-254 will be made as 
well as (-)-invictolide or (+)-bourgeanic acid since it contains three chiral fragments that 
can be made via our hydrogenation approach.  Fragments 131 and 132 will be joined via 
ester-formation then ring-closing metathesis.101 
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7.2.3 Stereo convergent synthesis of hydrogenation substrates  
An aspiration for hydrogenation methodology is practicality.  This depends on 
ease of access to the hydrogenation starting materials.  During our previous 
hydrogenation studies, most of our alkene substrates are synthesized through Wittig 
reactions between an aldehyde and a Wittig reagent.  Even though very good 
stereoselectivities for the double bond formation reactions (E/Z selectivity) can be 
achieved in these reactions, long reaction steps are always required due to some 
functional group modifications and protections.  As a consequence, developing facile 
and stereoselective ways to the syntheses of variety of alkene substrates will be very 
important since this can greatly improve the practicality of the developed hydrogenation 
methodology. 
In the previous synthesis of stereotriads T-W, the preparation of alkene 
substrates used to take 4-6 chemical transformations.  Hence even the hydrogenation 
reactions provided very good yields and diastereoselectivities, the whole process is not 
very efficient considering the long steps for preparing the starting materials. 
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Figure 7.10. New routes for synthesis hydrogenation substrates. 
 
Figure 7.10 illustrates one more direct and general methodology possible for 
preparation of many alkenes required in our hydrogenation work; this would produce 
optically active substrates with defined double bond geometries in two steps.  The idea 
arose from a recent publication from Pu’s group.  A novel H8BINOL-based chiral ligand 
(S)-133 was found to catalyzed the alkyl propionate addition to aliphatic aldehydes in 
the presence of ZnEt2 and Ti(OiPr)4 at room temperature with excellent 
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enantioselectivity.246 If the same reaction conditions are applied to a chiral aldehyde, a 
good diastereoselectivity should also be able to be obtained by varying the protecting 
group ‘PG’.  Thus, the key γ-hydroxy-α,β-acetylenic ester 134 could be obtained easily 
in one step.  Subsequent methylcupration of 134 in the proper reaction conditions, both 
the E-255 and Z-allylic alcohols256 can be obtained with high purity. 
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APPENDIX A 
GENERAL EXPERIMENTAL PROCEDURES 
  
General Experimental Methods 
All reactions were carried out under an atmosphere of dry nitrogen. Glasswares were 
oven-dried prior to use.  Unless otherwise indicated, common reagents or materials were 
obtained from commercial source and used without further purification. All the solvents 
were used after appropriate distillation or purification. 
  
Flash column chromatography was performed using silica gel 60 (230-400 mesh). 
Analytical thin layer chromatography (TLC) was carried out on Merck silica gel plates 
with QF-254 indicator and visualized by UV. IR spectra were recorded on a Bruker 
Tensor 27 spectrometer. Optical rotations were measured on Jasco DIP-360 digital 
polarimeter. 
  
1H and 13C spectra were recorded on a Varian 300 (300 MHz 1H; 75 MHz 13C) or Varian 
500 (500 MHz 1H; 125 MHz 13C) spectrometer at room temperature.  Chemical shifts 
were reported in ppm relative to the residual CDCl3 (δ 7.28 ppm 1H; δ 77.0 ppm 13C) 
CD3OD (δ 3.31 ppm 1H; δ 49.0 ppm 13C). Coupling constants (J) were reported in Hertz. 
  
General Catalytic Hydrogenation Conditions 
The alkene was dissolved in CH2Cl2 (0.5 M) and the iridium catalyst ((S)-1 or (R)-1) (1 
mol%) was then added.  The resulting solution was degassed by three cycles of freeze-
pump-thaw using nitrogen, then transferred to a Parr Bomb.  The bomb was flushed with 
hydrogen for 1 min without stirring.  The mixture was then stirred at 700 rpm under 50 
atm of H2.  After 4 h, the bomb was vented and the solvent was evaporated.  The crude 
product was passed through a silica plug (EtOAc/hexanes =3/7).  The enantiomeric and 
diastereomeric ratios of the crude materials were then measured via chiral capillary GC 
or HPLC analysis. 
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EXPERIMENTAL DATA FOR CHAPTER II 
 
HO
OH
OMe
O
1.2 eq TBDPSCl, imidazole
CH2Cl2, 0
oC, 1 h
TBDPSO
OH
OMe
O
 
 
(R,E)-Methyl 5-(tert-Butyldiphenylsilyloxy)-4-hydroxy-2-methylpent-2-enoate 
Imidazole (0.40 g, 5.85 mmol) was added in one portion to a stirred, solution of (R,E)-
methyl 4,5-dihydroxy-2-methylpent-2-enoate (0.72 g, 4.50 mmol) in CH2Cl2 (20 mL) at 0 
°C.  t-Butyldiphenylsilyl chloride (1.48 g, 5.40 mmol) was added slowly over ca 5 min.  
After 1 h stirring at 0 ˚C, the reaction mixture was quenched by addition of saturated 
NaHCO3 aqueous solution (10 ml).   The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 10 ml).  The combined organic layers were dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification by flash chromatography 
eluting with EtOAc/hexanes (20%) gave the allylic alcohol (1.63 g, 91%) as a colorless 
oil.  [α]23D  +10.90  (c 1.47, CHCl3); IR (neat) 3468 (br), 3049, 2951, 2929, 2862, 1717, 
1650, 1427, 1228, 1108, 745, 703 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.71-7.67 (m, 4H), 
7.50-7.39 (m, 6H), 6.65 (dd, J = 1.5, 8.1 Hz, 1H), 4.60-4.55 (m, 1H), 3.74 (s, 3H), 3.70-
3.60 (m, 2H), 2.81 (br, 1H), 1.76 (d, J=1.5 Hz, 1H), 1.11 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 167.9, 139.0, 135.5, 132.8, 132.7, 130.1, 130.0, 129.9, 127.8 (2 peaks), 69.5, 
66.4, 51.9, 26.8, 19.2, 12.9. HRMS (ESI): Exact mass calcd for C23H31O4Si [M+H]
+ 
399.1992.  Found 399.1994. 
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(R,E)-Methyl 4,5-bis(tert-Butyldiphenylsilyloxy)-2-methylpent-2-enoate 
Imidazole (0.83 g, 12.2 mmol) and t-butyldiphenylsilyl chloride (2.50 g, 9.10 mmol) 
were added sequentially to a stirred solution of (R)-E-methyl 5-(tert-
butyldiphenylsilyloxy)-4-hydroxy-2-methylpent-2-enoate (2.43 g, 6.10 mmol) in CH2Cl2 
(20 mL) at 25 ˚C.  After 30 min stirring at 25 ˚C, the reaction mixture was quenched by 
addition of saturated NaHCO3 aqueous solution (10 ml).  The layers were separated and 
the aqueous layer was extracted with CH2Cl2 (3 x 20 ml).  The combined organic layers 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
by flash chromatography eluting with EtOAc/hexanes (5%) gave the target ester (3.69 g, 
95%) as colorless oil.  [α]23D  -31.50  (c 3.40, CHCl3); IR (neat) 3075, 2952, 2935, 2862, 
1714, 1426, 1105, 1075, 698 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.81-7.70 (m, 8H), 
7.44-7.40 (m, 12H), 6.69 (dd, J = 1.5, 8.7 Hz, 1H), 4.70-4.67 (m, 1H), 3.86-3.83 (m, 1H), 
3.76 (s, 3H), 3.66-3.63 (m, 1H), 1.45 (d, J= 1.2 Hz, 3H), 1.15 (s, 9H), 1.09 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 168.0, 141.5, 135.9, 135.8, 135.5 (2 peaks), 133.6, 133.5, 
133.2, 129.6 (3 peaks), 128.2, 127.6 (2 peaks), 127.5, 127.4, 71.2, 67.3, 51.7, 26.9, 26.8, 
26.7, 19.2, 19.1, 12.7. HRMS (ESI): Exact mass calcd for C39H49O4Si2 [M+H]
+ 637.3169. 
Found 637.3156. 
 
  
123 
 
(R,E)-Methyl 4-(tert-Butyldiphenylsilyloxy)-5-hydroxy-2-methylpent-2-enoate (2) 
Hydrogen fluoride pyridine (0.19 ml) and pyridine (0.40 ml) were added to a solution of 
(R,E)-methyl 4,5-bis(tert-butyldiphenylsilyloxy)-2-methylpent-2-enoate (0.64 g, 1.01 
mmol) in THF (5 mL) at 0 oC slowly.  After 8 h stirring at 0 oC, the reaction was 
quenched with saturated NaHCO3 aqueous solution (5 ml).  The layers were separated 
and the aqueous layer was extracted with diethyl ether (3 x 10 ml).  The combined 
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification by flash chromatography eluting with EtOAc/hexanes (5%) recovered 
starting material 0.15 g (77% conv.) then eluting with EtOAc/hexanes (25%) gave 2 (0.28 
g, 92%) as a colorless oil.  [α]23D  -70.40 (c 1.84, CHCl3); IR (neat) 3468 (br), 3072, 3047, 
2952, 2932, 2860, 1714, 1658, 1432, 1253, 1105, 1083, 706 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.71-7.67 (m, 4H), 7.50-7.33 (m, 6H), 6.60 (d, J = 1.5, 8.7 Hz, 1H), 4.60-4.55 
(m, 1H), 3.68 (s, 3H), 3.65-3.40 (m, 2H), 2.11 (br, 1H), 1.40 (d, J=1.2 Hz, 1H), 1.07 (s, 
9H); 13C NMR (75 MHz, CDCl3) δ 167.8, 140.0, 135.8, 135.1, 133.2, 133.1, 129.9(2 
peaks) 128.9, 127.8, 127.6, 71.4, 66.0, 51.8, 26.9, 19.2, 12.6. HRMS (ESI): Exact mass 
calcd for C23H30LiO4Si [M+Li]
+ 405.2073. Found 405.2126. 
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(3S,5R)-5-(tert-Butyldiphenylsilyloxy)-3-methyltetrahydro-2H-pyran-2-one (3) 
Hydrogenation of 2 (159 mg, 0.40 mmol) was carried out according to the general 
procedure using D-1 (1 mol%, 6.4 mg) in CH2Cl2 (0.8 mL).  NMR of the crude product 
showed 100% conversion and partial lactonization.  Thus without isolation, the reaction 
mixture was diluted with CH2Cl2 (1 mL) then TsOH monohydrate (2 mg, 0.01 mmol) was 
added.  After 1 h, saturated aqueous NaHCO3 solution (2 mL) was added and the layers 
were separated.  The aqueous layer was extracted with CH2Cl2 (3 ×  5 mL).  The 
combined organic extracts were dried (Na2SO4) and concentrated in vacuo.  GC analysis 
of the derivative of this material (see GC section later in the supporting information) 
gives a cis:trans lactone in a ratio of 19:1.0.  Further recrystallization (Et2O) gave cis-
lactone 3 as a white crystal (109 g, 75%; cis:trans = 40:1.0 by GC analysis).  [α]23D  
+29.4  (c 1.41, CHCl3); IR (neat) 3072, 2962, 2859, 1750, 1683, 1455, 1110, 1057, 703 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.69-7.65 (m, 4H), 7.48-7.42 (m, 6H), 4.15-4.09 (m, 
3H), 2.43-2.22 (m, 2H), 1.74-1.65 (m, 1H), 1.26 (d, J = 6.6 Hz, 3H), 1.08 (s, 9H). 13C 
NMR (75 MHz, CDCl3) 174.7, 135.6 (2 peaks), 133.2 (2 peaks), 130.0(2 peaks), 127.8 (2 
peaks), 72.5, 65.6, 37.3, 32.8, 26.7, 19.0, 16.7.  HRMS (ESI): Exact mass calcd for 
C22H28LiO3Si [M+Li]
+ 375.1968. Found 375.2072. 
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(R,E)-5-(tert-Butyldiphenylsilyloxy)-2-methylpent-2-ene-1,4-diol (4) 
A solution of DIBAL (1 M in hexane, 7.78 mL, 7.78 mmol) was added to a solution of 
(R,E)-methyl 5-(tert-butyldiphenylsilyloxy)-4-hydroxy-2-methylpent-2-enoate (1.06 g, 
2.66 mmol) in THF (10 mL) at  -30 oC via syringe pump in a period of 30 min.  The 
reaction mixture was stirred for an additional 4 h before dropwise addition of anhydrous 
EtOAc (4 mL) at -30 oC was performed.  The resulting mixture was transferred quickly 
into a vigorously stirred mixture of hexanes/saturated potassium sodium tartrate aqueous 
solution (30 mL/10 mL).  The solution was continued to stir for 1h and the layers were 
separated.  The aqueous layer was extracted with hexanes (3 ×  20 mL).  The combined 
organic extracts were dried (Na2SO4) and concentrated in vacuo.  The residue was 
purified by flash chromatography on silica gel, eluting with EtOAc/hexanes (50%), 
which gave the di-alcohol 4 (0.85 g, 86%) as a colorless oil.  [α]19D  -25.90 (c 0.69, 
CHCl3); IR (neat) 3354 (br), 3069, 2932, 2859, 1427, 1102, 1058, 698 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.72-7.67 (m, 4H), 7.50-7.39 (m, 6H), 5.39-5.35 (m, 1H), 4.53-4.51 
(m, 1H), 3.97 (s, 2H), 3.65-3.53 (m, 2H), 2.75 (br, 1H), 1.61 (br, 1H), 1.60 (s, 3H), 1.11 
(s, 9H); 13C NMR (75 MHz, CDCl3) δ 139.7, 135.5, 133.1, 133.0, 129.9, 129.8, 127.8, 
122.8, 69.0, 67.8, 67.4, 26.8, 19.2, 14.0. HRMS (ESI): Exact mass calcd for 
C22H30LiO3Si [M+Li]
+ 377.2124. Found 377.2105. 
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(2R,4R)-5-(tert-Butyldiphenylsilyloxy)-2-methylpentane-1,4-diol (5) 
Hydrogenation of 4 (148 mg, 0.40 mmol) was carried out according to the general 
procedure using D-1 (1 mol%, 6.4 mg) in CH2Cl2 (0.8 mL).  NMR of the crude product 
showed 100% conversion to 5.  GC analysis of the derivative of the crude material (see 
GC section later in the supporting information) showed anti:syn ratio to be 24:1.0.  One 
simple column chromatography on silica gel, eluting with EtOAc/hexanes (5%) give 5 
(anti:syn = 56:1.0 from GC analysis) as a colorless oil (125 mg, 84%).  [α]21D +8.8  (c 1.1, 
CHCl3), (lit. [α]25D +4.1  (c 1.1, CHCl3)); IR (neat) 3351 (br), 3069, 2927, 2857, 1429, 
1114, 742, 706 cm-1; 1H NMR (300 MHz, CDCl3) 7.77-7.66 (m, 4H), 7.50-7.39 (m, 6H),  
3.90-3.82 (m, 1H), 3.65-3.31 (m, 6H), 1.84 (br, 1H), 1.44-1.26 (m, 1H), 1.09 (s, 9H), 0.91 
(d, J=6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) 135.9, 135.8, 133.3, 130.2, 128.1, 71.4, 
68.9, 68.6, 38.4, 34.8, 27.1, 19.5, 18.3. HRMS (ESI): Exact mass calcd. for C22H32LiO3Si 
[M+Li]
+
 379.2281. Found 379.2232.  
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(S,E)-Methyl 4-(tert-Butyldiphenylsilyloxy)-2-methylpent-2-enoate 
A solution of DIBAL (1 M in hexane, 30 mL, 30 mmol) was added to a solution of (S)-
ethyl 2-(tert-butyldiphenylsilyloxy)propanoate  (7.13 g, 20.0 mmol) in CH2Cl2 (40 mL) at 
-78 oC via syringe pump in a period of 1 h.  The reaction mixture was stirred at –78 oC 
for 1h and then additional 10 ml DIBAL was introduced slowly via syringe pump.  The 
solution was continued to stir for 1h before dropwise addition of anhydrous MeOH (10 
mL) at -78 oC and then the mixture was transferred quickly into a vigorously stirred 
mixture of CH2Cl2/saturated potassium sodium tartrate aqueous solution (300 mL/100 
mL).  The resulting solution was stirred for 1h and the layers were separated.  The 
aqueous layer was extracted with CH2Cl2 (3 × 100 mL).  The combined organic extracts 
were dried (Na2SO4) and concentrated in vacuo.  This crude aldehyde was immediately 
dissolved in CH2Cl2 (80 mL) and the Wittig reagent (10.5 g, 30 mmol) was added in one 
portion at 25 oC.  The reaction mixture was stirred at room temperature for 16 h then it 
was concentrated and added into silica gel (60 – 200 mesh).  Use vacuum pump to dry the 
silica gel at room temperature and load the silica gel on column.  Purification of the 
residue by flash chromatography on silica gel, eluting with EtOAc/hexanes (5% - 10%) 
gave desired ester as colorless oil (7.24 g, 95%).  GC analysis of this material showed > 
99% ee. (The (R,E)-methyl 4-(tert butyldiphenylsilyloxy)-2-methylpent-2-enoate was 
synthesized from commercial available (R)-methyl lactate).  [α]18D -51.80  (c 1.70, 
CHCl3); IR (neat) 3075, 2951, 2857, 1720, 1423, 1245, 1110, 1071, 703 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.71-7.62 (m, 4H), 7.43-7.35 (m, 6H),  6.74 (dd, J =1.5, 8.1 Hz, 1H), 
4.60-4.56 (m, 1H), 3.74 (s, 3H), 1.45 (d, J=1.5 Hz, 3H), 1.21 (d, J = 6.3 Hz, 3H), 1.07 (s, 
9H).  13C NMR (75 MHz, CDCl3) 168.5, 145.3, 135.8, 135.7, 134.0, 133.7, 129.6(2 
peaks), 127.6, 127.5, 125.3, 66.7, 51.8, 26.9, 23.1, 19.1, 12.2. HRMS (ESI): Exact mass 
calcd. for C23H30LiO3Si  [M+Li]
+
 389.2124. Found 389.1641. 
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(S,E)-4-(tert-Butyldiphenylsilyloxy)-2-methylpent-2-en-1-ol (6) 
A DIBAL solution (1 M in hexane, 41.6 mL, 41.6 mmol) was added to a solution of 
(S,E)-methyl 4-(tert-butyldiphenylsilyloxy)-2-methylpent-2-enoate (7.24 g, 18.9 mmol) 
in CH2Cl2 (40 mL) at 25 oC slowly.  The reaction mixture was stirred for 1 h and then 
quenched with anhydrous MeOH (10 mL) and diluted with CH2Cl2 (100 mL) and 
saturated potassium sodium tartrate aqueous solution (50 mL).  The resulting mixture was 
stirred for 1 h, and the layers were separated.  The aqueous layer was extracted with 
CH2Cl2 (3 × 50 mL).  The combined organic extracts were dried (Na2SO4) and 
concentrated in vacuo. The residue was purified by column chromatography, eluting with 
EtOAc/hexanes (20%), which gave alcohol 6 (6.28 g, 94%) as a colorless oil.  [α]19D  -6.9  
(c 1.44, CHCl3); IR (neat) 3337 (br), 2954, 2932, 2860, 1424, 1112, 996, 783 cm-1; 1H 
NMR (300 MHz, CDCl3) 7.72-7.67 (m, 4H), 7.43-7.36 (m, 6H),  5.42 (dd, J=1.2, 8.7 Hz, 
1H), 4.62-4.57 (m, 1H), 3.81 (d, J=5.7 Hz, 2H), 1.23 (dd, J=1.2, 7.5 Hz, 3H), 1.00 (s, 9H), 
0.98-0.91 (br, 1H). 13C NMR (75 MHz, CDCl3) 135.9, 135.8, 134.7, 134.4, 133.5, 130.6, 
129.5, 129.4, 127.5, 127.3, 68.3, 66.4, 26.9, 24.2, 19.1, 13.5. HRMS (ESI): Exact mass 
calcd. for C22H30LiO2Si [M+Li]
+
 361.2175. Found 361.2127. 
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(S,E)-2-Methylpent-2-ene-1,4-diol 
A solution of TBAF (1 M in THF, 4.70 mL, 4.70 mmol) was added to a solution of 6 
(1.10 g, 3.10 mmol) in THF (10 mL) was slowly at 25 oC.  The reaction mixture was 
raised to 40 oC and continued to stir for 4 h. After cooling the solution to room 
temperature, saturated NH4Cl aqueous solution (5 mL) was added followed by Et2O (10 
mL).  The layers were separated and the aqueous layer was extracted with Et2O (3 ×  5 
mL).  The combined organic extracts were dried (Na2SO4) and concentrated in vacuo. 
The residue was purified via flash chromatography on silica gel, eluting with 
EtOAc/hexane (80 - 100%), which gave diol as a colorless oil (0.25 g, 71%).  [α]19D  -
14.4  (c 1.11, CHCl3); IR (neat) 3323 (br), 2968, 2918, 2867, 1452, 1374, 1061, 1004, 857 
cm-1; 1H NMR (300 MHz, CDCl3) 5.51 (dd, J = 1.5, 8.4 Hz, 1H), 4.67-4.62 (m, 1H), 4.03 
(s, 2H), 1.73 (s, 3H), 1.67-1.61 (m, 2H), 1.28 (d, J = 6.3 Hz, 3H. 13C NMR (75 MHz, 
CDCl3) 136.8, 129.3, 68.2, 64.7, 23.8, 14.1. HRMS (ESI): Exact mass calcd. for 
C6H12LiO2 [M+H]
+
 123.0997. Found 123.1013. 
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(S,E)-5-(tert-Butyldiphenylsilyloxy)-4-methylpent-3-en-2-ol (8) 
Imidazole (0.19 g, 2.8 mmol) was added to a stirred solution of (S,E)-2-methylpent-2-
ene-1,4-diol (0.25 g, 2.3 mmol) in CH2Cl2 (10 mL) at 0 °C in one portion. t-
butyldiphenylsilyl chloride (0.70 g, 2.5 mmol) was then added slowly.  After stirring 2 h 
at 0 oC, the reaction mixture was quenched by addition of saturated NaHCO3 aqueous 
solution (10 ml).  The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 10 ml).  The combined organic layers were dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The residue was purified by flash chromatography, 
eluting with EtOAc/hexanes (15%), and gave the allylic alcohol 8 (0.59 g, 74%) as a 
colorless oil.  [α]18D  -15.8 (c 1.51, CHCl3); IR (neat) 3346 (br), 3072, 2963, 2865, 1427, 
1111, 1052, 700 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.72-7.68 (m, 4H), 7.48-7.37 (m, 
6H), 5.54 (dd, J = 1.5, 8.7 Hz, 1H), 4.67-4.57 (m, 1H), 4.07 (s, 2H), 1.66 (s, 3H), 1.29 (br, 
1H), 1.26 (d, J= 6.3 Hz, 3H), 1.09 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 136.0, 135.6, 
133.6 (2 peaks), 129.6, 128.1, 127.6, 68.1, 64.4, 26.8, 26.7, 23.4, 19.3, 13.6. HRMS (ESI): 
Exact mass calcd for C22H30LiO2Si [M+Li]
+ 361.2175. Found 361.2178. 
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(2S,4S)-4-(tert-Butyldiphenylsilyloxy)-2-methylpentan-1-ol (7) 
Hydrogenation of 6 (142 mg, 0.40 mmol) was carried out according to the general 
procedure using L-1 (1 mol%, 6.4 mg) in CH2Cl2 (0.8 mL).  NMR of the crude product 
showed 100% conversion to 7.  GC analysis of the derivative of the crude material (see 
GC section later in the supporting information) showed syn:anti ratio to be 38:1.0.  One 
simple column chromatography on silica gel, eluting with EtOAc/hexanes (3%) gave 7 
(syn:anti = 78:1.0 from GC analysis) as a colorless oil (97 mg, 68%).  [α]18D -6.3  (c 0.95, 
CHCl3); IR (neat) 3359 (br), 3069, 2960, 2934, 2853, 1429, 1110, 1035, 703 cm-1; 1H 
NMR (300 MHz, CDCl3) 7.73-7.69 (m, 4H), 7.49-7.39 (m, 6H),  4.03-3.94 (m, 1H), 3.40-
3.36 (m, 2H), 2.44-2.40 (m, 1H), 1.84-1.76 (m, 1H), 1.56-1.36 (m, 2H), 1.11 (d, J=6.0 Hz, 
3H), 1.08 (s, 9H), 0.78 (d, J=6.9 Hz, 3H), 0.91 (d, J = 9.0 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) 135.9 (2 peaks), 134.2, 133.9, 129.7, 129.6, 127.6, 127.5, 68.5, 68.4, 43.8, 31.9, 
27.0, 22.6, 19.1, 17.7. HRMS (ESI): Exact mass calcd. for C22H32LiO2Si [M+Li]
+
 
363.2332. Found 363.2299. 
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(2S,4R)-5-(tert-Butyldiphenylsilyloxy)-4-methylpentan-2-ol (9) 
Hydrogenation of 8 (142 mg, 0.40 mmol) was carried out according to the general 
procedure using D-1 (1 mol%, 6.4 mg) in CH2Cl2 (0.8 mL).  NMR of the crude product 
showed 100% conversion to 9.  GC analysis of the derivative of the crude material (see 
GC section later in the supporting information) showed syn:anti ratio to be 1.0:55.  One 
simple column chromatography on silica gel, eluting with EtOAc/hexanes (3%) gave 9 
(one diasterisomer from GC analysis) as a colorless oil (115 mg, 80%).  [α]22D +8.1  (c 
1.47, CHCl3); IR (neat) 3353 (br), 3066, 2957, 2932, 2862, 1424, 1108, 695 cm-1; 1H 
NMR (300 MHz, CDCl3) 7.70-7.67 (m, 4H), 7.48-7.40 (m, 6H),  3.93-3.92 (m, 1H), 3.51 
(d, J = 6.6 Hz, 2H), 2.61 (br, 1H), 1.90-1.84 (m, 1H), 1.56-1.33 (m, 2H), 1.21 (d, J= 6.0 
Hz, 3H), 1.08 (s, 9H), 0.89 (d, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) 135.6, 133.4, 
130.0, 127.7, 69.9, 66.5, 44.8, 33.8, 26.8, 24.2, 19.2, 17.6. HRMS (ESI): Exact mass 
calcd. for C22H32LiO2Si [M+Li]
+
 363.2332. Found 363.2332. 
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(R,E)-4-(tert-Butyldiphenylsilyloxy)-2,6-dimethylhept-2-en-1-ol (10) 
A DIBAL solution (1 M in hexane, 40 mL, 40 mmol) was added to a solution of (R)-
methyl 2-(tert-butyldiphenylsilyloxy)-4-methylpentanoate (7.0 g, 18.2 mmol) in CH2Cl2 
(40 mL) at -30 oC slowly over ca 1 h.  The reaction mixture was stirred for 4 h at -30 oC 
before dropwise addition of anhydrous MeOH (10 mL) and dilution with CH2Cl2 (100 
mL) and saturated potassium sodium tartrate aqueous solution (50 mL).  The resulting 
mixture was stirred for 1 h, and the layers were separated.  The aqueous layer was 
extracted with CH2Cl2 (3 × 100 mL).   The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo.  Purification by column chromatography eluting 
with EtOAc/hexanes (15%) gave the primary alcohol (4.7 g, 73%) as a colorless oil.   To 
a separate flask charged with (COCl)2  (0.24 mL, 2.7 mmol) in CH2Cl2 (10 mL) cooled to 
-78 oC was added DMSO (0.31 mL, 4.4 mmol) slowly.  After 5 min the previous alcohol 
(0.75g, 2.1 mmol) in CH2Cl2 (10 mL) solution was cooled to -78 oC and transferred via 
cannula into the previous mixture.  Stirring was continued for additional 5 min at low 
temperature, then Et3N (1.46 mL, 10.5 mmol) was introduced and the mixture was 
allowed to warm to 0 oC before NH4Cl(s) (10mL) was added.  Dilute the solution with 
Et2O (25 mL) and the layers were separated.  The aqueous layer was extracted with Et2O 
(3 x 25 mL).  The organic layers were combined and washed by H2O and brine.  Finally it 
was dried with Na2SO4, filtrated, and concentrated under reduced pressure.  The resulting 
aldehyde was used directly without further purification.  This crude aldehyde was 
immediately dissolved in CH2Cl2 (20 mL) and the Wittig reagent (2.2 g, 6.3 mmol) was 
added in one portion at 25 oC.  The reaction mixture was stirred at room temperature for 
16 h then it was concentrated and added into silica gel (60 – 200 mesh).  Use vacuum 
pump to dry the silica gel at room temperature and load the silica gel on column.  
Purification of the residue by flash chromatography on silica gel, eluting with 
EtOAc/hexanes (5% - 10%) gave desired ester as a colorless oil (0.70 g, 79%).  Finally, 
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the ester was dissolved in THF (5 mL) and the DIBAL (1M in hexanes, 4.1 mL, 4.1 
mmol) was added slowly.  The mixture was stirred at room temperature for 1 h then 
dropwise addition of anhydrous MeOH (2 mL) and dilution with THF (5 mL) and 
saturated potassium sodium tartrate aqueous solution (5 mL) was performed.  The 
resulting mixture was stirred for 1 h, and the layers were separated.  The aqueous layer 
was extracted with THF (3 × 10 mL).  The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo.  Purification by column chromatography eluting 
with EtOAc/hexanes (10%) gave allylic alcohol 10 (0.49 g, 75%) as a colorless oil.  
[α]19D  -3.2  (c 1.22, CHCl3); IR (neat) 3354 (br), 3043, 2960, 2860, 1424, 1110, 710 cm-1; 
1H NMR (300 MHz, CDCl3) 7.70-7.67 (m, 4H), 7.44-7.34 (m, 6H), 5.31-5.27 (m, 1H), 
4.52-4.45 (m, 1H), 3.72 (d, J= 6.0 Hz, 2H), 1.68-1.52 (m, 2H), 1.33-1.25 (m, 1H), 1.18 (s, 
3H), 1.05 (s, 9H), 0.83 (d, J= 6.6 Hz, 3H), 0.79 (d, J= 6.3 Hz, 3H), 0.72 (t, J= 6.6 Hz, 
1H). 13C NMR (75 MHz, CDCl3) 136.0, 135.9, 135.0, 134.5, 134.4, 129.5 (2 peaks), 
129.3, 127.4, 127.2, 68.5, 68.3, 47.6, 27.0, 24.2, 22.9, 22.8, 19.3, 13.6. HRMS (ESI): 
Exact mass calcd. for C25H36LiO2Si [M+Li]
+
 403.2645. Found 403.2636. 
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(2R,4R)-4-(tert-Butyldiphenylsilyloxy)-2,6-dimethylheptan-1-ol (11) 
Hydrogenation of 10 (0.95 g, 2.40 mmol) was carried out according to the general 
procedure using D-1 (1 mol%, 38 mg) in CH2Cl2 (2.4 mL).  NMR of the crude product 
showed 100% conversion to 11.  GC analysis of the derivative of the crude material (see 
GC section later in the supporting information) showed syn:anti ratio to be 57:1.0.  One 
simple column chromatography on silica gel, eluting with EtOAc/hexanes (3%) give 11 
(syn:anti = 170:1.00 from GC analysis) as a colorless oil (0.80 g, 84%).  [α]20D +2.0  (c 
0.97, CHCl3); IR (neat) 3348 (br), 3072, 2960, 2929, 2862, 1423, 1111, 1041, 703 cm-1; 
1H NMR (300 MHz, CDCl3) 7.74-7.70 (m, 4H), 7.49-7.37 (m, 6H),  3.92-3.84 (m, 1H), 
3.43-3.32 (m, 2H), 2.86 (br, 1H), 1.86-1.76 (m, 1H), 1.59-1.23 (m, 6H), 1.09 (s, 9H), 0.76 
(d, J = 6.9 Hz, 3H), 0.70 (d, J= 6.0 Hz, 3H), 0.59 (d, J = 6.3 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) 136.0 (2 peaks), 133.8, 130.0, 127.5 (2 peaks), 70.8, 68.7, 45.0, 41.3, 31.7, 27.0, 
24.4, 23.0, 22.1, 19.2, 18.0. HRMS (ESI): Exact mass calcd. for C25H39O2Si [M+H]
+
 
399.2719. Found 399.2747. 
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tert-Butyl((2R,4R)-1-iodo-2,6-dimethylheptan-4-yloxy)diphenylsilane (12) 
Iodine (1.02 g, 4.0 mmol) was added to a flask charged with PPh3 (1.05 g, 4.0 mmol), 
imidazole (0.41 g, 6.0 mmol) and CH2Cl2 (5 mL) at 0 oC.  After 10 min the previous 
alcohol solution in CH2Cl2 (3 mL) was added into this mixture and the flask was rinsed 
with CH2Cl2 (2 x 1mL).  The solution was stirred for additional 30 min.  After filtration 
of the precipitate and concentration, the residue was loaded on a silica gel column and 
flushed with hexanes to give the iodide 12 (0.94 g, 92%) as a colorless oil.  [α]21D  +10.1 
(c 1.58, CHCl3); IR (neat) 3069, 2960, 2921, 2854, 1427, 1108, 1052, 703 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.73-7.69 (m, 4H), 7.48 (m, 6H), 3.76-3.68 (m, 1H), 3.09 (dd, J= 
3.6, 9.6 Hz, 1H), 2.92 (dd, J= 5.4, 9.6 Hz, 1H), 1.67-1.24 (m, 7H), 1.06 (s, 9H), 0.78 (d, 
J= 6.3 Hz, 3H), 0.73 (d, J= 6.6 Hz, 3H), 0.67 (d, J= 6.6 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 136.0, 135.9, 134.3, 134.2, 130.0 (2 peaks), 127.5, 127.4, 69.8, 46.6, 43.8, 30.6, 
27.1, 24.5, 23.0, 22.5, 21.2, 19.4, 18.4. HRMS (ESI): Exact mass calcd. for C25H37ILiOSi 
[M+Li]
+
 515.1818. Found 515.1900. 
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(4S,6R)-6-(tert-Butyldiphenylsilyloxy)-1-(furan-3-yl)-4,8-dimethylnonan-1-one 
Sulfoxide 13 (0.77 g, 4.5 mmol) was added to a flask charged with NaH (100 mg, 4.20 
mmol) and DMF (4.0 mL) at room temperature.  After 10 min a solution of 12 (0.75g, 1.5 
mmol) in DMF (1 mL) was added into this mixture and the flask was rinsed with DMF (2 
x 0.5mL).  The reaction mixture was raised to 60 oC and continued to stir for 8 h.  After 
cooled the solution to room temperature, saturated NH4Cl aqueous solution (5 mL) was 
added followed by CH2Cl2 (20 mL).  The layers were separated and the aqueous layer 
was extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo.  The mixture was purified via flash chromatography 
on silica gel, eluting with EtOAc/hexane (50%) to give the intermediate ketofuran as a 
pair of diasterisomers.  These were dissolved in THF/H2O (9:1, 18 ml), and freshly 
prepared Al(Hg)7  (ca 200 mg) was added to the solution and the mixture was heated to 
60 oC and stirred for 8 h.  The solution was cooled to room temperature and the 
precipitate was removed via filtration then washed with THF (ca 10 mL) thoroughly.  
The filtrate was dried with Na2SO4 and concentrated in a vacuum.   The residue was 
loaded on a silica gel column and flushed with EtOAc/hexanes (5%) to give desired 
ketone (0.36 g, 49% for two steps) as a colorless oil.  [α]22D  +33.3  (c 1.2, CHCl3); IR 
(neat) 3130, 3069, 2960, 2926, 2854, 1680, 1108, 703 cm-1; 1H NMR (300 MHz, CDCl3) 
7.91 (s, 1H), 7.72-7.69 (m, 4H), 7.45 (s, 1H), 7.44-7.35 (m, 6H), 6.74 (s, 1H), 3.85-3.75 
(m, 1H), 2.65-2.44 (m, 2H), 1.77-1.70 (m, 1H), 1.38-1.20 (m, 7H), 1.05 (s, 9H), 0.74 (d, 
J= 4.8 Hz, 3H), 0.72 (d, J= 4.5 Hz, 3H), 0.61 (d, J= 6.0 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) 195.3, 146.9, 144.1, 136.0, 134.7, 134.4, 129.4 (2 peaks), 127.7, 127.6, 127.4 (2 
peaks), 108.6, 70.1, 46.4, 44.9, 38.0, 31.5, 29.1, 27.0, 24.3, 23.2, 22.4, 19.4, 19.3. HRMS 
(ESI): Exact mass calcd. for C31H42LiO3Si [M+Li]
+
 497.3063. Found 497.3063. 
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(4S,6R)-1-(Furan-3-yl)-6-hydroxy-4,8-dimethylnonan-1-one (14) 
A solution of TBAF (1 M in THF, 1.48 mL, 1.48 mmol) was added to a solution of 
(4S,6R)-6-(tert-butyldiphenylsilyloxy)-1-(furan-3-yl)-4,8-dimethylnonan-1-one (0.36 g, 
0.74 mmol) in THF (1.5 mL) over 5 min.  The reaction mixture was raised to 60 oC then 
stirred for 8 h.  After cooled the solution to room temperature, saturated NH4Cl aqueous 
solution (3 mL) was added followed by THF (10 mL).  The layers were separated and the 
aqueous layer was extracted with THF (3 × 5 mL).  The combined organic extracts were 
dried (Na2SO4) and concentrated in vacuo.  Purification was performed via flash 
chromatography on silica gel, eluting with EtOAc/hexane (20%) gave 14 as a colorless 
oil (0.17 g, 91%).  [α]20D  -4.2  (c 1.49, CHCl3), (lit.6 [α]25D -6.4 + 1.5 (c 1.1, CHCl3));; IR 
(neat) 3343 (br), 3133, 2957, 2918, 2865, 1670, 1561, 1465, 1152, 870 cm-1; 1H NMR 
(300 MHz, CDCl3) 8.05 (m, 1H), 7.45 (m, 1H), 6.78 (m, 1H), 3.89-3.86 (m, 1H), 2.84-
2.78 (m, 2H), 2.02-1.64 (m, 4H), 1.45-1.18 (m, 5H), 0.97-0.92 (m, 9H). 13C NMR (75 
MHz, CDCl3) 195.6, 147.0, 144.2, 127.7, 108.6, 67.3, 47.0, 45.5, 37.8, 29.8, 29.1, 24.6, 
23.6, 22.1, 20.4. HRMS (ESI): Exact mass calcd. for C15H24LiO3 [M+Li]
+
 259.1885. 
Found 259.1885. 
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Table B-1. Comparison of 13C NMR of natural and synthetic 14 
Atom number Synthetic  Natural 
C1  20.3  20.3  
C2  22.0  22.0 
C3  23.5  23.4  
C4  24.5  24.5  
C5  29.0  29.1  
C6  29.8  30.0  
C7  37.8  37.8  
C8  45.5  45.5  
C9  47.0  47.0  
C10  67.3  67.4  
C11  108.6  108.6  
C12  127.7  Missing  
C13  144.1  144.1  
C14  147.0  147.0  
C15  195.6  195.6  
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APPENDIX C 
EXPERIMENTAL DATA FOR CHAPTER III 
 
PMBO
O
THF, 25 oC, 1 h
MgBr(i)
(ii) (+)-DCHT
Ti(OiPr)4,
tBuOOH
CH2Cl2, - 20
oC, 72 h
PMBO
OH
(R)-S1
 
 
Vinyl magnesium bromide (1M in THF, 142 mL) was added to a round bottom flask and 
cooled to 0 oC.  The known PMB protected aldehyde1 (10.5 g, 47 mmol) was dissolved in 
anhydrous THF (50 mL) and added to the previous solution slowly over 1 h.  The 
reaction was stirred at 0 oC for 0.5 h and at 25 oC for 0.5 h, then the reaction was 
quenched by adding NH4Cl(s) (50 mL).  The layers were separated and the aqueous layer 
was extracted with CH2Cl2 (3 x 50 mL).  The combined organic layers were washed with 
brine(s) (20 mL), dried with Na2SO4, and concentrated in vacuo. Purification of the 
residue by flash chromatography on silica gel, eluting with EtOAc/hexanes (30:70) gave 
racemic alcohol as a colorless oil (10.7 g, 43 mmol, 91%).  A 500 ml flask was charged 
with 4Å molecular sieves (1.2 g, 25% by weight), racemic allylic alcohol (4.75 g, 
19mmol) and (+)-DCHT (0.90 g, 2.85 mmol) in CH2Cl2 (80 mL).  After cooling the 
mixture to -20 oC, Ti(OiPr)4 (0.61 mL, 2.09 mmol) was added dropwise via syringe.  The 
reaction mixture was stirred for 30 min at -20 oC followed by addition of tBuOOH (5.5M 
in decane, 2.42 mL, 13.3 mmol).  The resulting solution was then stirred at -20 oC for 72 
h and the reaction was quenched with freshly prepared FeSO4-Citric acid aqueous 
solution (50 mL) at -20 oC.2  The mixture was then vigorously stirred at 25 oC for 0.5 h, 
then the phases were separated and the aqueous layer was extracted with CH2Cl2 (3 x 50 
mL).  The combined organic layers were dried with Na2SO4 and concentrated in vacuo. 
Purification of the residue by flash chromatography on silica gel, eluting with 
EtOAc/hexanes (30:70) gave allylic alcohol (R)-S1 as a colorless oil (1.96 g, 7.8 mmol, 
46%).  The enantiomeric excess was determined >98% ee via chiral HPLC.  [α]21D  -6.4  
(c 1.85, CHCl3 ); IR (neat)821, 921, 1035, 1096, 1173, 1247, 1513, 1612, 2859, 2936, 
3420(br) cm-1; 1H NMR (300 MHz, CDCl3) δ 7.30-7.25 (m, 2H), 6.92-6.87 (m, 2H), 
5.93-5.82 (m, 1H), 5.27-5.10 (m, 2H), 4.45 (s, 2H), 4.15-4.06 (m, 1H), 3.82 (s, 3H), 3.47 
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(t, J = 7.5 Hz, 2H), 1.67-1.43 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 159.3, 141.4, 130.9, 
129.5, 114.9, 114.0, 73.4, 72.8, 70.2, 55.5, 37.0, 29.8, 22.3. HRMS (ESI): Exact mass 
calcd for C15H22LiO3 [M+Li]
+ 257.1729. Found 257.1726. 
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PMBO
OH Ac2O, Et3N, DMAP(cat)
CH2Cl2, 25
oC, 30 min
PMBO
OAc
(R)-S1 S2  
The alcohol (R)-S1 (2.93 g, 11.7 mmol) and DMAP (61 mg, 0.5 mmol) were dissolved in 
CH2Cl2 (30 mL).  Then Ac2O (1.66 mL, 17.6 mmol) and Et3N (3.26 mL, 23.4 mmol) 
were added sequentially.  The reaction was stirred at 25 oC for 30 min, then the reaction 
was quenched by adding NH4Cl(s) (10 mL).  The layers were separated and aqueous 
layer was extracted with CH2Cl2 (3 x 20 mL).  The combined organic layers were dried 
with Na2SO4 and concentrated in vacuo. Purification of the residue by flash 
chromatography on silica gel, eluting with EtOAc/hexanes (10:90) gave the desired ester 
S2 as a colorless oil (3.42 g, 11.7 mmol, 100%).  [α]21.4D  +5.7 (c 1.40, CHCl3); IR (neat) 
822, 1035, 1099, 1243, 1511, 1612, 1736, 2861, 2940 cm-1; 1H NMR (300 MHz, CDCl3) 
δ 7.30-7.25 (m, 2H), 6.92-6.87 (m, 2H), 5.84-5.72 (m, 1H), 5.27-5.16 (m, 3H), 4.44 (s, 
2H), 3.82 (s, 3H), 3.45 (t, J = 6.0 Hz, 2H), 2.07 (s, 3H), 1.69-1.35 (m, 6H); 13C NMR (75 
MHz, CDCl3) δ 170.6, 159.4, 136.7, 130.9, 129.5, 116.9, 114.0, 75.0, 72.8, 70.0, 55.5, 
34.2, 29.7, 22.1, 21.5. HRMS (ESI): Exact mass calcd for C17H24LiO4[M+Li]
+ 299.1835. 
Found 299.1829. 
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PMBO
OAc
i) OsO4, NaIO4
2,6-lutidine
ii) CH2Cl2, 25
oC, 16 h
iii) DIBAL-H, CH2Cl2
- 78 oC to 25 oC
PMBO
OH
OH
Ph3P OMe
O
S2 S3
 
To a solution of S2 (1.05 g, 3.59 mmol) in Dioxane/H2O (36 mL, 3:1) were added 2,6-
lutidine (0.83 mL, 7.18 mmol), OsO4 (2.5 wt. % solution in 2-methyl-2-propanol, 0.90 
mL, 0.072 mmol) and NaIO4 (3.07 g, 14.4 mmol) at 25 oC.  The reaction was stirred at 25 
oC for 3 h, then water (10 mL) and CH2Cl2 (20 mL) were added. The organic layer was 
separated, and the water layer was extracted by CH2Cl2 (3 x 10 mL). The combined 
organic layers were washed with brine and dried over Na2SO4.  After concentrated in 
vacuo, the resulting residue was dissolved in CH2Cl2 (50 mL) without any further 
purification and the Wittig reagent (3.1 g, 8.98 mmol) was added in one portion.  The 
reaction was stirred at 25 oC for 16 h, then the solvent was evaporated and the residue 
was purified by flash chromatography (EtOAc/Hexanes, 20/80).  The purified product 
was dissolved in CH2Cl2 (20 mL) and cooled to -78 oC.  DIBAL-H (1.0 M in Hexanes, 
16.5 mL, 16.5 mmol) was added carefully via syringe pump.  The reaction was stirred at -
78 oC for 1 h, then allowed to warm to r.t. over 1 h, after which time the reaction was 
quenched by adding EtOAc (2 mL).  The reaction mixture was diluted with CH2Cl2 (20 
mL) and a saturated aqueous solution of potassium sodium tartrate (10 mL) was added.  
The resulting mixture was stirred for 1 h and the layers were separated.  The aqueous 
layer was extracted with CH2Cl2 (3 x 20 mL).  The combined organic layers were dried 
(Na2SO4) and concentrated in vacuo.  The residue was purified by flash chromatography 
on silica gel, eluting with EtOAc/hexanes (80:20) to yield the diol S3 (0.95 g, 90% over 
three steps) as a colorless oil.  [α]21.5D  -2.0 (c 0.98, CHCl3); IR (neat) 819, 1033, 1086, 
1173, 1247, 1302, 1442, 1462, 1513, 1612, 2859, 2934, 3366 (br) cm-1; 1H NMR (300 
MHz, CDCl3) 7.29-7.25 (m, 2H), 6.92-6.87 (m, 2H), 5.48-5.44 (m, 1H), 4.44-4.39 (m, 
3H), 4.04 (s, 2H), 3.82 (s, 3H), 3.46 (d, J = 6.0 Hz, 2H), 1.73 (s, 3H), 1.68-1.37 (m, 8H) 
(mixed with the peak from H2O). 13C NMR (75 MHz, CDCl3) 159.4, 137.8, 130.9, 129.5, 
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128.2, 114.0, 72.8, 70.1, 68.4, 68.3, 55.5, 37.6, 29.9, 22.3, 14.3. HRMS (ESI): Exact 
mass calcd for C17H26LiO4[M+Li]
+
 301.1991. Found 301.1999. 
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PMBO
OH
OH
S3
TBDPSCl
imidazole
CH2Cl2
PMBO
OH
OTBDPS
S4  
To a solution of compound S3 (1.15 g, 3.91 mmol) and imidazole (0.29 g, 4.30 mmol) in 
CH2Cl2 (10 mL) was added a solution of TBDPSCl (1.07 g, 3.91 mmol) in CH2Cl2 (5 
mL, 2 x 1 mL for rinse) dropwise at -30 oC.  The reaction was stirred for 2 h, then 
quenched with NaHCO3(s) (10 mL).  The organic layer was separated and the aqueous 
layer was extracted with CH2Cl2 (3 × 10 mL).  The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo.  Purification by flash column chromatography, 
eluting with EtOAc/hexanes (20:80) gave alcohol S4 (1.70 g, 81%) as a colorless oil.  
[α]21.6D  +4.3 (c 0.93, CHCl3); IR (neat) 703, 821, 1036, 1112, 1247, 1427, 1457, 1512, 
1611, 2855, 2930, 3070, 3438 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.70-7.68 (m, 4H), 
7.43-7.41 (m, 6H), 7.28-7.26 (m, 2H), 6.90-6.87 (m, 2H), 5.51-5.48 (m, 1H), 4.45 (s, 
2H), 4.44-4.39 (m, 1H), 4.08 (s, 2H), 3.81 (s, 3H), 1.65-1.28 (m, 10H), 1.08 (s, 9H).  13C 
NMR (75 MHz, CDCl3) 159.3, 137.2, 135.8, 133.9(2 peaks), 130.9, 129.9, 129.5, 127.9(2 
peaks), 127.2, 114.0, 72.8, 70.3, 68.4(2 peaks), 55.5, 37.5, 29.9, 27.1, 22.3, 19.5, 14.1.  
HRMS (ESI): Exact mass calcd for C33H44LiO4Si[M+Li]
+
 539.3169. Found 539.3166. 
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PMBO
OH
OTBDPS
i) 0.2 mol% (S)-cat.
50 bar H2
CH2Cl2, 25
oC, 16 h
ii) TBAF, THF, 25oC, 1 h
PMBO
OH
OH
S4 S5  
(S)-Cat.
iPr
iPr
N
O
Ir
N
+
N
BARF-
(COD)
 
Hydrogenation of S4 (1.60 g, 3.0 mmol) was carried out according to the general 
procedure using (S)-Cat. (0.2 mol%, 12 mg) in CH2Cl2 (3.0 mL).  NMR of the crude 
product showed 100% reduction.  HPLC analysis of the crude material showed anti:syn 
ratio to be 61:1.0.  After hydrogenation the solvent was evaporated. Then the crude oil 
was dissolved in THF (5 mL) followed by addition of TBAF (1M in THF, 3.0 mL, 3.0 
mmol).  The resulting solution was stirred at 25 oC for 1 h, then the reaction was 
quenched by addition of NH4Cl(s) (5 mL).  The layers were separated, and the aqueous 
layer was extracted with Et2O (3 x 5 mL).  The organic extract was dried (Na2SO4) and 
concentrated in vacuo.  Purification by flash column chromatography, eluting with 
EtOAc/hexanes (50:50) gave diol S5 (0.86 g, 97%) as a colorless oil.  [α]23D  +11.1 (c 
0.90, CHCl3); IR (neat) 820, 1034, 1095, 1173, 1247, 1302, 1461, 1513, 1612, 2860, 
2930, 3348 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.30-7.26 (m, 2H), 6.92-6.88 (m, 2H), 
4.45 (s, 2H), 3.82 (s, 3H), 3.69-3.65 (m, 1 H), 3.58-3.45 (m, 5H), 3.37-3.31 (m, 1H), 
1.82-1.38 (m, 9H), 0.90 (d, J = 6.0 Hz, 3H).  13C NMR (75 MHz, CDCl3) 159.3, 130.7, 
129.5, 114.0, 72.8, 70.9, 70.2, 68.9, 55.5, 43.4, 38.4, 34.7, 29.8, 22.6, 18.3.  HRMS (ESI): 
Exact mass calcd for C17H28LiO4[M+Li]
+
 303.2148. Found 303.2126. 
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PMBO
OH
OH
S5
TEMPO, BAIB
CH2Cl2:H2O
PMBO
O
O
S6  
To A solution of diol S5 (0.80 g, 2.7 mmol) in 15 mL of CH2Cl2 and 4.5 mL of H2O were 
added TEMPO (42 mg, 0.27 mmol) and  PhI(OAc)2 (1.91 g,  5.94 mmol).  The reaction 
mixture was stirred for 2 h at 25 oC, and then was quenched with saturated aqueous 
NaHCO3, extracted with CH2Cl2, washed with brine, dried over MgSO4, and 
concentrated.  Purification by column chromatography (silica gel, 80:20 hexanes-EtOAc) 
afforded the desired lactone S6 (0.68 g, 86%) of as a colorless oil;  [α]23D  -17.1 (c 1.05, 
CHCl3); IR (neat) 733, 818, 1034, 1097, 1186, 1247, 1361, 1452, 1514, 1611, 1765, 
2849, 2938 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.31-7.26 (m, 2H), 6.93-6.88 (m, 2H), 
4.45 (s, 2H), 4.39-4.30 (m, 1 H), 3.83 (s, 3H), 3.48 (t, J = 6.0 Hz, 2H), 2.70-2.64 (m, 1H), 
2.54-2.45 (m, 1H), 1.84-1.46 (m, 6H), 1.29 (d, J = 6.0 Hz, 3H).  13C NMR (75 MHz, 
CDCl3) 179.8, 159.4, 130.8, 129.5, 114.0, 78.8, 72.8, 69.9, 55.5, 37.6, 36.2, 35.5, 29.7, 
22.4, 15.4. HRMS (ESI): Exact mass calcd for C17H24LiO4[M+Li]
+
 299.1835. Found 
299.1820. 
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i) DIBAL-H
ii) Ph3PMeBr,
nBuLiPMBO
O
O
PMBO
OH
S7S6  
To a solution of lactone S6 (427 mg, 1.50 mmol) in CH2Cl2 (10 mL) under nitrogen was 
added DIBAL-H (1M in CH2Cl2, 3.0 mL, 3.0 mmol) at –78 oC.  The reaction mixture was 
stirred at –78 oC for 1 h, and then was quenched with 1 mL of EtOAc.  The mixture was 
diluted with CH2Cl2 (20 mL) and saturated potassium sodium tartrate aqueous solution 
(10 mL) was added.  The resulting solution was stirred for 1 h at 25 oC and the layers 
were separated.  The aqueous layer was extracted with CH2Cl2 (3 x 20 mL).  The 
combined organic extracts were dried (Na2SO4) and concentrated in vacuo.  The residue 
was directly used in the next step.  To a solution of 2.68 g (7.5 mmol) of methyl triphenyl 
phosphonium bromide in 30 mL of THF under nitrogen was added 2.94 mL (7.35 mmol) 
of 2.5 M solution of n-BuLi in hexanes at 0 oC.   The solution was stirred at 0 oC for 30 
min, and then the crude lactol in 10 mL of THF was added.   The reaction was stirred at 0 
oC for 3 h, and then the reaction mixture was quenched with saturated aqueous NH4Cl, 
extracted with ether, washed with brine, dried over MgSO4, and concentrated.  
Purification by column chromatography (silica gel, 85/15 hexanes-EtOAc) gave 322 mg 
(76%) of alcohol S7 as a colorless oil; [α]20D  -4.1 (c 0.96, CHCl3); IR (neat) 814, 909, 
1035, 1097, 1172, 1247, 1302, 1453, 1514, 1613, 2861, 2932, 3070, 3430 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 7.29-7.26 (m, 2H), 6.92-6.88 (m, 2H), 5.85-5.73 (m, 1H), 5.07-4.94 
(m, 2H), 4.45 (s, 2H), 3.82 (s, 3H), 3.74-3.66 (m, 1H), 3.47 (t, J = 7.5 Hz, 2H), 2.39-2.29 
(m, 1H), 1.61-1.40 (m, 8H), 1.03 (d, J = 6.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
135.6, 135.5, 134.1, 130.1, 129.4, 127.5, 69.4, 41.2, 33.6, 29.1, 26.8, 22.2, 20.8, 19.3, 
16.6, 14.6. HRMS (ESI): Exact mass calcd for C18H29O3[M+H]
+ 293.2117. Found 
293.2119. 
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PMBO
OH
S7
DCC, DMAP
CH2Cl2, 25
oC
N
HOOC
Ph Boc
ii) TBSOTf, 2,6-lutidine, CH2Cl2;
TBAF, THF
i)
PMBO
OO
H
N
Ph
S8
 
To a solution of (S)-N-Boc-methylphenylalanine (461 mg, 1.65 mmol), allylic alcohol S7 
(322 mg, 1.1 mmol) and DMAP (27 mg, 0.22 mmol) in 5 mL of CH2Cl2 was added a 
solution of  DCC (454 mg, 2.2 mmol) in 5 mL of CH2Cl2.  The reaction mixture was 
stirred overnight, and then filtered on a pad of celite and washed with ether.  The residue 
was concentrated and purified by column chromatography (silica gel, 90:10 hexanes-
EtOAc) to give 609 mg (100%) of the coupled product as a colorless oil.  To a solution of 
the previous coupling product (609 mg, 1.1 mmol) in CH2Cl2 (15 mL) were added 2,6-
lutidine (0.38 mL, 3.3 mmol) and tert-butyldimethylsilyl trifluromethane sulfonate (0.63 
mL, 2.75 mmol) at 25 oC.  The resulting reaction mixture was allowed to stir for 1.5 h 
before saturated aqueous NH4Cl solution (10 mL) was added.  The aqueous mixture was 
extracted with ethyl acetate (3 x 20 mL).  The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo.  The residue was redissolved in THF (10 mL) and 
treated with tetra-n-butylammonium fluoride (1.0 M in THF, 1.3 mL, 1.3 mmol).  The 
reaction mixture was allowed to stir at rt for 1 h before saturated aqueous NH4Cl solution 
(10 mL) was added.  The aqueous mixture was extracted with ethyl acetate (4 x 20 mL).  
The combined organic layers were dried over Na2SO4 and concentrated in vacuo.   Silica 
gel column chromatography (hexanes-ethyl acetate, 70:30) of the resulting residue gave 
amine S8 (480 mg, 96% for 2 steps) as a colorless oil;  [α]20.3D  +10.3 (c 0.58, CHCl3); IR 
(neat) 700, 1036, 1098, 1179, 1247, 1453, 1511, 1611, 1726, 2850, 2929, 3325 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 7.28-7.20 (m, 7H), 6.89-6.87 (m, 2H), 5.78-5.66 (m, 1H), 
4.99-4.89 (m, 3H), 4.43 (s, 2H), 3.81 (s, 3H), 3.45-3.37 (m, 3H), 2.94 (d, J = 9.0 Hz, 2H), 
2.37 (s, 3H), 2.16-2.09 (m, 1H), 1.59-1.18 (m, 9H), 0.99 (d, J = 6.0 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ 174.3, 159.1, 143.9, 137.3, 130.6, 129.2(2 peaks), 128.4. 126.7. 
113.7. 112.8. 73.0. 72.6. 69.7. 64.8. 55.3. 40.5. 39.6. 34.8. 34.3. 33.8. 29.6. 21.6. 19.9.  
HRMS (ESI): calcd for C28H40NO4 [M+H]
+ 454.2957. Found 454.2962. 
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To a solution of dimethyl acid S18 (87 mg, 0.61 mmol) in DMF (9 mL) were added di-
iso-propylethyl amine (0.32 mL, 1.84 mmol) and PyBOP (345 mg, 0.66 mmol).  The 
resulting mixture was allowed to stir at rt for 2 min before amine S8 (230 mg, 0.51 mmol) 
in DMF (9 mL) were added.  The reaction mixture was stirred at rt for 24 h before it was 
partitioned between ethyl ether (50 mL) and saturated aqueous NaHCO3 solution (10 mL). 
The organic layer was washed with brine (10 mL).  The combined aqueous layer was 
extracted with diethyl ether (3 x 50 mL) and the combined organic extracts were dried 
over Na2SO4, filtered, and concentrated in vacuo.  Silica gel column chromatography 
(hexanes-ethyl acetate, 85:15) of the resulting residue gave amides as a mixture of 
rotamers (0.27 g, 0.47 mmol, 92%).  To a solution of 170 mg (0.29 mmol) of previous 
amide in 500 mL of dry CH2Cl2 under argon was added 25 mg (0.028 mmol) of 2nd 
generation Grubbs catalyst.   After stirring overnight at 40 oC, 13 mg (0.014 mmol) of 2nd 
generation Grubbs catalyst was added.  The solution was stirred for additional 8 h at 
reflux, and the reaction mixture was concentrated and purified by column 
chromatography (silica gel, 80/20 hexanes-EtOAc) to afford 140 mg (90%) of desired 
product S9 as a colorless oil.  [α]20D  -96.5 (c 0.29, CHCl3); IR (neat) 1099, 1171, 1220, 
1247, 1459, 1507, 1641, 1727, 2848, 2921, 2956 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.32-7.16 (m, 7H), 6.91-6.88 (m, 2H), 5.23-5.13 (m, 2H), 5.08-5.04 (m, 1H), 4.44 (s, 
2H), 3.82 (s, 3H), 3.62-3.59 (m, 1H), 3.51-3.44 (m, 3H), 3.37-3.33 (m, 1H), 2.80-2.74 
(m, 1H), 2.66 (s, 3H), 2.50-2.44 (m, 1H), 2.16-2.09 (m, 1H), 1.92-1.87 (m, 1H), 1.65-
1.27 (m, 8H), 1.18-1.15 (m, 1H), 1.12 (d, J = 10.0 Hz, 3H), 1.00 (d, J = 10.0 Hz, 3H), 
0.99 (d, J = 5.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.8, 170.3, 159.3, 139.0, 136.4, 
135.9, 130.9, 129.7, 129.5, 128.7, 126.7, 114.0, 73.5, 72.8, 70.0, 67.2, 55.5, 44.5, 43.3, 
39.7, 35.5, 34.7, 33.9, 30.4, 30.0, 27.1, 22.2, 20.2, 19.7, 18.9. HRMS (ESI): Exact mass 
calcd for C34H48NO5[M+H]
+ 550.3532. Found 550.3529. 
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The solution of 99 mg (0.18 mmol) of the macrocyclic olefin S9 and 60 mg (0.06 mmol) 
of 10% Pd/C in 6 mL of MeOH was putted in to a hydrogenation bomb.  The hydrogen 
pressure was raised to 5 bar and the reaction was stirred for 16 h.  The mixture was 
filtered on a plug of silica gel (5 cm), washed with MeOH, and concentrated to give 67 
mg (86%) of free saturated alcohol S10 as a colorless oil. [α]19.6D  -168 (c 1.01, CHCl3); 
IR (neat) 702, 752, 1079, 1173, 1212, 1276, 1456, 1634, 1738, 2853, 2922, 2956, 3431 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.31-7.17 (m, 5H), 5.19-5.14 (m, 1H), 3.68-3.49 (m, 
4H), 3.34-3.30 (m, 1H), 2.84-2.78 (m, 1H), 2.66 (s, 3H), 2.01 (t, J = 10.0 Hz, 1H), 1.71-
1.31 (m, 12H), 1.13 (d, J = 10.0 Hz, 3H), 1.10-1.01 (m, 2H), 0.91-0.86 (m, 6H), 0.78-
0.76 (m, 1H), 0.75-0.73 (m, 1H);  13C NMR (75 MHz, CDCl3) δ 177.0, 170.4, 139.0, 
129.7, 128.7, 126.7, 73.4, 67.2, 63.0, 39.9, 39.4, 37.3, 35.9, 34.7, 33.6, 32.9, 32.6, 31.7, 
27.5, 24.3, 22.5, 21.9, 21.6, 19.0.  HRMS (ESI): Exact mass calcd for C26H42NO4[M+H]
+ 
432.3114. Found 432.3117. 
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The alcohol S10 (40 mg, 0.09 mmol) was dissolved in CH2Cl2 (2 mL) at 0 oC.   DMSO 
(0.16 mL, 2.25 mmol) and DIPEA (0.16 mL, 0.90 mmol) were added.   To this solution at 
0 oC, SO3.Py complex (72 mg, 0.45 mmol) was added and the resulting solution was 
stirred at that temperature for 1 h.  The reaction was quenched with saturated aqueous 
NH4Cl (3 mL).  The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 mL x 3).   The combined organic solution was dried (Na2SO4) and 
concentrated in vacuo.  The crude aldehyde was purified through column 
chromatography, eluting with EtOAc/hexanes (20:80) to give desired aldehyde (39.3 mg, 
100%) as a colorless solid.  To a solution of the aldehyde prepared above and 225 mg 
(1.17 mmol) of Ohira-Bestmann’s reagent3 in 20 mL of MeOH was added 143 mg (1.04 
mmol) of K2CO3 under nitrogen.  The solution was stirred for 3 h at 35 oC, and then the 
reaction mixture was quenched with saturated aqueous NH4Cl, extracted with ether, dried 
over MgSO4, and concentrated.  Purification by column chromatography (silica gel, 95/5 
hexanes-EtOAc) gave 32.6 mg (87%, 2 steps) of (–)-spongidepsin as a crystalline solid; 
[α]21D  -152 (c 0.25, MeOH);  [α]23D  -203.2 (c 0.4, MeOH)4; IR (neat) 701, 754, 1070, 
1172, 1209, 1275, 1456, 1636, 1731, 2110, 2850, 2870, 2930, 2959, 3303 cm-1; 1H NMR 
(500 MHz, CD3OD) δ 7.34-7.17 (m, 5H), 5.20-5.13 (m, 1H), 4.02-3.98 (m, 1H), 3.46-
3.23 (m, 3H), 2.99-2.91 (m, 1H), 2.72 (s, 3H), 2.25-2.21(m, 3H), 1.94-1.89 (m, 1H), 
1.72-1.41 (m, 9H), 1.08 (d, J=7 Hz, 3H), 1.07 (m, 1H), 1.06 (m, 1H), 0.93 (d, J=7 Hz, 
3H), 0.91 (m, 1H), 0.90 (d, J=7 Hz, 3H), 0.79 (ddd, J=3, 11.5, 14 Hz, 1H); 13C NMR (75 
MHz, CD3OD) δ 179.6, 172.1, 139.7, 130.8, 129.7, 127.9, 84.8, 74.2, 70.1, 67.8, 40.6, 
40.5, 38.2, 36.0, 35.5, 34.7, 33.6, 32.7, 28.5, 25.7, 25.4, 22.6, 21.8, 19.1(2 peaks); HRMS 
(ESI): Exact mass calcd for C27H40NO3 [M+H]+: 426.3008, found: 426.3012. 
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The macrocyclic olefin S9 (140 mg, 0.26 mmol) was dissolved in CH2Cl2-H2O (2 mL, 
19:1.0) and DDQ (86 mg, 0.39 mmol) was added in one portion.  The solution was stirred 
at 25 oC for 1 h, then the reaction was quenched by adding NaHCO3(s) (2 mL).   The 
mixture was diluted with CH2Cl2 (5 mL) and the layers were separated.  The aqueous 
layer was extracted with CH2Cl2 (5 mL x 3).  The combined organic layers were dried 
(Na2SO4) and concentrated.  Purification by column chromatography (silica gel, 70/30 
hexanes-EtOAc) gave 99.1 mg (0.23 mmol, 89%) of alcohol S11 as a crystalline solid 
[α]20.7D  -157.8 (c 0.38, CHCl3); IR (neat) 702, 1078, 1173, 1220, 1277, 1413, 1455, 1630, 
1729, 2871, 2930, 2958, 3419 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.33-7.18 (m, 5H), 
5.23-5.06 (m, 3H), 3.67-3.61 (m, 3H), 3.51-3.46 (m, 1H), 3.38-3.34 (m, 1H), 2.81-2.75 
(m, 1H), 2.68 (s, 3H), 2.50-2.45 (m, 1H), 2.14-2.11 (m, 1H), 1.90 (t, J = 15.0 Hz, 1H), 
1.65-1.14 (m, 10H), 1.12 (d, J = 10.0 Hz, 3H), 1.01 (d, J = 10.0 Hz, 3H), 1.00 (d, J = 5.0 
Hz, 3H);  13C NMR (75 MHz, CDCl3) δ 176.9, 170.5, 138.9, 136.3, 135.9, 129.7, 128.7, 
126.8, 73.4, 67.2, 63.0, 44.5, 43.3, 39.7, 35.5, 34.7, 33.9, 32.8, 30.4, 27.1, 21.8, 20.2, 19.7, 
18.9.  HRMS (ESI): Exact mass calcd for C26H40NO4[M+H]
+ 430.2957. Found 430.2952. 
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The alcohol S11 (42.7 mg, 0.10 mmol) was dissolved in CH2Cl2 (2 mL) at 0 oC.   DMSO 
(0.18 mL, 2.5 mmol) and DIPEA (0.18 mL, 1.0 mmol) were added.  To this solution at 0 
oC, SO3.Py complex (80 mg, 0.50 mmol) was added and the resulting solution was stirred 
at that temperature for 1 h.  The reaction was quenched with NH4Cl (3 mL).  The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 mL x 3).  The 
combined organic solution was dried (Na2SO4) and concentrated in vacuo.  The crude 
aldehyde was purified though column chromatography, eluting with EtOAc/hexanes 
(20:80) to give desired aldehyde (42 mg, 100%) as colorless solid.  To a solution of the 
aldehyde prepared above and 0.25 g (1.3 mmol) of Ohira-Bestmann’s reagent4 in 20 mL 
of MeOH was added 159 mg (1.15 mmol) of K2CO3 under nitrogen.  After stirring for 3 h 
at 25 oC, the reaction mixture was quenched with saturated aqueous NH4Cl, extracted 
with ether, dried over MgSO4, and concentrated. Purification by column chromatography 
(silica gel, 95/5 hexanes-EtOAc) gave 37.6 mg (89%, 2 steps) of S12 as a crystalline 
solid; [α]18.7D  -136.8 (c 0.40, MeOH); IR (neat) 742, 941, 1171, 1219, 1272, 1384, 1471, 
1636, 1732, 2111, 2870, 2926, 2955, 3299 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.32-7.18 
(m, 5H), 5.23-5.07 (m, 3H), 3.64-3.34 (m, 3H), 2.76-2.70 (m, 1H), 2.67 (s, 3H), 2.51-
2.47 (m, 1H), 2.27-1.88 (m, 5H), 1.69-1.16 (m, 7H), 1.12 (d, J=10.0 Hz, 3H), 1.02 (d, 
J=5.0 Hz, 3H), 0.99 (d, J=10.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.9, 170.3, 
138.9, 136.3, 135.9, 129.7, 128.7, 126.8, 84.3, 73.0, 68.9, 67.2, 44.5, 43.3, 39.7, 34.7(2 
peaks), 34.0, 30.5, 27.1, 24.4, 20.2, 19.6, 18.9, 18.7;  HRMS (ESI): Exact mass calcd for 
C27H38NO3 [M+H]+: 424.2852, found: 424.2854. 
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The solution of 16 mg (0.04 mmol) of S12 and 4.3 mg (0.004 mmol) of 10% Pd/C in 1 
mL of MeOH was putted in to a hydrogenation bomb.  The hydrogen pressure was raised 
to 30 bar and the reaction was let go for 24 h.  The mixture was filtered on a plug of silica 
gel (5 cm), washed with MeOH, and concentrated to give 16 mg (93%) of free saturated 
macrolactone S13 as a white solid. [α]18.9D  -185 (c 0.68, CHCl3); IR (neat) 702, 752, 
1079, 1173.73, 1212, 1276, 1456, 1634, 1738, 2853, 2922, 2956, 3431 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.31-7.16 (m, 5H), 5.17-5.10 (m, 1H), 3.58-3.49 (m, 2H), 3.35-3.31 
(m, 1H), 2.86-2.76 (m, 1H), 2.66 (s, 3H), 2.01 (t, J = 10.0 Hz, 1H), 2.03-1.31 (m, 9H), 
1.13 (d, J = 5.0 Hz, 3H), 1.08-0.72 (m, 17H);  13C NMR (75 MHz, CDCl3) δ 177.0, 
170.3, 139.1, 129.7, 128.6, 126.7, 73.7, 67.2, 39.9, 39.4, 37.1, 36.0, 34.6, 33.6, 32.6, 32.1, 
31.7, 27.5, 25.3, 24.3, 22.8, 22.5, 21.6, 19.1, 14.3.  HRMS (ESI): Exact mass calcd for 
C27H44NO3[M+H]
+ 430.3321. Found 430.3315. 
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Ph3P (52 mg, 0.2 mmol) and imidazole (20 mg, 0.3 mmol) were dissolved in CH2Cl2 (1 
mL) and cooled to 0 oC.  I2 (51 mg, 0.2 mmol) was added in one portion and the reaction 
was stirred for 10 min at 0 oC.  The solution of S10 (43 mg, 0.1 mmol) in CH2Cl2 (1 mL) 
was added and the reaction mixture was allowed to stir for additional 30 min.  The 
reaction was quenched with NaHCO3(s) (1 mL) and the layers were separated.  Aqueous 
layer was extracted with CH2Cl2 (2 mL x 3).  The combined organic layer was dried over 
MgSO4, and concentrated. Purification by column chromatography (silica gel, 90/10 
hexanes-EtOAc) gave 27 mg (50%) of primary alkyl iodine as a colorless oil.  The above 
product (25 mg, 0.05 mmol) was dissolved in anhydrous DMSO (1 mL) and NaN3 (33 
mg, 0.5 mmol) was added.  After 2 h, TLC indicated all the starting material was 
consumed.  The reaction was diluted with Et2O (2 mL) and washed with H2O (1 mL x 3) 
and brine (1 mL).  The aqueous layer was also extracted with Et2O (5 mL x 3).  The 
combined organic layers were dried (Na2SO4) and concentrated.  Purification by column 
chromatography (silica gel, 90/10 hexanes-EtOAc) gave 17 mg (50%) of S14 as a 
crystalline solid. 
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S14 (8.0 mg, 0.017 mmol) and (-)-spongidepsin (7.5 mg, 0.017 mmol) were dissolved in 
tBuOH/H2O (0.6 mL, 2:1).  Sodium ascorbate (67 mg, 0.34 mmol), the solution of CuSO4 
(14 mg, 0.085 mmol) in H2O (0.15 mL) and TBTA (45 mg, 0.085 mmol) were added 
sequentially.  The reaction was stirred for 24 h at 23 oC.  Then it was quenched with 
NaHCO3(s) (2 mL) and diluted with CH2Cl2 (5 mL).  The layers were separated, and 
aqueous layer was extracted with CH2Cl2 (5 mL x 3).  The combined organic layer was 
dried over MgSO4, and concentrated.  Purification by column chromatography (silica gel, 
60/40 hexanes-EtOAc) gave 12 mg (84%) of desired dimer S15 as a colorless solid.  
[α]21D  -157 (c 1.17, CHCl3); IR (neat) 752, 1079, 1212, 1222, 1275, 1297, 1363, 1460, 
1632, 1639, 1731, 1736, 2853, 2869, 2925, 2955 cm-1; 1H NMR (500 MHz, CDCl3) 
7.34-7.16 (m, 10H), 5.18-5.10 (m, 2H), 4.34-4.31 (m, 2H), 3.70-3.46 (m, 5H), 3.30-3.25 
(m, 2H), 2.83-2.71 (m, 2H), 2.66 (s, 3H), 2.65 (s, 3H), 2.10-0.73 (m, 50H);  13C NMR (75 
MHz, CDCl3) 177.1 (2 peaks), 170.5, 170.4, 148.0, 138.9 (2 peaks), 129.7, 128.7, 128.6, 
126.7 (2 peaks), 121.0, 73.3, 72.9, 67.0, 50.1, 39.9, 39.8, 39.3, 37.3, 37.2, 35.6, 35.3, 
34.6, 33.5, 32.5, 31.6 (2 peaks), 30.3, 27.5, 25.8, 25.7, 24.3 (2 peaks), 22.6, 22.5, 21.6, 
19.0.  HRMS (ESI): Exact mass calcd for C53H80N5O6[M+H]
+ 882.6109. Found 882.6107. 
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S14 (8.0 mg, 0.017 mmol) and S12 (7.5 mg, 0.017 mmol) were dissolved in tBuOH/H2O 
(0.6 mL, 2:1).  Sodium ascorbate (67 mg, 0.34 mmol), the solution of CuSO4 (14 mg, 
0.085 mmol) in H2O (0.15 mL) and TBTA (45 mg, 0.085 mmol) were added 
sequentially.  The reaction was stirred for 24 h at 23 oC.  Then it was quenched with 
NaHCO3(s) (2 mL) and diluted with CH2Cl2 (5 mL).  The layers were separated, and 
aqueous layer was extracted with CH2Cl2 (5 mL x 3).  The combined organic layer was 
dried over MgSO4, and concentrated.  Purification by column chromatography (silica gel, 
60/40 hexanes-EtOAc) gave 12 mg (87%) of desired dimer S16 as a colorless solid.  
[α]21D  -156 (c 0.99, CHCl3); IR (neat) 701, 753, 1011, 1079, 1173, 1218, 1275, 1297, 
1377, 1412, 1460, 1631, 1640, 1731, 1736, 2853, 2928, 2955, 3031 cm-1; 1H NMR (500 
MHz, CDCl3) 7.32-7.16 (m, 10H), 5.21-5.05 (m, 4H), 4.34-4.31 (m, 2H), 3.65-3.31 (m, 
6H), 2.76-2.72 (m, 4H), 2.66 (s, 3H), 2.65 (s, 3H), 2.50-2.44 (m, 1H), 2.13-0.72 (m, 
44H);  13C NMR (75 MHz, CDCl3) 177.1, 176.9, 170.5, 170.4, 147.9, 138.9, 136.3, 
135.9, 129.7 (2 peaks), 128.7 (2 peaks), 126.7, 121.0, 73.2, 72.9, 67.0 (2 peaks), 50.1, 
39.8, 39.7, 35.3, 34.7, 34.6, 33.9, 33.5, 30.4, 30.3, 27.5, 27.1, 24.3, 22.6, 22.5, 21.6, 20.2, 
19.6, 19.0, 18.9. HRMS (ESI): Exact mass calcd for C53H78N5O6[M+H]
+ 880.5952. 
Found 880.5959. 
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To a solution of oxalyl chloride (0.83 mL, 9.52 mmol) in CH2Cl2 (15 mL) at -78 oC was 
added DMSO (1.27 mL, 21.8 mmol) dropwise.  After 5 min, a -78 oC solution of TBDPS 
protected alcohol (1.68 g, 4.53 mmol) 5 in CH2Cl2 (10 mL, 2× 1 mL for rinsing) was 
rapidly added via cannula.  After 5 min, Et3N (3.2 mL, 22.7 mmol) was introduced and 
the reaction mixture was allowed to warm to 0 oC before NH4Cl (10 mL) was added 
followed by Et2O (25 ml).  The layers were separated, the organic layer was washed 
sequentially with H2O (2 mL) and brine (3 mL).  The organic extract was dried (Na2SO4) 
and concentrated in vacuo.  The resulting residue was carried out to the next step without 
any further purification.  In a separate round bottom flask, methyltriphenylphosphonium 
bromide (2.43 g, 6.8 mmol) suspension in THF (15 mL) was cooled to 0 oC and nBuLi 
(2.5 M in Hexanes, 2.6 mL, 6.6 mmol) was added dropwise.   The reaction was stirred for 
1 h before the crude aldehyde in THF solution (1.5 mL, 2× 0.5 mL for rinsing) was 
cannulated.  After 1 h, saturated NH4Cl aqueous solution (20 mL) was added and the 
mixture was stirred and allowed to warm to 25 oC.  The layers were then separated and 
the aqueous layer was extracted with Et2O (3 × 10 mL).  The combined organic extracts 
were dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
chromatography, eluting with EtOAc/hexanes (5:95) gave alkene S176 (1.44 g, 87% over 
two steps) as a colorless oil.  
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To a solution of compound S17 (1.44 g, 3.94 mmol) in THF (20 mL) was added dropwise 
a solution of TBAF (1 M in THF, 4.0 mL, 4.0 mmol) at 25 oC.  The reaction was stirred 
for 1 h, then was diluted with Et2O (20 mL) and NH4Cl(s) (10 mL) was added.  The 
organic layer was separated and the aqueous layer was extracted with ether (3 × 20 mL). 
The combined organic extracts were dried (Na2SO4) and concentrated in vacuo at 10 oC. 
Purification by flash column chromatography, eluting with Et2O/Pentane (15:85) gave 
alcohol7 (0.46 g, 92%) as a colorless oil.  The above alcohol (0.21g, 1.6 mmol) was 
dissolved in CH3CN/H2O (1:1, 20 mL).  TEMPO (0.50g, 3.2 mmol) and BAIB (1.55g, 
4.8mmol) were added in one portion.  The mixture was stirred at 25 oC for 4 h, then it 
was quenched with NH4Cl(s) (10 mL).  The layers were separated and aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL).  The combined organic extracts were dried (Na2SO4) 
and concentrated in vacuo.  Purification by column chromatography (silica gel, 80/20 
Hexanes-EtOAc) gave 0.20 g (88%) of unsaturated dimethyl acid S185 as colorless oil.  
[α]21D  -5.8 (c 1.03, CHCl3); IR (neat) 913.33, 996.28, 1242.21, 1418.71, 1464.03, 
1706.11, 2930.96, 2975.33, 3081.42 cm-1; 1H NMR (300 MHz, CDCl3) 5.71-5.59 (m, 
1H), 5.05-4.94 (m, 2H), 2.58-2.46 (m, 1H), 2.30-2.16 (m, 1H), 1.77-1.72 (m, 1H), 1.42-
1.33 (m, 1H), 1.19 (d, J = 6.0 Hz, 3 H), 1.04 (d, J = 6.0 Hz, 3 H);  13C NMR (75 MHz, 
CDCl3) 183.1, 143.6, 113.8, 40.2, 37.4, 36.1, 20.9, 16.9. 
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Table C-1. Comparison of 13C NMR of natural and synthetic (-)-spongidepsin 
atom number natural (-)-spongidepsin (δc)5a synthetic (-)-spongidepsin (δc) 
C1 18.9 19.1 
C2 19.1 19.1 
C3 21.8 21.8 
C4 22.6 22.6 
C5 25.4 25.4 
C6 25.7 25.7 
C7 28.5 28.5 
C8 32.7 32.7 
C9 33.6 33.6 
C10 34.7 34.7 
C11 35.4 35.5 
C12 35.9 36.0 
C13 38.2 38.2 
C14 40.5 40.5 
C15 40.6 40.6 
C16 67.7 67.8 
C17 70.1 70.1 
C18 74.1 74.2 
C19 84.8 84.8 
C20 127.8 127.9 
C21 129.7 129.7 
C22 130.7 130.8 
C23 139.7 139.7 
C24 172.1 172.1 
C25 179.6 179.6 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of (R)-S1  
 
 
 
 
 180 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S2 
 
 
 181 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S3 
 
 
 182 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S4 
 
 
 183 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of hydrogenation product 
of S4 
 
 
 184 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S5 
 
 
 185 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S6 
 
 
 186 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S7 
 
 
 187 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S8 
 
 
 188 
1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S9 
 
 
 189 
1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S10 
 
 
 190 
1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S11 
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Reported 1HNMR of (-)-spongidepsin 500 MHz (CD3OD)  Angew. Chem. Int. Ed. 2004, 
2148  
 
1HNMR of (-)-spongidepsin synthesized in this work 500 MHz (CD3OD) 
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Reported 1HNMR of (-)-spongidepsin 300 MHz (CDCl3)  Org. Lett., 2007, 2771 
 
1HNMR of (-)-spongidepsin synthesized in this work 500 MHz (CDCl3) 
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Reported 13C NMR of (-)-spongidepsin 75 MHz (CD3OD)  Org. Lett., 2007, 2771 
 
13C NMR of (-)-spongidepsin synthesized in this work 125 MHz (CD3OD) 
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1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S12 
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1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S13 
 
 
 196 
1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S15 
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1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S16 
 
 
 198 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of S18 
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Antiproliferative assay 
Human embryonic kidney cells (HEK-293) (3.4 104 cells/well, 50 µL, in Eagle’s Minimal 
Essential Medium (EMEM)) were plated on 96-well plates and allowed to adhere at 37 
°C in 5% CO2 and 95% air for 2 h.  Thereafter, the cells were treated with 50 µL aliquot 
of each test compounds (Spongidepsin 1, 15, 16, 18 and 19) in EMEM + 4% Fetal 
Bovine Serum (FBS) at different concentrations, ranging from 100 nM to 20 µM.  The 
final concentration of FBS was 2%.  The cells were then incubated for 72 h at 37 °C.  
The cells' viability was assessed through an MTT conversion assay.  Briefly, 25 µL of 
MTT (5 mg/mL, in Hank’s balanced salt solution, HBSS) were added and the cells were 
incubated for an additional 2.5 h. Thereafter, the cells were lysed and the dark blue 
crystals solubilized with 100 µL of an aqueous solution containing 35 % (v/v) N,N-
dimethylformamide,15 % (v/v) glacial acetic acid,  15% (w/v) SDS with an adjusted pH 
of 3.8. 
  
The optical density (OD) of each well (at 570 nm) was measured with a BioTek Synergy 
4 Microplate Reader.  The viability of each cell line in response to the treatment with 
tested compounds was calculated as: % dead cells = 100 - (OD treated/OD control) x 100. 
The results obtained in the antiproliferative assay for (-)-Spongidepsin 1 and the 
derivatives synthesized herein, expressed as an IC50 value (µM), are:  
 
 
Figure C-1.  Anti-proliferation assay on HEK 293 cells treated with (-)-spongidepsin and 
the derivatives prepared herein.  Assay were run for 3 days at 37 °C in EMEM+2% FBS. 
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Table C-2. In vitro antiproliferative activity of (-)-spongidepsin and derivatives  
 HEK 293 (µM) 
Spongidepsin 1 5.68 (0.66)a 
15 8.27 
16 7.32 
18 non cytotoxic 
19 non cytotoxic 
6-MP 7.45 (0.007)a 
  
a Literature data.8  
 
The IC50 value is the concentration of compound that affords 50% reduction in cell 
growth (after 3 day incubation).  HEK-293 is a human epithelial kidney cell line. 
 
The cytotoxicity data in the literature comes from a TL paper (reference 9).  We were 
curious about the difference we were getting, and emailed the authors about it several 
times: they did not reply.  In the paper we do not want to make an issue about just how 
cytotoxic compound (-)-spongidepsin is.  It is cytotoxic, and our data (which is hard to 
screw up in repeated side-by-side assays) shows it is about as much as 6-mercaptopurine.  
Also the relative cytotoxicity of (-)-spongidepsin and its analogs is clear here. Again, 
this is hard to screw up in repeated side-by-side assays; hence we are quite confident of 
the data shown. 
 
Moreover, we did a literature survey of published cytotoxicity values for 6-
mercaptopurine on HEK cells (the ones in the paper).  Ref 9 quotes an IC50 or 0.007 µM, 
and we found 7.5 µM.  The three reports from three different groups that we found quote 
IC50 values of 1.19, 1.710, and 5.211 µM, ie about the same as ours (within exp error) and 
about 100X greater than ref  9. 
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Figure C-2.  Anti-proliferation assay on Panc-1 cells treated with Spongidepsin and the 
derivatives prepared herein.  Assay were run for 3 days at 37 °C in PFHM-II medium 
(protein and serum free medium). 
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APPENDIX D 
EXPERIMENTAL DATA FOR CHAPTER IV 
 
General Procedure for synthesis of vinyl ether esters: 
Acetoacetate (50mmol) and orthoformate (50mmol) were added to a 100ml round bottom 
flask and cooled to 0 oC. Concentrated H2SO4 (0.20ml) was then added slowly. The 
mixture was stirred for 36h at 25 oC. A slight excess of quinoline (0.50ml) was added. 
Purification of the residue by flash chromatography on silica gel, eluting with 
EtOAc/hexanes (5:95) gave the corresponding vinyl ether esters as colorless oils. 
 
Starting with ethyl acetoacetate and trimethyl orthoformate (adding 
1eq. anhydrous CaCl2) (74% yield) [2]  
1H NMR (300 MHz, CDCl3) δ 4.93 (1H, s), 4.05 (2H, q, J = 7.2 Hz), 
3.54 (3H, s), 2.20 (3H, s), 1.18 (3H, t, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3) δ 173.0, 
167.8, 90.9, 59.2, 55.3, 18.8, 14.4.  
 
Starting with methyl acetoacetate and trimethyl orthoformate (65% 
yield) [3] 
1H NMR (300 MHz, CDCl3) δ 5.04 (1H, s), 3.69 (3H, s), 3.64 (3H, 
s), 2.31 (3H, s); 13C NMR (75 MHz, CDCl3) δ 173.0, 168.0, 90.3, 55.1, 50.3, 18.6.  
 
 Starting with ethyl acetoacetate and triethyl orthoformate (60% yield)  
1H NMR (300 MHz, CDCl3) δ 5.01 (1H, s), 4.14 (2H, q, J = 7.2 Hz), 
3.83 (2H, q, J = 7.2 Hz), 2.31 (3H, s), 1.35 (3H, t, J = 7.2 Hz), 1.28 
(3H, t, J = 7.2 Hz). 13C NMR (75 MHz, CDCl3) δ 172.5, 168.2, 91.2, 63.89, 59.4, 19.3, 
14.6, 14.4. MS (ESI): Exact mass calcd for C8H15O3[M+H]
+ 159.10. Found 159.10. 
 
Starting with methyl isobutyrylacetate and trimethyl orthoformate 
(65% yield) [4] 
1H NMR (300 MHz, CDCl3) δ 4.87 (1H, s), 4.02-3.93 (1H, m), 3.63 
(3H, s), 3.59 (3H, s), 1.04 (6H, d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 180.8, 168.1, 
OEtMeO
O
2a
MeO OMe
O
2b
EtO OEt
O
2c
OMe
OMe
O
2d
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88.6, 55.6, 50.8, 29.3, 19.8. MS (ESI): Exact mass calcd for C8H15O3[M+H]
+ 159.10. 
Found 159.10.  
 
To a cooled solution (0 oC) of compound 2b (0.86 g, 6.6 mmol) in 
CH2Cl2 (30 mL) was added Me(OMe)NH.HCl  (1.93 g, 19.8 
mmol) followed by dropwise addition of AlMe3 solution (2 M in 
toluene, 9.9 ml, 19.8 mmol). The resulting mixture was heated to 40oC for 4 h. The 
reaction was then cooled to 0oC first then was diluted with CH2Cl2 (20 mL) and carefully 
add H2O (10 mL). Saturated potassium sodium tartrate aqueous solution (40 mL) was 
then added. The resulting mixture was vigorously stirred for 30 min and the layers were 
separated. The aqueous layer was extracted with CH2Cl2 (3×30 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated in vacuo. Purification by flash 
column chromatography, eluting with EtOAc/hexanes (15:85) gave Wenireb amide 2e 
(0.43 g, 41%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 5.55 (1H, s), 3.67 (3H, s), 
3.64 (3H, s), 3.18 (3H, s), 2.29 (3H, s); 13C NMR (75 MHz, CDCl3) δ 172.0, 169.2, 88.8, 
61.4, 55.3, 32.6, 19.1. MS (ESI): Exact mass calcd for C7H14NO3 [M+H]
 + 160.10. Found 
160.10. 
 
To compound 2b (3.0 g, 23 mmol) in a 100 ml round bottom flask was 
added a solution of KOH (1.3 g, 23 mmol) in H2O (80 mL). The 
mixture was stirred at 25 oC for 1d until the solution became 
homogeneous.  Extracted with Et2O (50 mL) and the aqueous layer was acidified to pH 2 
and then extracted with Et2O (3×30 mL) again. The latter ether extracts were dried 
(Na2SO4) and concentrated in vacuo. Purification by recrystallization (Hexanes) gave 
desired acid 2f (1.7 g, 65%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 5.05 (1H, s), 
3.68 (3H, s), 2.31 (3H, s); 13C NMR (75 MHz, CDCl3) δ 175.5, 173.9, 90.7, 55.9, 19.5. 
MS (ESI): Exact mass calcd for C5H7O3[M-H]
+ 115.04. Found 115.02. 
 
To a cooled solution (0 oC) of compound 2f (0.45 g, 3.8 mmol) in 
CH2Cl2 (3.8 mL) was added t-butyl 2,2,2-trichloroacetimidate 
(1.70 g, 7.6 mmol) in cyclohexane (15.2 ml) followed by dropwise 
MeO OtBu
O
2g
MeO OH
O
2f
MeO N
O
2e
OMe
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addition of BF3.OEt2 (0.076 ml). The mixture was stirred at room temperature for 8h. 
Diluted with CH2Cl2 (10 mL) and NaHCO3(s) (20 mL) was carefully added at 0 oC. The 
aqueous layer was extracted with CH2Cl2 (3×20 mL). The combined organic extracts 
were dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
chromatography, eluting with EtOAc/hexanes (5:95) gave ester 2g (0.33 g, 50%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ 4.96 (1H, s), 3.62 (3H, s), 2.27 (3H, s), 1.49 
(9H, s); 13C NMR (75 MHz, CDCl3) δ 172.2, 167.7, 92.8, 79.4, 55.5, 28.6, 19.0. MS (CI): 
Exact mass calcd for C9H16O3 [M+H]
 + 173.1. Found 173.2. 
 
General Procedure for synthesis of vinyl ether alchols: 
To a cooled solution (0 oC) of vinyl ether ester (5 mmol) in CH2Cl2 was added dropwise a 
solution of DIBAL-H (1 M in Hexanes, 15mmol). Stirring was continued for 1 h and then 
the reaction was cooled to 0 oC and quenched by slow addition of MeOH. The reaction 
was diluted with CH2Cl2 and a saturated aqueous solution of potassium sodium tartrate 
was added. The resulting mixture was vigorously stirred for 30 min and the layers were 
separated. The aqueous layer was extracted with CH2Cl2. The combined organic extracts 
were dried (K2CO3) and concentrated in vacuo. Purification by flash column 
chromatography on Al2O3, eluting with EtOAc/hexanes (30:70) gave the corresponding 
vinyl ether alcohols as colorless oils. 
 
Reduced from 2a (88% yield)[4] 
1H NMR (300 MHz, CDCl3) δ 4.75 (1H, t, J = 7.5 Hz), 4.17 (2H, d, J 
= 7.5 Hz), 3.55 (3H, s), 1.88 (3H, s), 1.15 (1H, br); 13C NMR (75 
MHz, CDCl3) δ 158.4, 96.1, 59.5, 54.5, 16.4.  
 
 
Reduced from 2c (80% yield) 
1H NMR (300 MHz, CDCl3) δ 4.73 (1H, t, J = 7.5 Hz), 4.16 (2H, dd, J 
= 2.7, 7.5 Hz), 3.74 (2H, q, J = 7.2 Hz), 1.89 (3H, s), 1.32 (3H, t, J = 
7.2 Hz), 1.07 (1H, br); 13C NMR (75 MHz, CDCl3) δ 157.7, 96.5, 62.4, 59.6, 16.6, 14.8. 
MS (ESI): Exact mass calcd for C6H12LiO2[M+Li]
+ 123.10. Found 123.10. 
MeO OH
4a
EtO OH
4b
 205 
 
Methyl 3-oxoheptanoate (20mmol) and trimethyl orthoformate 
(20mmol) were added to a 100ml round bottom flask and cooled to 
0 oC. Concentrated H2SO4 (0.1ml) was then added slowly. The 
mixture was stirred for 36h at 25 oC. A slight excess of quinoline (0.50ml) was added. 
Purification of the residue by flash chromatography on silica gel, eluting with 
EtOAc/hexanes (5:95) gave the corresponding vinyl ether esters as colorless oils. Directly 
reducing the ester gave the 4c as colorless oil (51% yield for 2 steps). 1H NMR (300 
MHz, CDCl3) δ 4.72 (1H, t, J = 7.5 Hz), 4.17 (2H, d, J = 7.5 Hz), 3.54 (3H, s), 2.22 (2H, 
t, J = 7.5 Hz), 1.64-1.46 (2H, m), 1.36-1.29 (2H, m), 1.29 (1H, br), 0.92 (3H, t, J = 7.2 
Hz); 13C NMR (75 MHz, CDCl3) δ 162.2, 96.0, 59.3, 54.5, 30.5, 30.3, 22.7, 14.2. MS 
(CI): Exact mass calcd for C8H17O2[M+H]
+ 145.0. Found 145.1. 
 
 
Reduced from 2d (78% yield)[5] 
1H NMR (300 MHz, CDCl3) δ 4.53 (1H, t, J = 7.8 Hz), 4.10 (2H, d, J = 
7.8 Hz), 3.45 (3H, s), 2.86-2.77 (1H, m), 2.10 (1H, br), 1.00 (6H, d, J = 
6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 165.5, 94.1, 58.3, 54.4, 28.5, 20.5. MS (ESI): 
Exact mass calcd for C7H15O2[M+H]
+ 131.11. Found 131.20. 
 
To a cooled solution of compound 4a (0.21 g, 2.0 mmol) and 
imidazole (0.17 g, 2.5 mmol) in CH2Cl2 (10 mL) was added 
TBDPSCl (0.63 g, 2.3 mmol). The mixture was stirred at 25 oC 
for 1 h, then the reaction was quenched by addition of saturated NaHCO3 aqueous 
solution (5 mL). The layers were seperated and aqueous layer was extracted with CH2Cl2 
( 3×10 mL). The combined organic extracts were dried (K2CO3) and concentrated in 
vacuo. Purification by flash chromatography on basic Al2O3 eluting with EtOAc/Hexanes 
(10:90) gave the desired product 4e (0.53 g, 75%) as a colorless oil. 1H NMR (300 MHz, 
CDCl3) δ 7.74-7.71 (4H, m), 7.43-7.40 (6H, m), 4.63 (1H, t, J = 7.2 Hz), 4.24 (2H, d, J = 
7.2 Hz), 3.48 (3H, s), 1.64 (3H, s), 1.07 (9H, s); 13C NMR (75 MHz, CDCl3) δ 156.4, 
OMe
OH
4d
MeO OH
4c
MeO OTBDPS
4e
 206 
136.0, 134.5, 129.8, 127.9, 96.8, 61.2, 54.4, 27.2, 19.5, 16.5. MS (CI): calcd for 
C21H29O2Si [M+H]
+ 341.2. Found 341.3. 
 
To a cooled solution of compound 4a (0.32 g, 3.0 mmol) and DMAP 
(36 mg, 0.30 mmol) in CH2Cl2 (12 mL) was added Ac2O (0.43 mL, 
4.5 mmol) and Et3N (0.63 mL, 4.5 mmol) sequentially. The reaction 
mixture was stirred at 25 oC for 30 min, then the reaction was quenched by addition of 
saturated NH4Cl aqueous solution (5 mL). The layers were seperated and aqueous layer 
was extracted with CH2Cl2 ( 3×10 mL). The combined organic extracts were washed by 
water, saturated brineand then dried by Na2SO4 and concentrated in vacuo. Purification 
by flash chromatography on basic Al2O3 eluting with EtOAc/Hexanes (5:95) gave the 
desired product 4f (0.31 g, 72%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 4.69-
4.59 (2H, m), 4.64 (1H, s), 3.55 (3H, s), 2.06 (3H, s), 1.89 (3H, s); 13C NMR (75 MHz, 
CDCl3) δ 171.5, 160.4, 91.3, 62.0, 54.7, 21.4, 16.6. MS (CI): calcd for C7H13O3[M+H]
+ 
145.1. Found 145.0. 
 
General catalytic hydrogenation conditions: the corresponding alkene was dissolved in 
CH2Cl2 (0.5 M) and the Iridium catalyst (L-cat) (1 mol %) was then added. The resulting 
solution was degassed by three cycles of freeze-pump-thaw and then transferred to a Parr 
Bomb. The bomb was flushed with hydrogen for 1 min without stirring. The mixture was 
then stirred at 700 rpm under 50 bar H2. After 48h (for esters and its derivatives) or 12 h 
(for alcohols and its derivatives[6]), the bomb was vented and the solvent evaporated. The 
crude product was passed through a silica plug (EtOAc/hexanes =3:7). The enantiomeric 
ratio of the crude material was then measured through chiral capillary GC analysis using 
β- or a γ-CD column[7] (carrier gas: helium; column pressure: 18.21 Psi; gas flow rate: 1.6 
mL/min; gradient temperature: 5 oC/min: 60 oC hold time: 10 min, 120 oC, 15 min).  
 
1H NMR (300 MHz, CDCl3) δ 4.16 (2H, q, J = 7.2 Hz), 3.82-3.76 (1H, 
m), 3.35 (3H, s), 2.58 (1H, dd, J = 7.2, 15 Hz), 2.37 (1H, dd, J = 6.0, 15 
Hz), 1.28 (3H, t, J = 7.2 Hz), 1.22 (3H, d, J = 6.3 Hz); 13C NMR (75 
MeO OAc
4f
OMe
OEt
O
3a
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MHz, CDCl3) δ 171.3, 73.9, 61.7, 56.3, 35.7, 21.2, 19.2. MS (CI): calcd for C7H15O3 
[M+H]+ 147.1. Found 147.0. 
 
1H NMR (300 MHz, CDCl3) δ 3.75-3.68 (1H, m), 3.63 (3H, s), 3.28 (3H, 
s), 2.52 (1H, dd, J = 7.2, 15 Hz), 2.32 (1H, dd, J = 5.7, 15 Hz), 1.15 (3H, 
d, J = 6.3 Hz); 13C NMR (75 MHz, CDCl3) δ 172.0, 73.7, 56.4, 51.7, 
41.6, 19.2. MS (ESI): calcd for C6H13O3 [M+H]
+ 133.09. Found 133.09. 
 
1H NMR (300 MHz, CDCl3) δ 4.15 (2H, q, J = 7.2 Hz), 3.89-3.86 (1H, 
m), 3.60-3.42 (2H, m), 2.58 (1H, dd, J = 7.2, 15 Hz), 2.36 (1H, dd, J = 
6.0, 15 Hz), 1.27 (3H, t, J = 7.2 Hz), 1.21 (3H, d, J = 6.3 Hz), 1.18 (3H, t, 
J = 7.2 Hz); 13C NMR (75 MHz, CDCl3) δ 171.9, 72.2, 64.3, 60.6, 42.4, 20.2, 15.7, 14.5. 
MS (ESI): calcd for C8H16LiO3[M+Li]
+ 167.13. Found 167.10. 
 
1H NMR (300 MHz, CDCl3) δ 3.89-3.83(1H, m), 3.70 (3H, s), 3.35 
(3H, s), 3.20 (3H, s), 2.82 (1H, dd, J = 6.9, 15.6 Hz), 2.38 (1H, dd, J 
= 5.7, 15.6 Hz), 1.23 (3H, d, J = 6.0 Hz); 13C NMR (75 MHz, CDCl3) 
δ 172.6, 73.8, 61.5, 56.2, 39.2, 32.2, 19.6. MS (ESI): calcd for C7H16NO3[M+H]
+ 162.11. 
Found 161.95. 
 
1H NMR (300 MHz, CDCl3) δ 3.84-3.78 (1H, m), 3.40 (3H, s), 2.65-2.47 
(2H, m), 1.26 (3H, d, J = 6.3 Hz); 13C NMR (75 MHz, CDCl3) δ 177.0, 
73.7, 56.5, 41.6, 19.2. MS (ESI): calcd for C5H9O3[M-H]
+ 117.06. Found 
117.03. 
 
The hydrogenation product 3g cannot be separated on GC, so directly 
reduced to alcohol 5a.  
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1H NMR (300 MHz, CDCl3) δ 3.75-3.70 (2H, m), 3.58-3.52 (1H, m), 3.32 
(3H, s), 2.94 (1H, br), 1.72-1.67 (2H, m), 1.16 (3H, d, J = 6.3 Hz); 13C 
NMR (75 MHz, CDCl3) δ 76.8, 61.0, 56.1, 38.7, 19.0.[8] 
 
GC analysis: cannot separate on chiral column.  
1H NMR (300 MHz, CDCl3) δ 3.81-3.78 (2H, m), 3.71-3.63 (2H, m), 
3.44-3.39 (1H, m), 2.91 (1H, br), 1.75-1.71 (2H, m), 1.24-1.19 (6H, m); 
13C NMR (75 MHz, CDCl3) δ 76.0, 64.0, 61.7, 38.8, 19.7, 15.9.  
 
To a cooled solution of compound 5b (11.8 mg, 0.1 mmol) and DMAP 
(1.2 mg, 0.01 mmol) in CH2Cl2 (0.5 mL) was added Ac2O (15.3 mg, 0.15 
mmol) and Et3N (15.2 mg, 0.15 mmol) sequentially. The reaction 
mixture was stirred at 25 oC for 30 min, then the reaction was quenched by addition of 
saturated NH4Cl aqueous solution (0.5 mL). The layers were seperated and the aqueous 
layer was extracted with CH2Cl2 ( 3×1 mL). The combined organic extracts were washed 
by water, saturated brineand then dried by Na2SO4 and concentrated in vacuo. 
Purification by flash chromatography on small piptte column eluting with 
EtOAc/Hexanes (5:95) gave the desired product 5b’ (14.1 mg, 88%) as a colorless oil. 1H 
NMR (300 MHz, CDCl3) δ 4.15 (2H, t, J = 6.6 Hz), 3.59-3.50 (2H, m), 3.48-3.34 (1H, m), 
2.03 (3H, s), 1.81-1.70 (2H, m), 1.18-1.14 (6H, m); 13C NMR (75 MHz, CDCl3) δ 171.3, 
72.1, 64.0, 61.8, 36.0, 21.2, 20.0, 15.7. MS (CI): calcd for C8H17O3 [M+H]
+ 161.1. Found 
161.0. 
 
1H NMR (300 MHz, CDCl3) δ 3.73-3.80 (2H, m), 3.38-3.41 (1H, 
m), 3.36 (3H, s), 2.74 (1H, br), 1.78-1.35 (4H, m), 1.35-1.27 (4H, 
m), 0.91 (3H, t, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 81.3, 
61.2, 56.6, 35.7, 32.9, 27.4, 23.1, 14.3. MS (CI): calcd for C8H17O2 [M-H]
+ 145.1. Found 
145.0. 
 
OMe
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1H NMR (300 MHz, CDCl3) δ 3.74 (2H, t, J = 6.0 Hz), 3.36 (3H, s), 
3.18-3.15 (1H, m), 2.87 (1H, br), 1.98-1.92 (1H, m), 1.68-1.65 (2H, m), 
0.89 (3H, d, J = 6.9 Hz), 0.86 (3H, d, J = 6.9 Hz); 13C NMR (75 MHz, 
CDCl3) δ 86.0, 61.4, 57.4, 31.7, 29.7, 18.7, 17.0. MS (ESI): calcd for C7H16LiO2 [M+Li]
+ 
139.13. Found 139.13. 
 
1H NMR (300 MHz, CDCl3) δ 7.75-7.71 (4H, m), 7.46-7.42 (6H, m), 
3.87-3.74 (2H, m), 3.63-3.56 (1H, m), 3.34 (3H, s), 1.82-1.68 (2H, 
m), 1.18 (3H, d, J = 6.0 Hz), 1.11 (9H, s); 13C NMR (75 MHz, 
CDCl3) δ 135.8, 134.2, 129.8, 127.8, 73.9, 60.8, 56.2, 39.6, 27.1, 27.0, 19.5. MS (CI): 
calcd for C21H31O2Si [M+H]
+ 343.2. Found 343.3. 
 
1H NMR (300 MHz, CDCl3) δ 4.17 (2H, t, J = 6.6 Hz), 3.45-3.33 (1H, 
m), 3.33 (3H, s), 2.06 (3H, s), 1.82-1.76 (2H, m), 1.18 (3H, d, J = 6.3 
Hz); 13C NMR (75 MHz, CDCl3) δ 171.3, 73.9, 61.7, 56.3, 35.7, 21.2, 
19.2. MS (ESI): calcd for C7H15O3 [M+H]
+ 147.10. Found 147.10. 
 
Methods used to determine the absolute chemistry of hydrogenation products 
Preparation of  enantiomer pure 5a [9] 
(R)
OH
OH
TBDPSCl, imidazole
CH2Cl2, 25 oC, 1 h
(R)
OH
OTBDPS
MeOTf, CH2Cl2
25 oC, 24 h
NtBu tBu
(R)
OMe
OTBDPS
TBAF, THF
25 oC, 1 h
(R)
OMe
OH
 
 
Preparation of enantiomer pure 5b 
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OMe
OAc
5f
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(R)
OH
OH
TBDPSCl, imidazole
CH2Cl2, 25 oC, 1 h
(R)
OH
OTBDPS
(R)
OEt
OTBDPS
TBAF, THF
25 oC, 1 h
(R)
OEt
OH
NaH, EtI, HMPA
THF, ref lux, 24 h
 
 
Preparation of enantiomer pure 5f, 5b’ 
 
(R)
OR
OH
Ac2O, Et3N, DMAP(cat)
CH2Cl2, 25 oC, 30 min
( R)
OR
OAc
R = Me, Et  
 
Preparation of enantiomer rich 3e 
 
(S)
OMe
OMe
O Me(OMe)NH.HCl, AlMe3
CH2Cl2, 40 oC, 4 h
(S)
OMe
N
O
OMe
 
 
Preparation of enantiomer rich 3b, 3d, 5c, 5d [9], [10] 
 
R
O
OMe
O [((R)-BINAP)RuBr2]2(acetone)
23 bar H2, 50 oC, 48 h
R (R)
OH
OMe
O
MeOTf, CH2Cl2
25 oC, 24 h
NtBu tBu
R (R)
OMe
OMe
O DIBAL-H, 25 oC, 1 h
R (R)
OMe
OH
R = Me, i-Pr, n-Bu
CH2Cl2
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Reference: 
1) Armarego, W. L. F. and Perrin, D. D. Purification of Laboratory Chemicals; 4th 
Edition, Butterworth Heinemann, Oxford, 1996.  
2) Smissman, E. E.; Voldeng A. N., J. Org. Chem. 1964, 11, 3161. 
3) Krebs, O.; Taylor, R. J. K., Org. Lett. 2005, 6, 1063. 
4) Ireland, R.E.; Thaisrivongs, S.; Vanier, I.N.; Wilcox, C. S., J. Org. Chem. 1980, 1, 48. 
5) Stereochemistry assumed to be (Z)-olefin based on comparing the 1H NMR with other 
substrates. 
6) Need adding 1 equivalent anhydrous K2CO3 . 
7) Staerk D. U.,  Shitangkoon A., Vigh G., J. Chromatogr. A. 1995, 702, 251.  
8) Get the true sample from Aldrich Company. 
9) Evans D. A.; Ratz A. M.; Huff B. E.; Sheppard G. S., Tetrahedron Lett. 1994, 39, 
7171. 
10) Genet J. P.; Ratovelomanana-Vidal V.; Pfister X.; Guerriro P.; Lenoir J.Y., 
Tetrahedron Lett. 1995, 27, 4801. 
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GC data: 
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Computational Details 
All calculations were performed using the Gaussian 031 implementation of 
Tao-Perdew-Staroverov-Scuseria (TPSS) density functional theory (DFT).2 As a third 
generation of density functional, TPSS is generally superior to all previously developed 
nonempirical functionals, and virtually matches in accuracy the most popular 
functional-B3LYP.3-6 
The basis sets for transition metals (Ir, Rh, Pt and Ni) were Stuttgart/Dresden (SDD) 
with the effective core potential (ECP)7 while those for phosphorus and chlorine were 
LANL2DZ plus a d-polarization and a p-diffuse function8 with ECP.9,10 Further, an 
f-polarization function was also added to the second- and third-row transition metals.11 
6-31++G(d',p') basis sets were used for all C, N and O in the directly-bound conjugated 
ligand systems, such as imidazolidine, oxazoline and pyridine, and hydrides, dihydrogen.  
The same basis sets were also applied to all atoms in ethene12-14while 6-31G was used for 
the rest atoms.12 In addition, density fitting functions were included to accelerate the 
computation with DFT.15,16 Density fitting functions can be included for this pure 
DFT—and only pure DFT—to save tremendous computational expense by expanding the 
density in a set of atom-centered functions when computing the Coulombic interaction 
instead of computing all of the two-electron integrals.15,16  A comparison of TPSS with or 
without density fitting functions included for an organometallic reaction shows only 
marginal difference for both relative energies and structural parameters.17 TPSS 
reproduces these properties at least as precisely as B3LYP.  Especially, TPSS can 
recognize relatively weak interactions (such as agostic interactions) very well while 
B3LYP significantly underestimates them.  Furthermore, using smaller basis sets for the 
atoms far from the reaction center does not degrade the computational precision and 
accuracy significantly but can accelerate the calculations considerably.17 
All structures were fully optimized in dichloromethane solution and frequency analyses 
were performed to ensure a minimum was achieved.  The thermodynamic functions, 
including enthalpies, entropies and free energies, were calculated at 298.15 K and 1 atm.  
The solvation free energies were computed by using polarizable conductor calculation 
model (CPCM).18,19 
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The catalysts investigated in the calculations are seen below.  The acid-base balance is 
shown in Scheme S1.  The pKa values for the ethene and hydrides coordinated 
intermediates in acetonitrile and dichloromethane solution are listed in Tables S1 and S2, 
respectively.  The calculation for pKa is based on the Born-Haber Cycle and the 
corresponding methods are shown in Scheme S2 and Equations 1-5. 
Ph2P N
O
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t-Bu
BARF-
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NCy3P
PF6
-
N
N
O
R1
Ir
N
R2
+
BARF-
Crabtree's catalyst
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O
Ph2P N
O
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Ph3P Cl
PPh3
 
Scheme D-1.  The acid-base balance.
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H++
Acid Base
in gas phase
!Gsolv !Gsolv
!Ggas
!Gtotal
HB+gas Bgas
HB+solv Bsolv in solution
Scheme D-2.  The Born-Haber cycle  
)()( acidGbaseGG gasgasgas !="               (1) 
)]()([ baseGacidGGG solvsolvgastotal !"!+!=!           (2) 
Set      )1()2(
totaltotaltotal
GGG !"!=!!             (3) 
            
K 298.15 = 
cal/mol/K 1.987 = 
/3026.2K
a
T
R
RTGp total!=
             (4) 
Then   RTGpp total /3026.2)1(K)2(K aa !!+=           (5) 
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Scheme D-3. Selected examples of calculated pKa values in acetonitrile.  
 
 
Table D-1. Calculated pKa in acetonitrile. 
Acid Base    
Catalyst Ggas 
(Hartree)a 
ΔGsolv 
(kcal/mol) 
Ggas 
(Hartree)a 
ΔGsolv 
(kcal/mol) 
ΔGtotal 
(kcal/mol) 
pKa 
(expl.) 
pKa 
(calc.) 
[HNi(dmpe)2]+ -673.727152 -11.96 -673.313930 17.98 289.24 24.4±0.220 21.7±2.2 
[HPt(dmpe)2]+ -630.694836 -9.68 -630.278621 19.34 290.20 31.121 32.3±2.2 
[HNi(dppe)2]+ -2207.251396 15.93 -2206.844821 39.23 278.43 14.7±0.320 13.8±2.2 
[HPt(dppe)2]+ -2155.752957 18.49 -2155.319423 39.60 293.16 22.220 24.6±2.2 
Crabtree’s -1145.473993 -10.09 -1145.076729 15.59 274.97 - 11.3±2.2 
Wilkinson’s -1608.110244 8.51 -1607.571089 -18.01 311.80 - 36.1±2.2 
Burgess’ -1592.227152 -18.12 -1591.817578 5.86 280.99 - 17.4±2.2 
Pfaltz’ 1 -1289.821847 -15.32 -1289.420063 5.99 273.43 - 11.5±2.2 
Pfaltz’ 2 -1325.770711 -17.62 -1325.373954 4.34 270.93 - 9.8±2.2 
 a 1 Hartree = 627.5095 kcal/mol. 
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For example, based on equations 1-5: 
kcal/mol30.283)12.8186.5(5095.627)227152.592178-1591.8175(
)]()([)(
=++!+=
"#"+"=" baseGacidGGG solvsolvgastotal Burgess'  
So, if choose metal hydride [HNi(dmpe)2]+ as the reference, 
kcal/mol94.524.28930.283
)]][HNi(dmpe)()( 2total
!=!=
"!"=""
+
totaltotal
GGG sBurgess'  
The calculated pKa value of metal hydride from Burgess’s catalyst will be: 
0.2015.298/987.1/100094.53026.24.24
/3026.2)][HNi(dmpe)(K)(K 2aa
=!!"=
##+=
+ RTGpp totalsBurgess'  
Here, the calculated pKa’s listed were calculated first as pKa differences.  These 
values where then compared with the experimental pKa’s for each reference 
compound to give a set of pKa values against the reference.  The values quoted are 
averaged from this procedure, where the errors shown are standard deviation.19,20 
 
 
 
 
 
 
 
Table D-2. Calculated pKa in dichloromethane. 
Acid Base   
Catalyst Ggas 
(Hartree) 
ΔGsolv 
(kcal/mol) 
Ggas 
(Hartree) 
ΔGsolv 
(kcal/mol) 
ΔGtotal 
(kcal/mol) 
pKaa 
(relative) 
Crabtree’s -1145.473993 -18.63 -1145.076729 4.87 273.433277 1.4 
Wilkinson’s -1608.110244 8.51 -1607.571089 -18.01 270.928787 30.0 
Burgess’ -1592.227152 -18.12 -1591.817578 5.86 272.786934 7.4 
Pfaltz’ 1 -1289.821847 -15.32 -1289.420063 5.99 311.804884 1.8 
Pfaltz’ 2 -1325.770711 -17.62 -1325.373954 4.34 280.991576 0.0 
a The pKa for Pfaltz’ catalyst 2 is set to 0. 
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Table D-3.  Cartesian coordinates and electronic energies for all species listed in Tables 
S1, S2.  
1. Crabtree’s catalyst 
Acid E = -1146.068380600 Hartree 
Ir     1.007947    -1.422781    -0.186460 
 P    -0.911763     0.058889    -0.122330 
 C    -1.055132     0.918301     1.573613 
 C     0.075800     1.957506     1.782204 
 C     0.114372     2.440916     3.249886 
 C    -1.246669     3.013422     3.692101 
 C    -2.380022     1.998481     3.448665 
 C    -2.422853     1.530725     1.973935 
 H    -0.866603     0.074311     2.263915 
 H     1.049290     1.534926     1.494722 
 H    -0.101267     2.823272     1.123573 
 H     0.906209     3.197326     3.366958 
 H     0.384312     1.592407     3.903765 
 H    -1.211413     3.295949     4.755203 
 H    -1.455493     3.937606     3.125891 
 H    -2.236849     1.121270     4.103694 
 H    -3.352958     2.437774     3.717184 
 H    -3.234405     0.802147     1.845579 
 H    -2.656079     2.391607     1.330757 
 C    -0.999212     1.326397    -1.545587 
 C    -1.982948     2.507657    -1.329120 
 C    -2.120061     3.342359    -2.624328 
 C    -0.755992     3.881194    -3.093858 
 C     0.257939     2.733484    -3.261070 
 C     0.379557     1.878675    -1.978539 
 H    -1.381115     0.702100    -2.375588 
 H    -2.972790     2.159903    -1.006549 
 H    -1.593402     3.161335    -0.531636 
 H    -2.820968     4.172228    -2.445360 
 H    -2.565805     2.716494    -3.416828 
 H    -0.867858     4.429479    -4.041509 
 H    -0.373949     4.604241    -2.352248 
 H    -0.057593     2.083538    -4.095758 
 H     1.249312     3.132160    -3.528908 
 H     1.067762     1.042165    -2.157097 
 H     0.809254     2.487393    -1.165372 
 C    -2.441172    -1.064222    -0.366408 
 C    -2.681317    -1.974220     0.865987 
 C    -3.762048    -3.039095     0.569896 
 C    -5.078054    -2.393193     0.097482 
 C    -4.833236    -1.484091    -1.121053 
 C    -3.763840    -0.403112    -0.830729 
 H    -2.093536    -1.710179    -1.191999 
 H    -1.746693    -2.477370     1.158900 
 H    -3.004602    -1.364076     1.725147 
 H    -3.930560    -3.645887     1.473002 
 H    -3.388163    -3.725011    -0.209763 
 H    -5.814413    -3.172040    -0.152284 
 H    -5.512633    -1.798161     0.919681 
 H    -4.502622    -2.098361    -1.976596 
 H    -5.767622    -0.990321    -1.429359 
 H    -3.602014     0.187377    -1.744171 
 H    -4.147404     0.284100    -0.060280 
 N     2.773182    -0.075311     0.177811 
 C     3.292792     0.115868     1.421797 
 H     2.726162    -0.313804     2.246647 
 C     4.479745     0.813641     1.660247 
 H     4.836872     0.927504     2.683098 
 C     5.185498     1.349282     0.573697 
 H     6.114711     1.898055     0.725803 
 C     4.665772     1.155266    -0.712893 
 H     5.172594     1.544207    -1.595273 
 C     3.471525     0.443794    -0.866928 
 H     3.045493     0.271010    -1.852552 
 H     0.967627    -1.498078     1.617562 
 H    -0.088067    -2.483557    -0.619548 
 H     0.466208    -2.129085     1.355452 
 H     1.000327    -1.004618    -1.727266 
 C     2.443105    -2.777194    -1.256597 
 C     2.471178    -3.121285     0.101327 
 H     1.869271    -3.368386    -1.967386 
 H     3.240906    -2.170087    -1.683974 
 H     1.916332    -3.988333     0.457951 
 H     3.288100    -2.779909     0.738107 
 
Base E = -1145.661164160 Hartree 
Ir     1.034080    -1.389419    -0.257848 
 P    -0.868022     0.034415    -0.126630 
  
248 
 C    -1.061717     0.883978     1.574871 
 C     0.060801     1.925710     1.802996 
 C     0.104896     2.380793     3.278549 
 C    -1.258042     2.935367     3.739491 
 C    -2.386017     1.916709     3.481504 
 C    -2.429056     1.476578     1.998220 
 H    -0.848568     0.026647     2.238335 
 H     1.031462     1.505277     1.506075 
 H    -0.117748     2.806434     1.162470 
 H     0.892552     3.140598     3.412611 
 H     0.381148     1.519081     3.911639 
 H    -1.221379     3.202410     4.808257 
 H    -1.477310     3.866954     3.187526 
 H    -2.228089     1.028156     4.117982 
 H    -3.360639     2.344094     3.769230 
 H    -3.235000     0.742164     1.861570 
 H    -2.682086     2.349335     1.377070 
 C    -1.043906     1.348611    -1.510718 
 C    -2.051114     2.501241    -1.274204 
 C    -2.213842     3.363256    -2.548439 
 C    -0.862121     3.938755    -3.014115 
 C     0.176710     2.816358    -3.204843 
 C     0.320351     1.940545    -1.939994 
 H    -1.408154     0.733218    -2.355828 
 H    -3.032260     2.125199    -0.954743 
 H    -1.676959     3.148830    -0.463449 
 H    -2.931572     4.177457    -2.354759 
 H    -2.646844     2.743558    -3.353826 
 H    -0.989857     4.507728    -3.949519 
 H    -0.492601     4.652811    -2.256451 
 H    -0.129334     2.175718    -4.051035 
 H     1.156992     3.244619    -3.472695 
 H     1.021441     1.116064    -2.125367 
 H     0.736430     2.547863    -1.117432 
 C    -2.403273    -1.087992    -0.360781 
 C    -2.604500    -2.011468     0.868013 
 C    -3.651369    -3.107249     0.572249 
 C    -4.992661    -2.500891     0.114117 
 C    -4.788781    -1.570173    -1.097441 
 C    -3.747041    -0.462915    -0.807674 
 H    -2.048547    -1.725954    -1.189111 
 H    -1.642703    -2.465529     1.146618 
 H    -2.948655    -1.416194     1.731399 
 H    -3.798322    -3.730578     1.469470 
 H    -3.261998    -3.773693    -0.217186 
 H    -5.710893    -3.298822    -0.135903 
 H    -5.435977    -1.924034     0.945816 
 H    -4.445657    -2.168079    -1.960303 
 H    -5.744870    -1.107501    -1.393242 
 H    -3.612252     0.139390    -1.718770 
 H    -4.145740     0.209563    -0.030476 
 N     2.770595    -0.068365     0.130857 
 C     3.256353     0.086657     1.392048 
 H     2.646067    -0.366101     2.172142 
 C     4.447392     0.763189     1.676836 
 H     4.778909     0.851606     2.711649 
 C     5.192257     1.310316     0.621911 
 H     6.124806     1.843174     0.810970 
 C     4.707383     1.146202    -0.683447 
 H     5.247750     1.541984    -1.543568 
 C     3.506928     0.455366    -0.884225 
 H     3.097116     0.290950    -1.879248 
 H     0.757763    -1.518798     1.385493 
 H     1.004562    -0.983944    -1.876182 
 H    -0.063912    -2.496723    -0.551062 
 C     2.443116    -2.792375    -1.117350 
 C     2.326217    -3.038538     0.287740 
 H     1.953981    -3.455045    -1.829949 
 H     3.335724    -2.294943    -1.504549 
 H     1.749101    -3.890140     0.646194 
 H     3.130367    -2.725423     0.958026 
 
 
2. Wilkinson’s catalyst 
Acid E = -1608.64423489 Hartree 
Rh    -0.003829    -0.150191    -0.215730 
 P    -2.358400     0.012168     0.028421 
 C    -2.928419     0.345273     1.781367 
 C    -4.165375    -0.132726     2.259870 
 H    -4.801476    -0.744269     1.620359 
 C    -4.583788     0.160364     3.568024 
 H    -5.538734    -0.228196     3.925943 
 C    -3.778461     0.941078     4.411385 
 H    -4.104342     1.165554     5.428340 
 C    -2.545433     1.421456     3.942054 
  
249 
 H    -1.905659     2.021305     4.591607 
 C    -2.118773     1.118780     2.639769 
 H    -1.146954     1.470479     2.292012 
 C    -3.497552    -1.354653    -0.546125 
 C    -3.029101    -2.684663    -0.521801 
 H    -2.003989    -2.891962    -0.204808 
 C    -3.873691    -3.736175    -0.915835 
 H    -3.495609    -4.759615    -0.896030 
 C    -5.186447    -3.474762    -1.336771 
 H    -5.838202    -4.293781    -1.646176 
 C    -5.659108    -2.151640    -1.361595 
 H    -6.678866    -1.937799    -1.686868 
 C    -4.821806    -1.096061    -0.968870 
 H    -5.201161    -0.073753    -0.996105 
 C    -3.042672     1.487425    -0.905237 
 C    -3.241259     1.395675    -2.301234 
 H    -3.077074     0.446986    -2.815613 
 C    -3.671897     2.509695    -3.038408 
 H    -3.824747     2.416407    -4.114996 
 C    -3.906611     3.735279    -2.393939 
 H    -4.242266     4.601363    -2.966454 
 C    -3.711433     3.835796    -1.007744 
 H    -3.897375     4.781196    -0.495071 
 C    -3.282931     2.721306    -0.268105 
 H    -3.142667     2.816212     0.809106 
 P     2.331961     0.049115     0.018887 
 C     3.323903    -1.237268    -0.898709 
 C     3.518586    -1.113292    -2.292014 
 H     3.159691    -0.229283    -2.822032 
 C     4.192207    -2.113249    -3.009859 
 H     4.339168    -1.998189    -4.085154 
 C     4.674447    -3.253245    -2.346451 
 H     5.197139    -4.032000    -2.904200 
 C     4.476825    -3.386734    -0.963581 
 H     4.840021    -4.272930    -0.440820 
 C     3.802335    -2.389060    -0.242785 
 H     3.644806    -2.512617     0.827838 
 C     2.943254    -0.082560     1.782296 
 C     2.275550    -0.948821     2.674681 
 H     1.417216    -1.526392     2.325630 
 C     2.724298    -1.077710     3.998765 
 H     2.201947    -1.754868     4.676779 
 C     3.830851    -0.340411     4.450156 
 H     4.171584    -0.437310     5.482518 
 C     4.493832     0.526432     3.567697 
 H     5.351073     1.109334     3.909205 
 C     4.055857     0.653588     2.239404 
 H     4.578180     1.338112     1.571130 
 C     3.103419     1.649232    -0.575803 
 C     2.341987     2.835537    -0.567582 
 H     1.296285     2.796436    -0.258486 
 C     2.911046     4.055663    -0.965240 
 H     2.303610     4.962201    -0.954513 
 C     4.250142     4.107250    -1.382914 
 H     4.690901     5.054124    -1.699105 
 C     5.018176     2.931795    -1.397260 
 H     6.059791     2.959994    -1.721842 
 C     4.451548     1.711821    -0.994764 
 H     5.059147     0.806420    -1.014221 
Cl     0.312832    -2.615070     0.275695 
 H    -0.111035     1.411800    -0.131689 
 H     0.013994     0.001582     1.341666 
 C     0.114773     0.457667    -2.447751 
 C    -0.130238    -0.904488    -2.405013 
 H    -0.687670     1.177117    -2.603922 
 H     1.121015     0.847503    -2.599667 
 H    -1.138903    -1.301475    -2.521460 
 H     0.673673    -1.635719    -2.471947 
 
Base E = -1608.09285965 Hartree 
Rh     0.008362    -0.555366    -0.332793 
 P    -2.192852    -0.045149     0.015018 
 C    -2.769385     0.368061     1.770885 
 C    -4.117941     0.252245     2.169538 
 H    -4.863537    -0.121606     1.467482 
 C    -4.516758     0.594976     3.471953 
 H    -5.564905     0.486956     3.760950 
 C    -3.573494     1.067115     4.399567 
 H    -3.882060     1.328474     5.414414 
 C    -2.228922     1.187325     4.013671 
 H    -1.481518     1.542221     4.726670 
 C    -1.831766     0.836207     2.712293 
 H    -0.782712     0.899140     2.417207 
 C    -3.491854    -1.335453    -0.477106 
 C    -3.080623    -2.683804    -0.404993 
 H    -2.052554    -2.919229    -0.104056 
  
250 
 C    -3.969729    -3.715897    -0.750530 
 H    -3.632591    -4.752870    -0.690215 
 C    -5.270525    -3.418593    -1.189475 
 H    -5.955686    -4.222457    -1.469608 
 C    -5.682449    -2.077912    -1.281025 
 H    -6.688756    -1.834535    -1.631593 
 C    -4.799727    -1.043991    -0.924916 
 H    -5.130375    -0.006617    -1.008933 
 C    -2.857623     1.460094    -0.897263 
 C    -3.112222     1.386189    -2.288409 
 H    -3.037138     0.425492    -2.801593 
 C    -3.473967     2.528720    -3.020234 
 H    -3.665508     2.441967    -4.092319 
 C    -3.586794     3.775053    -2.382457 
 H    -3.867381     4.663840    -2.951622 
 C    -3.330315     3.864562    -1.002525 
 H    -3.416593     4.826154    -0.490580 
 C    -2.968108     2.722695    -0.271413 
 H    -2.771458     2.813048     0.798328 
 P     2.212457     0.051625     0.001145 
 C     3.492159    -0.827460    -1.063505 
 C     3.902385    -0.322032    -2.318360 
 H     3.577887     0.669133    -2.640200 
 C     4.732123    -1.076209    -3.164759 
 H     5.038417    -0.660521    -4.127804 
 C     5.163250    -2.355357    -2.777667 
 H     5.807306    -2.943029    -3.435633 
 C     4.743023    -2.877157    -1.542460 
 H     5.051031    -3.879418    -1.237087 
 C     3.912024    -2.127053    -0.697810 
 H     3.567319    -2.564874     0.238695 
 C     2.906996    -0.250460     1.725996 
 C     2.423235    -1.379502     2.424338 
 H     1.675988    -2.024370     1.948743 
 C     2.892997    -1.669198     3.715608 
 H     2.510269    -2.549559     4.236651 
 C     3.831907    -0.830199     4.339106 
 H     4.185681    -1.051107     5.349019 
 C     4.304604     0.302091     3.656509 
 H     5.026770     0.969898     4.132778 
 C     3.850539     0.586361     2.356948 
 H     4.224954     1.475965     1.849998 
 C     2.657618     1.861310    -0.295375 
 C     1.591481     2.782514    -0.306165 
 H     0.576691     2.389615    -0.185237 
 C     1.828412     4.154893    -0.489180 
 H     0.987957     4.852274    -0.497371 
 C     3.138824     4.625198    -0.674436 
 H     3.325853     5.691236    -0.823297 
 C     4.209775     3.714681    -0.679966 
 H     5.231373     4.070923    -0.833318 
 C     3.970834     2.343032    -0.492651 
 H     4.808854     1.643374    -0.512683 
Cl     0.413349    -3.176877     0.127543 
 H     0.049586    -0.479826     1.258698 
 C     0.145685     0.261549    -2.393910 
 C    -0.133435    -1.116671    -2.474302 
 H    -0.634853     1.007076    -2.555898 
 H     1.155961     0.624876    -2.593623 
 H    -1.144988    -1.474168    -2.676799 
 H     0.659993    -1.843762    -2.648278 
 
3. Burgess’s catalyst 
Acid E = -1592.90637528 Hartree 
Ir     0.512424    -1.123172    -0.817026 
 C     1.567925    -0.783615     0.904308 
 N     1.595033    -1.575182     2.026770 
 C     2.466347    -1.057147     2.984991 
 C     2.999300     0.081001     2.460247 
 N     2.449142     0.240894     1.187882 
 N    -1.440893    -1.629574     0.257324 
 C    -2.678119    -1.216835     0.392343 
 O    -3.534413    -2.108732     0.964591 
 C    -2.827665    -3.367645     1.123283 
 C    -1.351433    -2.970532     0.931099 
 C    -0.582254    -2.907641     2.270424 
 C     0.955730    -2.895672     2.184778 
 H     2.627125    -1.546994     3.937450 
 H     3.719786     0.784137     2.856344 
 H    -3.198573    -4.056849     0.351976 
 H    -3.071150    -3.757377     2.118130 
 H    -0.842143    -3.665788     0.251645 
 H    -0.842380    -3.826389     2.821215 
 H    -0.942734    -2.062086     2.876216 
 H     1.366233    -3.302865     3.116795 
  
251 
 H     1.301648    -3.538692     1.363009 
 C     2.902325     1.287010     0.277975 
 C     2.336241     2.581345     0.390942 
 C     2.831715     3.576940    -0.474035 
 C     3.848721     3.297173    -1.394343 
 C     4.404766     2.014174    -1.460891 
 C     3.953572     0.976764    -0.622405 
 C     1.273591     2.930839     1.435736 
 C     4.646335    -0.387565    -0.652599 
 C     4.889403    -0.909822    -2.087790 
 C     5.986763    -0.322549     0.126532 
 C     1.923562     3.595071     2.678378 
 C     0.167371     3.856066     0.876412 
 C    -3.399918     0.080556     0.062974 
 C    -4.082617     0.593406     1.380487 
 C    -2.507387     1.214558    -0.489965 
 C    -4.523613    -0.240188    -0.982348 
 C    -4.929655     1.853064     1.084547 
 C    -3.358647     2.479069    -0.780221 
 C    -5.364542     1.027474    -1.262326 
 C    -6.027806     1.506733     0.050778 
 C    -4.021754     2.970942     0.525699 
 C    -4.450814     2.140118    -1.822947 
 H     2.421595     4.585489    -0.420422 
 H     4.217437     4.084691    -2.052836 
 H     5.211205     1.816837    -2.167302 
 H     3.997500    -1.115882    -0.145667 
 H     0.796152     1.994783     1.765801 
 H     5.837340    -0.007715     1.169789 
 H     6.469419    -1.311399     0.133711 
 H     6.679031     0.390940    -0.345162 
 H     3.960594    -0.922590    -2.675981 
 H     5.627916    -0.298736    -2.627434 
 H     5.283796    -1.935894    -2.046000 
 H     1.155758     3.824881     3.432477 
 H     2.676376     2.945541     3.146603 
 H     2.419552     4.536225     2.397913 
 H    -0.257063     3.469112    -0.061052 
 H    -0.645365     3.952619     1.611296 
 H     0.547064     4.869525     0.680398 
 H    -4.717746    -0.198035     1.802181 
 H    -3.302820     0.827159     2.125983 
 H    -1.720411     1.456826     0.243250 
 H    -2.018438     0.893956    -1.421502 
 H    -4.062984    -0.601972    -1.917871 
 H    -5.166606    -1.045091    -0.597101 
 H    -6.140556     0.773025    -2.001237 
 H    -5.395688     2.184771     2.025805 
 H    -2.693739     3.261055    -1.180323 
 H    -4.613411     3.880026     0.330468 
 H    -3.251070     3.240819     1.267898 
 H    -5.044048     3.040575    -2.050448 
 H    -3.987636     1.812268    -2.769545 
 H    -6.693599     0.722952     0.449091 
 H    -6.653256     2.392762    -0.145174 
 C    -0.552591    -1.075612    -2.808272 
 C    -0.188180    -2.396124    -2.526362 
 H     0.690805    -2.843391    -2.986571 
 H     0.042497    -0.475321    -3.495421 
 H    -1.583745    -0.755851    -2.662105 
 H    -0.931936    -3.097794    -2.147891 
 H    -0.040929     0.595398    -0.796215 
 H     0.698930     0.607613    -1.198434 
 H     1.884646    -1.028863    -1.593991 
 H     0.941224    -2.635352    -0.543880 
 
Base E = -1592.48290523 Hartree 
Ir     0.484824    -1.049270    -0.846459 
 C     1.552425    -0.802207     0.858384 
 N     1.562069    -1.626109     1.972098 
 C     2.442493    -1.160353     2.950784 
 C     3.009470    -0.022790     2.462026 
 N     2.466825     0.189892     1.192077 
 N    -1.482705    -1.616177     0.252286 
 C    -2.722331    -1.245241     0.399633 
 O    -3.586314    -2.197052     0.895182 
 C    -2.841941    -3.439106     0.988972 
 C    -1.373430    -2.996469     0.820264 
 C    -0.596173    -3.002587     2.156090 
 C     0.941112    -2.955811     2.047462 
 H     2.581266    -1.678200     3.892196 
 H     3.741831     0.652685     2.884741 
 H    -3.189473    -4.099791     0.181184 
 H    -3.075563    -3.889930     1.962048 
 H    -0.843076    -3.616039     0.087209 
 H    -0.835447    -3.956965     2.656270 
  
252 
 H    -0.964273    -2.197210     2.811630 
 H     1.374895    -3.429290     2.939040 
 H     1.265539    -3.515525     1.157889 
 C     2.978179     1.231007     0.319252 
 C     2.464127     2.542260     0.443526 
 C     3.046427     3.548927    -0.350487 
 C     4.093489     3.259026    -1.232868 
 C     4.582203     1.950960    -1.334081 
 C     4.040916     0.907277    -0.559851 
 C     1.335096     2.882878     1.415110 
 C     4.637925    -0.498649    -0.644964 
 C     4.835476    -0.975886    -2.102081 
 C     5.978275    -0.565784     0.131907 
 C     1.884197     3.569042     2.691740 
 C     0.250648     3.766521     0.758536 
 C    -3.443250     0.062190     0.121465 
 C    -4.425091     0.366504     1.302443 
 C    -2.492707     1.272060    -0.041781 
 C    -4.298865    -0.117663    -1.178089 
 C    -5.233148     1.652668     1.009225 
 C    -3.310411     2.551719    -0.345165 
 C    -5.103814     1.171457    -1.465580 
 C    -6.060467     1.457321    -0.284058 
 C    -4.271218     2.848277     0.829200 
 C    -4.127942     2.357476    -1.644573 
 H     2.672537     4.571371    -0.279839 
 H     4.529235     4.053039    -1.842176 
 H     5.400425     1.736450    -2.022985 
 H     3.933852    -1.196704    -0.173295 
 H     0.856080     1.939234     1.712134 
 H     5.848977    -0.283101     1.187389 
 H     6.388189    -1.587804     0.099478 
 H     6.723371     0.113922    -0.311179 
 H     3.893271    -0.919293    -2.663628 
 H     5.596408    -0.380778    -2.631088 
 H     5.174998    -2.023112    -2.105386 
 H     1.063432     3.788141     3.393183 
 H     2.616018     2.933872     3.212347 
 H     2.380984     4.519898     2.442160 
 H    -0.109513     3.312297    -0.174024 
 H    -0.603404     3.883315     1.443558 
 H     0.627905     4.775734     0.530915 
 H    -5.111436    -0.479679     1.450085 
 H    -3.847303     0.487802     2.234984 
 H    -1.914490     1.405321     0.887187 
 H    -1.753997     1.081286    -0.830383 
 H    -3.636491    -0.345674    -2.027984 
 H    -4.981782    -0.973385    -1.051034 
 H    -5.686639     1.023553    -2.389912 
 H    -5.911570     1.841572     1.857998 
 H    -2.611558     3.392997    -0.474473 
 H    -4.845215     3.770570     0.632692 
 H    -3.695499     3.015385     1.756366 
 H    -4.690098     3.277836    -1.879717 
 H    -3.449455     2.164597    -2.492716 
 H    -6.769820     0.620925    -0.158834 
 H    -6.657867     2.361917    -0.490766 
 C    -0.562329    -0.619894    -2.705511 
 C    -0.341100    -2.025451    -2.608749 
 H     0.441778    -2.499202    -3.200011 
 H     0.058082    -0.015242    -3.366699 
 H    -1.564977    -0.221924    -2.544666 
 H    -1.174247    -2.684416    -2.350113 
 H     0.303013     0.596868    -0.743437 
 H     1.797257    -0.763145    -1.665349 
 H     0.980175    -2.645250    -0.691415 
 
 
4. Pfaltz’ catalyst 1 
Acid E = -1290.29206527 Hartree 
Ir     0.282933    -1.542008    -0.530759 
 P    -1.243151     0.156501    -0.054440 
 N     1.781960    -0.272189     0.533166 
 O     2.668017     0.554079     2.436840 
 C     1.562448     0.274183     1.703684 
 C     3.790612    -0.083987     1.746036 
 C     3.270774    -0.251696     0.306003 
 C     0.289989     0.646405     2.359513 
 C    -0.981974     0.682231     1.714218 
 C    -2.104793     1.101030     2.450284 
 C    -2.000724     1.473328     3.800821 
 C    -0.755199     1.430167     4.437995 
 C     0.376513     1.025119     3.720428 
 H     3.984407    -1.038376     2.255705 
 H     4.651151     0.580147     1.860195 
  
253 
 H     3.567027    -1.226284    -0.103557 
 C     3.765234     0.866272    -0.680487 
 C     3.517770     2.285809    -0.117962 
 C     3.058762     0.749390    -2.049975 
 C     5.284736     0.643837    -0.895369 
 C    -1.051928     1.695715    -1.068926 
 C    -0.753620     2.945959    -0.491168 
 C    -0.619857     4.083060    -1.306205 
 C    -0.784833     3.980293    -2.695545 
 C    -1.087182     2.735962    -3.275643 
 C    -1.217570     1.597474    -2.468606 
 C    -3.035209    -0.282862    -0.173762 
 C    -3.998725     0.671793    -0.564473 
 C    -5.355964     0.316597    -0.616172 
 C    -5.759011    -0.983872    -0.273806 
 C    -4.802154    -1.934948     0.118142 
 C    -3.443857    -1.590313     0.164700 
 H     3.855509     3.034405    -0.849925 
 H     2.448753     2.467554     0.067096 
 H     4.068621     2.473240     0.815591 
 H     3.528086     1.436781    -2.769675 
 H     1.997087     1.026270    -1.979140 
 H     3.141026    -0.267359    -2.466894 
 H     5.676986     1.401243    -1.589413 
 H     5.860966     0.729981     0.038363 
 H     5.489298    -0.347003    -1.330976 
 H    -1.464676     0.638223    -2.928457 
 H    -0.633567     3.041253     0.588687 
 H    -0.391339     5.047210    -0.850598 
 H    -0.683699     4.865053    -3.324780 
 H    -1.225476     2.652183    -4.354122 
 H    -2.702198    -2.335060     0.453809 
 H    -3.695770     1.683787    -0.835465 
 H    -6.094523     1.056658    -0.926133 
 H    -6.813782    -1.257169    -0.317453 
 H    -5.110632    -2.947717     0.379436 
 H    -3.082429     1.122045     1.969357 
 H    -2.892655     1.784535     4.345069 
 H    -0.658420     1.707481     5.487571 
 H     1.345756     0.996294     4.213285 
 C     1.759789    -3.091496    -1.284147 
 C     1.418435    -3.395874     0.038465 
 H     2.085236    -3.133856     0.860418 
 H     0.691225    -4.175615     0.255221 
 H     1.286353    -3.622917    -2.108477 
 H     2.703705    -2.599599    -1.518052 
 H    -0.836436    -2.528306    -1.079650 
 H    -0.204201    -2.009726     0.918692 
 H     0.871859    -0.723457    -2.028911 
 H     0.225554    -1.209565    -2.276898 
 
Base E =  -1289.87970964 Hartree 
Ir     0.339604    -1.627646    -0.325244 
 P    -1.195074     0.069255    -0.101580 
 N     1.786765    -0.181239     0.598978 
 O     2.639919     1.006049     2.335730 
 C     1.540029     0.553754     1.649495 
 C     3.773805     0.281138     1.773065 
 C     3.271547    -0.148240     0.381237 
 C     0.250952     0.960911     2.243032 
 C    -1.017743     0.826906     1.602726 
 C    -2.166897     1.254306     2.294758 
 C    -2.094462     1.803052     3.584816 
 C    -0.848077     1.942453     4.208700 
 C     0.308502     1.527310     3.539613 
 H     3.981943    -0.573187     2.434578 
 H     4.623888     0.970027     1.773660 
 H     3.600358    -1.166999     0.139913 
 C     3.735177     0.809732    -0.776805 
 C     3.364167     2.282404    -0.482257 
 C     3.106729     0.398850    -2.125881 
 C     5.275255     0.674623    -0.902370 
 C    -1.078448     1.556819    -1.229507 
 C    -1.186154     2.881144    -0.757913 
 C    -1.110675     3.962901    -1.652419 
 C    -0.937600     3.731713    -3.025534 
 C    -0.833374     2.413545    -3.502044 
 C    -0.894863     1.332850    -2.610048 
 C    -3.003451    -0.374387    -0.190431 
 C    -3.982309     0.509907    -0.688560 
 C    -5.331506     0.120675    -0.731483 
 C    -5.713901    -1.150259    -0.273867 
 C    -4.741227    -2.035800     0.220021 
 C    -3.391506    -1.654820     0.256782 
 H     3.699698     2.920572    -1.314457 
 H     2.275909     2.408271    -0.387846 
  
254 
 H     3.837624     2.662334     0.436160 
 H     3.482231     1.063571    -2.920826 
 H     2.012731     0.462129    -2.099269 
 H     3.372506    -0.633999    -2.396785 
 H     5.632359     1.284320    -1.746379 
 H     5.810317     1.018074    -0.002960 
 H     5.569760    -0.369295    -1.096976 
 H    -0.780310     0.310769    -2.975218 
 H    -1.324060     3.075768     0.306543 
 H    -1.185043     4.983278    -1.272095 
 H    -0.878328     4.571867    -3.719503 
 H    -0.693432     2.225600    -4.567966 
 H    -2.627321    -2.345333     0.615858 
 H    -3.695413     1.497653    -1.052037 
 H    -6.079711     0.810426    -1.126121 
 H    -6.762110    -1.452032    -0.310064 
 H    -5.030624    -3.028981     0.567601 
 H    -3.142210     1.144053     1.820858 
 H    -3.008621     2.113553     4.093206 
 H    -0.771719     2.364300     5.211630 
 H     1.278491     1.627700     4.021990 
 C     1.839751    -3.019417    -1.054977 
 C     1.537330    -3.319986     0.309695 
 H     2.237410    -3.033839     1.098417 
 H     0.913464    -4.178012     0.555415 
 H     1.433746    -3.642158    -1.850958 
 H     2.780188    -2.529099    -1.310082 
 H    -0.260292    -1.959067     1.200496 
 H     0.520843    -1.145307    -1.903317 
 H    -0.700723    -2.679265    -0.893715 
 
 
5. Pfaltz’ catalyst 2 
Acid E = -1326.21435527 Hartree 
Ir     0.247694    -0.573338    -1.107004 
 P    -1.566921     0.093006     0.168098 
 C    -1.989931     1.883478     0.259956 
 C    -2.953540     2.292564     1.209694 
 C    -3.322438     3.641581     1.292446 
 C    -2.747758     4.585781     0.423050 
 C    -1.801506     4.179428    -0.529918 
 C    -1.417597     2.830948    -0.610455 
 H    -3.411143     1.560157     1.876288 
 H    -4.062599     3.954932     2.029446 
 H    -3.042346     5.633802     0.486652 
 H    -1.361087     4.908034    -1.211384 
 H    -0.685717     2.516510    -1.354845 
 C    -3.153539    -0.733915    -0.274861 
 C    -3.557352    -1.927543     0.357499 
 C    -4.741744    -2.564462    -0.044338 
 C    -5.520590    -2.022280    -1.078953 
 C    -5.117389    -0.834862    -1.711849 
 C    -3.938253    -0.188744    -1.312937 
 H    -2.964617    -2.342452     1.171800 
 H    -5.057076    -3.480505     0.456650 
 H    -6.440639    -2.519462    -1.387820 
 H    -5.722691    -0.406058    -2.511066 
 H    -3.638989     0.738830    -1.803858 
 O    -1.468809    -0.450629     1.766209 
 C    -0.250834    -0.473551     2.598674 
 C     0.283475     0.947722     2.821548 
 H    -0.480846     1.563247     3.313412 
 C    -0.768888    -1.095740     3.908592 
 H    -1.074105    -2.141447     3.759191 
 H     0.559703     1.429658     1.874026 
 H     1.173902     0.927462     3.468315 
 H    -0.011465    -1.055779     4.703115 
 H    -1.644012    -0.527753     4.249528 
 N     1.460072    -0.807355     0.743339 
 O     3.127211    -1.077123     2.245629 
 C     2.712635    -0.586465     1.053589 
 C     2.001432    -1.801506     2.832160 
 C     0.798392    -1.424012     1.931734 
 H     0.256985    -2.322768     1.604891 
 H     2.242594    -2.871350     2.795022 
 H     1.928327    -1.475788     3.873658 
 C     3.753217     0.146297     0.309856 
 C     5.073620    -0.356946     0.299154 
 C     6.086435     0.354093    -0.356236 
 C     5.799108     1.584197    -0.971745 
 C     4.493853     2.103354    -0.933594 
 C     3.469152     1.386091    -0.301479 
 H     7.100632    -0.044855    -0.376063 
 H     4.275945     3.070334    -1.387917 
 H     5.297959    -1.299707     0.797639 
  
255 
 H     6.592589     2.142807    -1.468976 
 H     2.459401     1.792113    -0.254942 
 H    -0.628500    -2.105816    -1.447315 
 H    -0.175481    -2.323285    -0.775353 
 H     0.657681     0.960777    -1.154122 
 H    -0.648923    -0.266796    -2.389743 
 C     1.845450    -0.401477    -2.758485 
 C     1.886383    -1.699400    -2.260415 
 H     2.643550    -1.989895    -1.531891 
 H     1.395601    -2.510805    -2.797282 
 H     1.307987    -0.174779    -3.676895 
 H     2.570251     0.338327    -2.426541 
 
Base E = -1325.80867529 Hartree 
Ir     0.194158    -0.898190    -1.007966 
 P    -1.517096     0.128238     0.086752 
 C    -1.887255     1.941943    -0.120712 
 C    -2.768621     2.583720     0.777392 
 C    -3.052275     3.949188     0.632733 
 C    -2.467597     4.683832    -0.414460 
 C    -1.598016     4.048087    -1.314098 
 C    -1.304359     2.681509    -1.165857 
 H    -3.227054     2.013671     1.586919 
 H    -3.730977     4.439447     1.333068 
 H    -2.691066     5.746278    -0.526600 
 H    -1.143193     4.613807    -2.129165 
 H    -0.618269     2.177810    -1.849603 
 C    -3.199667    -0.631385    -0.096800 
 C    -3.479930    -1.858866     0.536036 
 C    -4.722755    -2.480922     0.353054 
 C    -5.692040    -1.893694    -0.478365 
 C    -5.413038    -0.678613    -1.122031 
 C    -4.173464    -0.046262    -0.929098 
 H    -2.721653    -2.323896     1.165720 
 H    -4.932069    -3.428019     0.853564 
 H    -6.656486    -2.382928    -0.625360 
 H    -6.158247    -0.217289    -1.772267 
 H    -3.968924     0.900835    -1.430117 
 O    -1.435427    -0.025009     1.796363 
 C    -0.191270     0.063503     2.563846 
 C     0.385252     1.487385     2.501540 
 H    -0.344317     2.205375     2.900506 
 C    -0.675298    -0.279579     3.988519 
 H    -0.990022    -1.331634     4.054824 
 H     0.626167     1.773128     1.468923 
 H     1.306189     1.559116     3.101612 
 H     0.099684    -0.089321     4.744331 
 H    -1.542406     0.351089     4.225708 
 N     1.500565    -0.640588     0.796849 
 O     3.155848    -0.603448     2.353589 
 C     2.743724    -0.354048     1.069480 
 C     2.036350    -1.245953     3.029001 
 C     0.836012    -1.018732     2.078972 
 H     0.277562    -1.947067     1.909609 
 H     2.282647    -2.311279     3.142590 
 H     1.954425    -0.781431     4.016261 
 C     3.786691     0.252096     0.223489 
 C     5.146941     0.060158     0.558191 
 C     6.150817     0.668057    -0.206325 
 C     5.809088     1.485743    -1.296754 
 C     4.457293     1.690980    -1.620833 
 C     3.446878     1.077341    -0.869311 
 H     7.198610     0.506095     0.050601 
 H     4.186661     2.328362    -2.463847 
 H     5.407984    -0.565391     1.410812 
 H     6.592376     1.960961    -1.889533 
 H     2.395436     1.211592    -1.125499 
 H    -0.759123    -1.172884    -2.243993 
 H    -0.533045    -2.174311    -0.210158 
 H     0.598422     0.541512    -1.738930 
 C     1.808892    -1.523637    -2.357527 
 C     1.317664    -2.657585    -1.652064 
 H     1.894125    -3.065706    -0.819986 
 H     0.655605    -3.368751    -2.143365 
 H     1.512479    -1.357432    -3.392111 
 H     2.767370    -1.088514    -2.078112 
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Synthesis of Alkene 6. According to the method of Paintner and co-workers,28 methanol 
was added to methyl butynoate, using trimethylphosphine as a nucleophilic catalyst to 
give corresponding vinyl ether esters.  Then ester was reduced by DIBAL to give the 
vinyl ether alcohol 6. 
CO2Me
TBDPSO
MeOH, PMe3 (cat)
CH2Cl2, 25
 oC, 16 h OMeMeO
O
TBDPSO
DIBAL-H, THF
-30 oC, 1 h
OHMeO
TBDPSO
6  
Methyl butynoate (5.0 mmol) in CH2Cl2 (20 mL) was added 
dropwise to a solution of methanol (15 mmol) and PMe3 (0.5 mL, 
1.0 M in THF, 0.5 mmol) in CH2Cl2 (20 mL) at 0 oC by means of 
a syringe.  Then the reaction mixture was allowed to warm to r.t. and stirred overnight.  
The solution was concentrated under reduced pressure.  The crude product was purified 
by flash chromatography.   1H NMR (300 MHz, CDCl3) 7.74-7.70 (4H, m), 7.43-7.40 
(6H, m), 4.96 (1H, s), 4.91 (2H, s), 3.63(3H, s), 3.62 (3H, s), 1.10 (9H, s); 13C NMR (75 
MHz, CDCl3) 172.8, 167.5, 135.9, 133.8, 129.8, 127.8, 91.0, 61.6, 55.8, 51.1, 27.1, 19.6. 
MS (ESI): Exact mass calcd for C22H29O4Si[M+H]
+
 385.2; Found 385.2. 
To a cooled solution (-30 oC) of ester (0.89 g, 2.3 mmol) in THF 
(10 mL) was added DIBAL-H (1.0 M in Hexanes, 6.9 mL, 6.9 
mmol) slowly via a syringe pump.  The reaction mixture was 
stirred at -30 oC for 1 h, then the reaction was quenched with MeOH (5 mL).  Et2O (20 
mL) was added and saturated solution of potassium sodium tartrate in water (20 mL) was 
then added.  The resulting mixture was vigorously stirred for 1 h and the layers were 
separated.  The aqueous layer was extracted with Et2O (3×20 mL).  The combined 
organic extracts were dried by K2CO3 and concentrated in vacuo. Purification by flash 
chromatography on basic Al2O3 eluting with EtOAc/Hexanes (20:80) gave the desired 
product 6 (0.46 g, 76%) as a colorless oil.  1H NMR (300 MHz, CDCl3) 7.74-7.70 (4H, 
m), 7.49-7.39 (6H, m), 4.85 (1H, t, J = 7.8 Hz), 4.26 (2H, s), 4.10-4.05 (2H, m), 3.53 (3H, 
s), 1.49 (1H, t, J = 5.7 Hz), 1.07 (9H, s); 13C NMR (75 MHz, CDCl3) 159.6, 135.9, 133.3, 
130.0, 127.9, 99.4, 62.0, 58.4, 54.7, 27.0, 19.4. MS (ESI): calcd for C21H28KO3Si[M+K]
+
 
395.1; Found 395.1. 
OMeMeO
O
TBDPSO
OHMeO
TBDPSO
6
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General Catalytic Hydrogenation Conditions.  The corresponding alkenes were 
dissolved in CH2Cl2 (0.5 M) and the Iridium catalyst (1 mol %) was then added.  The 
resulting solution was degassed by three cycles of freeze-pump-thaw and then transferred 
to a Parr Bomb.  The bomb was flushed with hydrogen for 1 min without stirring.  The 
mixture was then stirred at 700 rpm under 50 bar H2.  After 12 h, the bomb was vented 
and the solvent evaporated.  The crude product was directly dissolved in 0.5 mL CDCl3 
and 1H NMR was taken.  
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1H NMR for Determining the Product Ratio of Hydrogenation of Substrate 6 
MeO
TBDPSO
OH
50 bar H2, 1 mol% 1
CH2Cl2, 25
oC, 12 h
1.0 eq K2CO3
MeO
TBDPSO
OH
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MeO
TBDPSO
OH
50 bar H2, 1 mol% 2
CH2Cl2, 25
oC, 12 h
1.0 eq K2CO3
MeO
TBDPSO
OH O
TBDPSO
+
6.7 : 1.0  
 
 
 
 
 
 
 
 
 
262 
 
MeO
TBDPSO
OH
50 bar H2, 1 mol% 3
CH2Cl2, 25
oC, 12 h
1.0 eq K2CO3
MeO
TBDPSO
OH O
TBDPSO
+
1.3 : 1.0  
 
 
 
 
General Procedure for Deuteration: Alkene substrate (0.1 mmol), and the desired 
amount of iridium complex were added to a test tube containing a small stir bar and 
sealed with a rubber septum.  Then, dry CH2Cl2 (0.2 mL) was added.  The resulting 
solution was degassed by three cycles of freeze-pump-thaw and then the septum was 
removed and the tube was quickly placed in a bomb.  The bomb was flushed with 
deuterium gas, and then pressurized with the desired amount of deuterium.  The mixture 
was stirred at 700 rpm/s for 20 h.  Upon completion, the bomb was vented, and the 
reaction mixture was placed in an NMR tube along with an additional 0.5 mL CHCl3 and 
1 drop of CDCl3.   2H NMR was then taken. 
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The 1H NMR of Substrate 9 
 
The 1H NMR of Substrate 10 
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The 1H NMR of Hydrogenation Product of 9 and 10 
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The catalysts used for deuteration reactions 
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The 2H NMR of Deuteration Product of Substrate 9 (entry 1) 
 
The 2H NMR of Deuteration Product of Substrate 9 (entry 4) 
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The 2H NMR of Deuteration Product of Substrate 10 (entry 1) 
 
The 2H NMR of Deuteration Product of Substrate 10 (entry 4) 
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The 2H NMR of Deuteration Product of Substrate 9 (entry 2, w/ K2CO3) 
 
The 2H NMR of Deuteration Product of Substrate 9 (entry 5, w/ K2CO3) 
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The 2H NMR of Deuteration Product of Substrate 10 (entry 2, using catalyst Ir*(L), w/ 
K2CO3) 
 
The 2H NMR of Deuteration Product of Substrate 10 (entry 5, using catalyst Ir*(N,P-II) 
w/ K2CO3) 
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The 2H NMR of Deuteration Product of Substrate 10 (entry 6, w/0.5 eq 11) 
 
The 2H NMR of Deuteration Product of Substrate 10 (entry 3, w/ 0.015 eq 12) 
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The 2H NMR of Deuteration Product of Substrate 14 (with catalyst Ir* (N,P-I)) 
 
The 2H NMR of Deuteration Product of Substrate 14 (with catalyst Ir*(N,P-II)) 
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APPENDIX E 
EXPERIMENTAL DATA FOR CHAPTER VI 
 
TBDPSO OMe
O P
O
OEt
OEt
nBuLi, THF
-78 oC, 1 h
TBDPSO
O
P
O
OEt
OEt
THF/H2O (40:1)
25 oC, 2 h
O
OBn
TBDPSO
O
OBn
1  
 
nBuLi (2.5M in Hexanes, 12.5 mL) was added to a solution of diethyl ethylphosphonate 
(5.66 g, 34.1mmol) in THF (70 mL) at -78 oC over 10 min.  The resulting mixture was 
stirred at -78 oC for 0.5 h.  Then a solution of 3-(tert-butyldiphenylsilanyloxy)-2-(R)-
methylpropionic acid methyl ester (4.86 g, 13.6 mmol) in THF (70 mL) was added to this 
mixture over 30 min.  The solution was continued to stir for 0.5 h at -78 oC and then 
NH4Cl(s) (50 mL) was added to quench the reaction.  The mixture was warmed to r.t. and 
diluted with H2O (20 mL).  The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 100 mL).  The combined organic layers were dried with 
Na2SO4, and concentrated in vacuo.  Purification of the residue by flash chromatography 
on silica gel, eluting with EtOAc/hexanes (30:70) gave the desired phosphonate as a 
colorless oil (6.41 g, 13.1 mmol, 96%).  1H NMR indicated the product as a mixture of 
two diastereoisomers.  The purified phosphonate (7.30 g, 14.9 mmol) was dissolved in 
THF (80 mL) and H2O (2 mL).  The solution was cooled to 0 oC and Ba(OH)2 (2.55 g, 
14.9 mmol) was added in one portion.  The mixture was stirred for 0.5 h and then a 
solution of benzyloxyacetaldehyde (2.3 mL, 16.4 mmol) in THF (10 mL) was added 
dropwise.  The resulting mixture was continued to stir for 2 h at 25 oC before quenched 
with NaHCO3(s) (50 mL).  The mixture was diluted with Et2O (50 mL) and the 
precipitates were removed via filtration on a buchner funnel.  The filtrate were separated 
and the aqueous layer was extracted with Et2O (3 x 50 mL).  The combined organic 
layers were dried with Na2SO4 and concentrated in vacuo. Purification of the residue by 
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flash chromatography on silica gel, eluting with EtOAc/hexanes (5:95) gave enone 1 as a 
colorless oil (6.30 g, 12.9 mmol, 87%). [α]21D  -19.1  (c 0.83, CHCl3 ); 1H NMR (300 
MHz, CDCl3) δ 7.64-7.60 (m, 4H), 7.41-7.26 (m, 11H), 6.72 (t, J = 4.5 Hz, 1H), 4.56 (s, 
2H), 4.28-4.25 (m, 2H), 3.86-3.83 (m, 1H), 3.64-3.52 (m, 2H), 1.75 (s, 3H), 1.03 (d, J = 
6.0 Hz, 3H), 1.00 (s, 9H),; 13C NMR (75 MHz, CDCl3) δ 204.6, 138.9, 137.9, 135.8, 
135.8, 133.8, 133.6, 129.9, 128.8, 128.1, 128.1, 127.9, 73.3, 67.8, 67.2, 42.0, 27.0, 19.4, 
14.7, 12.2. HRMS (ESI): Exact mass calcd for C31H39O3Si [M+H]
+ 487.2668. Found 
487.2684. 
 
TBDPSO
O
OBn
1
DIBAL-H, toluene
-78 oC, 1 h
TBDPSO
OH
OBn
2  
To a solution of enone 1 (4.31 g, 8.86 mmol) in toluene (100 mL) cooled to -78 oC was 
added the neat DIBAL (3.16 mL, 17.7 mmol) in a period of 5 min.  The reaction mixture 
was stirred for an additional 2 h before dropwise addition of anhydrous EtOAc (5 mL) at 
-78 oC and transferred quickly into a vigorously stirred mixture of EtOAc/saturated 
potassium sodium tartrate aqueous solution (300 mL/100 mL).  Stirring was continued 
for 1h and the layers were separated.  The aqueous layer was extracted with EtOAc (3 × 
50 mL).  The combined organic extracts were dried (Na2SO4) and concentrated in vacuo. 
1H NMR of the crude product suggested the syn:anti diastereoisomer ratio was 1.0:14. 
After purification by flash chromatography on silica gel, eluting with EtOAc/hexanes 
(10:90), the desired anti-allylic alcohol 2 can be obtained with 88% isolated yield and the 
syn:anti diastereoisomer ratio was further increased to >99% de (check by HPLC).  
[α]20.6D  -14.0 (c 0.71, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.69-7.65 (m, 4H), 7.45-
7.23 (m, 11H), 5.66 (t, J = 7.5 Hz, 1H), 4.51 (s, 2H), 4.11 (d, J = 10.0 Hz, 2H), 4.00 (d, J 
= 10.0 Hz, 1H), 3.90 (s, 1H), 3.80-3.78 (m, 1H), 3.67-3.63 (m, 1H), 1.96-1.89 (m, 1H), 
1.64 (s, 3H), 1.06 (s, 9H), 0.73 (d, J = 5.0 Hz, 3H);  13C NMR (75 MHz, CDCl3) δ 140.0, 
138.7, 135.8, 132.9, 128.1, 127.8, 124.8, 95.0, 83.2, 72.3, 69.2, 66.6, 37.5, 27.0, 19.3, 
14.0, 11.8. HRMS (ESI): Exact mass calcd for C31H40NaO3Si[M+Na]
+ 511.2644. Found 
511.2633. 
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TBDPSO
OH
OBn
2
TBAF, THF
23 oC, 1 h
HO
OH
OBn
3  
The allylic alcohol 2 (0.59 g, 1.2 mmol) was dissolved in THF (5 mL) followed by 
addition of TBAF (1M in THF, 1.4 mL, 1.4 mmol).  The resulting solution was stirred at 
25 oC for 1 h, then the reaction was quenched by addition of NH4Cl(s) (5 mL).  The 
layers were separated, and the aqueous layer was extracted with Et2O (3 x 5 mL).  The 
organic extract was dried (Na2SO4) and concentrated in vacuo.  Purification by flash 
column chromatography, eluting with EtOAc/hexanes (50:50) gave diol 3 (0.30 g, 1.2 
mmol, 100%) as a colorless oil.  [α]22.1D  -11.0 (c 1.09, CHCl3); 1H NMR (300 MHz, 
CDCl3) 7.37-7.26 (m, 5H), 5.62 (t, J = 6.0 Hz, 1H), 4.52 (s, 2H), 4.08-4.02 (m, 2H), 3.92 
(d, J = 9.0 Hz, 1H), 3.74-3.61 (m, 2H), 2.93 (br, 1H), 2.60 (br, 1H), 1.97-1.85 (m, 1H), 
1.65 (s, 1H), 0.75 (d, J = 9.0 Hz, 3H). 13C NMR (75 MHz, CDCl3) 140.2, 138.4, 128.7, 
128.1, 128.0, 125.1, 84.4, 72.7, 68.4, 66.5, 37.4, 14.0, 11.6. HRMS (ESI): Exact mass 
calcd for C15H22NaO3[M+Na]
+
 273.1467. Found 273.1472. 
 
TBDPSO
O
OBn
1
HO
O
OBn
4
TBAF, THF
0 oC, 1 h
 
The enone 1 (4.78 g, 9.8 mmol) was dissolved in THF (100 mL) followed by addition of 
TBAF (1M in THF, 10.3 mL, 10.3 mmol).  The resulting solution was stirred at 0 oC for 
1 h, then the reaction was quenched by addition of NH4Cl(s) (20 mL).  The layers were 
separated, and the aqueous layer was extracted with Et2O (3 x 20 mL).  The organic 
extract was dried (Na2SO4) and concentrated in vacuo.  Purification by flash column 
chromatography, eluting with EtOAc/hexanes (30:70) gave enone 4 (1.60 g, 6.6 mmol, 
67%) as a colorless oil.  [α]22.2D  -12.5 (c 1.27, CHCl3); 1H NMR (300 MHz, CDCl3) 7.41-
7.26 (m, 5H), 6.78-6.72 (m, 1H), 4.58 (s, 2H), 4.30-4.22 (m, 2H), 3.92-3.64 (m, 2H), 
3.47-3.35 (m, 1H), 2.21 (t, J = 6.0 Hz, 1H), 1.74 (s, 3H), 1.13 (d, J = 9.0 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) 140.0, 137.8, 136.9, 128.8, 128.2, 128.1, 73.4, 67.7, 65.1, 41.5, 
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15.3, 12.1 (missing the peak for the carbonyl carbon).  HRMS (ESI): Exact mass calcd 
for C15H21O3[M+H]
+
 249.1491. Found 249.1488. 
 
HO
O
OBn
4
HO
OH
OBn
5
Me4N(AcO)3BH
MeCN/HOAc (1:1)
-30 oC, 48 h
 
Tetramethylammonium triacetoxyborohydride (13.9 g, 52.8 mmol) was dissolved in 
CH3CN/AcOH (60 mL, 1:1) and the mixture was stirred for 30 min at 25 oC.  The 
resulting clear solution was cooled to -30 oC and a solution of 4 in MeCN (6 mL, 2 x 2 
mL for rinse) was added dropwise.  The reaction mixture was stirred at -30 oC for an 
additional 48 h before dropwise addition of saturated potassium sodium tartrate aqueous 
solution (20 mL).  Stirring was continued for 1h and the layers were separated.  The 
aqueous layer was extracted with CH2Cl2 (3 × 30 mL).  The combined organic extracts 
were washed with NaHCO3(s) (30 mL), Brine (30 mL) and then dried with Na2SO4.  The 
solution was concentrated in vacuo.  Purification by flash column chromatography, 
eluting with EtOAc/hexanes (50:50 to 80:20) gave diol 5 (1.40 g, 5.6 mmol, 81%) as a 
colorless oil.  1H NMR of the crude product indicated the syn:anti diastereoisomer ratio 
was >19:1.0. [α]21.9D  -32.2 (c 0.62, CHCl3); 1H NMR (300 MHz, CDCl3) 7.39-7.26 (m, 
5H), 5.70 (t, J = 6.0 Hz, 1H), 4.53 (s, 2H), 4.18-4.08 (m, 3H), 3.72-3.64 (m, 2H), 2.07-
1.83 (m, 3H), 1.63 (s, 3H), 0.91 (d, J = 9.0 Hz, 8H). 13C NMR (75 MHz, CDCl3) 140.8, 
138.6, 128.7, 128.1, 127.9, 78.4, 72.6, 67.1, 66.5, 37.7, 13.9, 10.6. HRMS (ESI): Exact 
mass calcd for C15H22NaO3[M+Na]
+
 273.1467. Found 273.1463. 
 
TBDPSO
OH
OBn
5 6
HO
OH
OBn
TBDPSCl, imidazole
CH2Cl2, -30 
oC, 2 h
 
To a solution of compound 5 (0.88 g, 3.5 mmol) and imidazole (0.26 g, 3.85 mmol) in 
CH2Cl2 (10 mL) was added a solution of TBDPSCl (1.02 g, 3.7 mmol) in CH2Cl2 (5 mL, 
2 x 1 mL for rinse) dropwise at -30 oC.  The reaction was stirred for 2 h, then quenched 
with NaHCO3(s) (10 mL).  The organic layer was separated and the aqueous layer was 
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extracted with CH2Cl2 (3 × 10 mL).  The combined organic extracts were dried (Na2SO4) 
and concentrated in vacuo.  Purification by flash column chromatography, eluting with 
EtOAc/hexanes (20:80) gave alcohol 6 (1.30 g, 2.7 mmol, 76%) as a colorless oil.  
[α]22.2D  -15.0 (c 0.80, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.70-7.65 (m, 4H), 7.47-
7.26 (m, 11H), 5.74 (t, J = 6.0 Hz, 1H), 4.51 (s, 2H), 4.28 (m, 1H), 4.11 (d, J = 6.0 Hz, 
2H), 3.72-3.64 (m, 2H), 2.42 (d, J = 3.0 Hz, 1H), 1.91-1.82 (m, 1H), 1.58 (s, 3H), 1.08 (s, 
9H), 0.90 (d, J = 6.0 Hz, 3H).  13C NMR (75 MHz, CDCl3) 140.2, 138.7, 135.8, 133.4, 
130.0, 128.0, 127.8, 121.9, 77.4, 72.3, 67.9, 66.5, 37.9, 27.1, 19.5, 13.8, 10.5.  HRMS 
(ESI): Exact mass calcd for C31H41O3Si[M+H]
+
 489.2825. Found 489.2848. 
 
TBDPSO
OH
OBn
6
Ac2O, Et3N, DMAP
CH2Cl2, 25 
oC, 1 h
TBDPSO
OAc
OBn
7  
To a solution of compound 6 (0.86 g, 1.75 mmol) and DMAP (22 mg, 0.18 mmol) in 
CH2Cl2 (10 mL) was added Ac2O (0.33 mL, 3.5 mmol) and Et3N (0.49 mL, 3.5 mmol) 
dropwise at 25 oC.  The reaction was stirred for 1 h, and then quenched with NaHCO3(s) 
(5 mL).  The organic layer was separated and the aqueous layer was extracted with 
CH2Cl2 (3 × 10 mL).  The combined organic extracts were dried (Na2SO4) and 
concentrated in vacuo.  Purification by flash column chromatography, eluting with 
EtOAc/hexanes (5:95) gave acetate 7 (0.85 g, 1.6 mmol, 92%) as a colorless oil.  [α]20.8D  
-20.6 (c 0.87, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.67-7.60 (m, 4H), 7.43-7.26 (m, 
11H), 5.53 (t, J = 6.0 Hz, 1H), 4.44 (s, 2H), 4.11-3.97 (m, 2H), 3.49 (d, J = 9.0 Hz, 2H), 
2.05 (s, 3H), 2.04-1.96 (m, 1H), 1.56 (s, 3H), 1.05 (s, 9H), 0.89 (d, J = 9.0 Hz, 3H).  13C 
NMR (75 MHz, CDCl3) 170.3, 138.5, 136.4, 135.9, 135.8, 133.9, 133.8, 127.8, 123.6, 
77.8, 77.5, 72.1, 66.3, 65.6, 37.7, 27.1, 21.3, 19.5, 13.8, 11.7.  HRMS (ESI): Exact mass 
calcd for C33H42NaO4Si[M+Na]
+
 553.2750. Found 553.2765. 
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TBDPSO
2 8
(S)-Cat.
syn:anti  
crude: 1.0:48
purified: 1.0:48
  89% isolated
(R)-Cat.
syn:anti  
crude: 7.9:1.0
not purified
>99% conv.
50 bar H2
1 mol % Cat.
CH2Cl2
25 °C, 4 h
OH
OBn
TBDPSO
OH
OBn
 
Hydrogenation of 2 (175 mg, 0.36 mmol) was carried out according to the general 
procedure using (S)-Cat. (1 mol%, 6 mg) in CH2Cl2 (0.72 mL).  NMR of the crude 
product showed 100% reduction.  HPLC analysis of the crude material showed syn:anti 
ratio to be 1.0:48.  One simple column chromatography on silica gel, eluting with 
EtOAc/hexanes (5:95) give anti,anti triad 8 (syn:anti = 1.0:48 from HPLC analysis) as a 
colorless oil (155 mg, 0.32 mmol, 89%).  [α]20.8D  -21.7 (c 0.92, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 7.72-7.66 (m, 4H), 7.49-7.27 (m, 11H), 4.57 (d, J = 12.0 Hz, 1H), 4.51 
(d, J = 12.0 Hz, 1H), 3.80-3.36 (m, 6H), 1.99-1.79 (m, 3H), 1.61-1.53 (m, 1H), 1.07 (s, 
9H), 0.99 (d, J = 6.0 Hz, 3H), 0.87 (d, J = 9.0 Hz, 3H).  13C NMR (75 MHz, CDCl3) 
138.9, 135.8, 133.1, 130.1, 128.6, 128.0, 128.0, 127.8, 127.7, 81.1, 73.1, 69.2, 69.0, 37.5, 
33.2, 30.3, 27.1, 19.4, 17.3, 14.2.  HRMS (ESI): Exact mass calcd for C31H43O3Si[M+H]
+
 
491.2981. Found 491.3002. 
 
HO
3 9
(S)-Cat.
syn:anti  
crude: 1.0:12
not purified
(R)-Cat.
syn:anti  
crude: 21:1.0
purified: >99% de
 91% isolated
(i) 100 bar H2, 1 mol % Cat.
CH2Cl2, 25 °C, 12 h
(ii) (MeO)2CMe2, TsOH H2O
CH2Cl2, 25 
oC, 1 h
OH
OBn
O
OBn
O
>99% conv.
 
Hydrogenation of 3 (310 mg, 1.2 mmol) was carried out according to the general 
procedure using (R)-Cat (1 mol%, 19 mg) in CH2Cl2 (1 mL).  NMR of the crude product 
showed 100% conversion.  Thus without purification, the crude diol was dissolved in 
CH2Cl2 (10 mL).  TsOH (22.8 mg, 0.12 mmol) and 2,2-Dimethoxypropane (0.74 mL, 6.0 
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mmol) were then added to the solution of diol and the resulting mixture was stirred for 1 
h at 25 oC.  The reaction was quenched by adding NaHCO3(s) (5 mL).  The organic layer 
was separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL).  The 
combined organic extracts were dried (Na2SO4) and concentrated in vacuo.  HPLC 
analysis of the crude material showed syn:anti ratio to be 21:1.0.  Purification by column 
chromatography EtOAc/hexanes (5:95) gave the anti,syn triad 92 as a colorless oil (319 
mg, 91% from 3, HPLC analysis showed syn:anti >99% de). [a]21.1D  -34.7  (c 0.92, 
CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.40-7.28 (m, 5H), 4.56 (d, J = 12.0 Hz, 1H), 
4.49 (d, J = 12.0 Hz, 1H), 3.70-3.65 (m, 1H), 3.56-3.36 (m, 4H), 1.97-1.60 (m, 4H), 1.34 
(s, 3H), 1.33 (s, 3H), 0.88 (d, J = 6.0 Hz, 3H), 0.72 (d, J = 6.0 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 138.9, 128.6, 128.0, 127.8, 98.3, 76.7, 73.2, 68.4, 66.7, 33.8, 31.1, 30.1, 
29.9, 19.2, 12.7, 12.5.  
  
TBDPSO
6 10
(S)-Cat.
syn:anti  
crude: only the syn,syn 
diastereoisomer
purified: >99% de
  90% isolated
(R)-Cat.
syn:anti  
crude: 1.0:7.7
not purified
>99% conv.
50 bar H2
1 mol % Cat.
CH2Cl2
25 °C, 4 h
OH
OBn
TBDPSO
OH
OBn
 
Hydrogenation of 6 (250 mg, 0.50 mmol) was carried out according to the general 
procedure using (S)-Cat. (1 mol%, 8 mg) in CH2Cl2 (1.0 mL).  NMR of the crude 
product showed 100% reduction to 10.  HPLC analysis of the crude material can only 
detect the syn,syn triad.  One simple column chromatography on silica gel, eluting with 
EtOAc/hexanes (5:95) give syn,syn triad 10 as a colorless oil (230 mg, 0.45 mmol, 90%).  
[α]21.1D  -8.9 (c 0.89, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.71-7.65 (m, 4H), 7.48-7.29 
(m, 11H), 4.53 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 12.0 Hz, 1H), 3.73-3.47 (m, 5H), 2.72 
(d, J = 3.0 Hz, 1H), 1.91-1.69 (m, 3H), 1.46-1.37 (m, 1H), 1.08 (s, 9H), 1.01 (d, J = 6.0 
Hz, 3H), 0.96 (d, J = 6.0 Hz, 3H).  13C NMR (75 MHz, CDCl3) 138.6, 135.8, 133.4, 
130.0, 130.0, 128.6, 128.0, 127.9, 127.8, 77.5, 73.3, 68.8, 68.6, 37.2, 33.6, 33.5, 27.1, 
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19.5, 15.1, 11.3.  HRMS (ESI): Exact mass calcd for C31H43O3Si[M+H]
+
 491.2981. 
Found 491.2995. 
 
TBDPSO
7 11
(S)-Cat.
syn:anti  
crude: 3.5:1.0
not purified
(R)-Cat.
syn:anti  
crude: 1.0:18
purified: >99% de
  83% isolateded
>99% conv.
(i) 80 bar H2
1 mol % Cat.
CH2Cl2
25 °C, 36 h
OAc
OBn
TBDPSO
OH
OBn
(ii) DIBAL-H
CH2Cl2
-78 oC, 1 h
 
Hydrogenation of 7 (440 mg, 0.83 mmol) was carried out according to the general 
procedure using (R)-Cat (1 mol%, 15 mg) in CH2Cl2 (1.5 mL).  NMR of the crude 
product showed 100% conversion.  Thus without purification, the crude acetate was 
dissolved in CH2Cl2 (10 mL) and cooled to -78 oC.  DIBAL-H (1.0 M in Hexanes, 2.0 
mL, 2.0 mmol) was added dropwise and the solution was stirred at -78 oC for 1 h.  EtOAc 
(2 mL) was added to the mixture followed by addition of saturated potassium sodium 
tartrate aqueous solution (5 mL).  Stirring was continued for 1h and the layers were 
separated.  The aqueous layer was extracted with EtOAc (3 × 10 mL).  The combined 
organic extracts were dried (Na2SO4) and concentrated in vacuo.  HPLC analysis of the 
crude material showed syn:anti ratio to be 1.0:18.  Purification by column 
chromatography EtOAc/hexanes (5:95) gave the syn,anti triad 11 as a colorless oil (340 
mg, 0.69 mmol, 83% from 7, HPLC analysis showed syn:anti >99% de). [α]21.4D  -5.5  (c 
1.08, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.70-7.65 (m, 4H), 7.45-7.28 (m, 11H), 4.55 
(d, J = 12.0 Hz, 1H), 4.51 (d, J = 12.0 Hz, 1H), 3.73-3.51 (m, 5H), 3.00 (d, J = 3.0 Hz, 
1H), 1.99-1.51 (m, 4H), 1.08 (s, 9H), 0.93 (d, J = 6.0 Hz, 3H), 0.85 (d, J = 6.0 Hz, 3H).  
13C NMR (75 MHz, CDCl3) 138.7, 135.9, 133.6, 130.0, 129.9, 128.6, 127.9, 127.9, 
127.8, 77.5, 73.2, 68.9, 68.9, 37.0, 34.3, 33.4, 27.2, 19.5, 16.7, 9.6.  HRMS (ESI): Exact 
mass calcd for C31H43O3Si[M+H]
+
 491.2981. Found 491.2969. 
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O
OBn
O
9
5 mol % Pd/C, 1 atm H2
EtOH, 25 oC, 8 h O
OH
O
12  93%  
To a solution of 9 (1.06 g, 3.64 mmol) in MeOH (20 mL) was added Pd/C (10% on 
carbon, 194 mg, 0.18 mmol) in one portion.  The air inside the reaction flask was 
vacuumed out and then hydrogen gas was purged into the flask.  The mixture was stirred 
under 1 atm H2 pressure at rt for 8 h.  The mixture was filtered on a plug of silica gel (5 
cm), washed with MeOH, and concentrated to give 0.68 g (93%) of free saturated alcohol 
12 as a colorless oil.   [α]22.0D  -42.8 (c 0.70, CHCl3); 1H NMR (300 MHz, CDCl3) δ 3.78-
3.65 (m, 3H), 3.61-3.46 (m, 2H), 2.14-2.10 (m, 1H), 2.01-1.89 (m, 2H), 1.85-1.59 (m, 
2H), 1.43 (s, 3H), 1.38 (s, 3H), 0.93 (d, J = 6.0 Hz, 3H), 0.75 (d, J = 6.0 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 98.5, 77.9, 66.5, 60.4, 37.3, 31.1, 30.8, 29.9, 19.3, 12.7, 12.4. 
HRMS (ESI): Exact mass calcd for C11H23O3[M+H]
+ 203.1647. Found 203.1654. 
 
O
OH
O
12
(i) SO3 Py, DMSO, 
iPr2NEt
 CH2Cl2, 0 
oC, 1 h
(ii) Ph3PMeBr, 
nBuLi
Et2O, 0 
oC, 1 h OO
13  74%  
The alcohol 12 (0.68 g, 2.0 mmol) was dissolved in CH2Cl2 (60 mL) at 0 oC.   DMSO 
(6.0 mL, 84.5 mmol) and DIPEA (5.9 mL, 33.8 mmol) were added.  To this solution at 0 
oC, SO3.Py complex (2.69 g, 16.9 mmol) was added and the resulting solution was stirred 
at that temperature for 1 h.  The reaction was quenched with NH4Cl (20 mL).  The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL).  The 
combined organic solution was dried (Na2SO4) and concentrated in vacuo.   The resulting 
residue was carried out to the next step without any further purification.  In a separate 
round bottom flask, methyltriphenylphosphonium bromide (2.41 g, 6.76 mmol) 
suspension in THF (20 mL) was cooled to 0 oC and nBuLi (2.0 M in Pentane, 3.4 mL, 6.8 
mmol) was added dropwise.   The reaction was stirred for 0.5 h before the crude aldehyde 
in THF solution (8 mL, 2× 1 mL for rinsing) was cannulated.  After 1 h, saturated NH4Cl 
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aqueous solution (10 mL) was added and the mixture was stirred and allowed to warm to 
25 oC.  The layers were then separated and the aqueous layer was extracted with Et2O (3 
× 10 mL).  The combined organic extracts were dried (Na2SO4) and concentrated in 
vacuo at 10 oC.  Purification by flash column chromatography, eluting with Et2O/pentane 
(5:95) gave alkene 13 (0.49 g, 74% over two steps) as a colorless oil.  [α]19.6D  -27.1 (c 
0.81, CHCl3); 1H NMR (300 MHz, CDCl3) δ 5.86-5.72 (m, 1H), 5.06-4.96 (m, 2H), 3.71 
(dd, J = 3.0, 12.0 Hz, 1H), 3.54-3.45 (m, 2H), 2.22-1.70 (m, 1H), 1.71-1.31 (m, 12H), 
1.13 (d, J = 10.0 Hz, 3H), 1.10-1.01 (m, 2H), 0.91-0.86 (m, 6H), 0.78-0.76 (m, 4H), 1.40 
(s, 3H), 1.38 (s, 3H), 0.90 (d, J = 9.0 Hz, 3H), 0.71 (d, J = 6.0 Hz, 3H);  13C NMR (75 
MHz, CDCl3) δ 138.2, 116.0, 98.3, 76.2, 66.7, 38.5, 33.6,31.1, 30.0, 19.3, 12.8, 12.5. 
HRMS (ESI): Exact mass calcd for C12H23O2[M+H]
+ 199.1698. Found 199.1670. 
 
OH
HO
14  80%
OO
13
(i) 10 mol% Pd/C, 1 atm H2
 MeOH, 25 oC, 8 h
(ii) TsOH H2O, MeOH
25 oC, 4 h
 
To a solution of 13 (0.49 g, 2.5 mmol) in MeOH (10 mL) was added Pd/C (10% on 
carbon, 266 mg, 0.25 mmol) in one portion.  The air inside the reaction flask was 
vacuumed out and then hydrogen gas was purged into the flask.  The mixture was stirred 
under 1 atm H2 pressure at rt for 8 h.  The mixture was filtered on a plug of silica gel (5 
cm) and washed with MeOH (5 mL).  To the filtrate the TsOH (48 mg, 0.25 mmol) was 
added in one portion and the solution was stirred for 4 h at 25 oC.  The reaction mixture 
was quenched with saturated aqueous NaHCO3 (5 mL), extracted with ether (3 x 10 mL), 
dried over MgSO4, and concentrated.  Purification by column chromatography (silica gel, 
EtOAc/hexanes, 50:50) gave 0.32 g (80%, 2 steps) of diol 14 as a colorless liquid;  
[α]21.7D  -21.9 (c 0.73, CHCl3); 1H NMR (300 MHz, CDCl3) δ 3.79-3.63 (m, 2H), 3.53-
3.47 (m, 1H), 2.94-2.91 (m, 1H), 2.34 (d, J = 6.0 Hz, 1H), 1.96-1.82 (m, 1H), 1.67-1.60 
(m, 1H), 1.41-1.24 (m, 4H), 0.94 (t, J = 6.0 Hz, 3H), 1.72-1.41 (m, 9H), 1.08 (d, J=7 Hz, 
3H), 1.07 (m, 1H), 1.06 (m, 1H), 0.93 (d, J=7 Hz, 3H), 0.90 (d, J = 9.0 Hz, 3H), 0.84 (d, 
J = 6.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 80.7, 69.1, 37.7, 36.5, 35.1, 20.7, 14.5, 
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13.8, 12.5; HRMS (ESI): Exact mass calcd for C9H21O2 [M+H]+: 161.1542, found: 
161.1535. 
OH
HO
14
TBSOTf
iPr2NEt
CH2Cl2
25 oC, 2 h OTBS
TBSO
15  97%  
The diol 14 (0.32 g, 2.0 mmol) was dissolved in CH2Cl2 (10 mL) and TBSOTf (1.15 mL, 
5.0 mmol) and iPr2NEt (1.05 mL, 6.0 mmol) were added sequentially.  The solution was 
stirred at 25 oC for 2 h, then the reaction was quenched by adding NH4Cl(s) (10 mL).   
The mixture was diluted with CH2Cl2 (10 mL) and the layers were separated.  The 
aqueous layer was extracted with CH2Cl2 (3 x 20 mL).  The combined organic layers 
were dried (Na2SO4) and concentrated.  Purification by column chromatography (silica 
gel, hexanes) gave 15 (0.75 g, 1.94 mmol, 97%) as a colorless liquid.  [α]20.9D  +12.3 (c 
0.65, CHCl3); 1H NMR (500 MHz, CDCl3) δ 3.70 (dd, J = 5.0, 10.0 Hz, 1H), 3.51-3.50 
(m, 1H), 3.42 (dd, J = 5.0, 10.0 Hz, 1H), 1.83-1.78 (m, 1H), 1.63-1.53 (m, 1H), 1.34-1.13 
(m, 4H), 0.91-0.89 (m, 36H), 0.86 (d, J = 5.0 Hz, 3H);  13C NMR (75 MHz, CDCl3) 
δ 77.2, 65.9, 40.6, 37.4, 36.0, 26.4, 26.2, 26.0, 21.0, 18.6, 14.8, 14.6, 14.5, -2.7, -3.6, -3.7, 
-5.0, -5.1.  HRMS (ESI): Exact mass calcd for C21H49O2Si[M+H]
+ 389.3271. Found 
389.3257. 
 
TsOH H2O
MeOH/CH2Cl2 (3:1)
0 oC, 1.5 h OTBS
HO
16  86%
OTBS
TBSO
15  
The silyl ether 15 (0.70 g, 1.8 mmol) was dissolved in CH2Cl2/MeOH (20 mL, 1/3) at 0 
oC.   TsOH (34 mg, 0.18 mmol) was added in one portion.  The resulting solution was 
stirred at that temperature for 1 h.  Et3N (5 mL) was then added to the reaction and all the 
solvents were evaporated under vacuum.  The residue was purified though column 
chromatography, eluting with EtOAc/hexanes (10:90) to give desired primary alcohol 16 
(0.42 g, 1.55 mmol, 86%) as a colorless liquid.  [α]21.5D  13.9 (c 1.15, CHCl3); 1H NMR 
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(500 MHz, CDCl3) δ 3.68-3.58 (m, 2H), 3.52 (dd, J = 5.0, 10.0 Hz, 1H), 2.63 (t, J = 7.5 
Hz, 1H), 1.91-1.84 (m, 1H), 1.66-1.61 (m, 1H), 1.47-1.37 (m, 2H), 1.24-1.13 (m, 2H), 
0.98 (d, J = 5.0 Hz, 3H), 0.94-0.90 (m, 15H), 0.13 (s, 3H), 0.10 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 81.5, 66.5, 38.4, 37.8, 35.6, 26.3, 21.1, 18.5, 16.6, 15.4, 14.6, -3.7, -3.9;  
HRMS (ESI): Exact mass calcd for C15H35O2Si [M+H]+: 275.2406, found: 275.2419. 
 
OTBS
HO
16
(i) SO3 Py, DMSO, 
iPr2NEt
CH2Cl2, 0 
oC, 1 h
CO2MePh3P
PhCH3, 80 
oC, 16 h
(ii)
OTBS
MeO
O
18  96%
 
The alcohol 16 (275 mg, 1.0 mmol) was dissolved in CH2Cl2 (30 mL) at 0 oC.   DMSO 
(0.11 mL, 1.5 mmol) and DIPEA (0.87 mL, 5.0 mmol) were added.  To this solution at 0 
oC, SO3.Py complex (478 mg, 3.0 mmol) was added and the resulting solution was stirred 
at that temperature for 1 h.  The reaction was quenched with NH4Cl (10 mL).  The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 20 mL).  The 
combined organic solution was dried (Na2SO4) and concentrated in vacuo.  Without any 
further purification, the resulting crude aldehyde was immediately dissolved in toluene 
(10 mL) and the Wittig reagent (1.74 g, 5.0 mmol) was added in one portion at 25 oC. 
The reaction mixture was then put on an oil bath (preheated to 80 oC) and stirred for 16 h. 
After being cooled to 25 oC, the reaction mixture was diluted with hexanes (80 mL) and 
filtrated through Celite.  The filtrate was concentrated and purification of the residue by 
flash chromatography on silica gel, eluting with EtOAc/hexanes (5:95) gave alkene 18 as 
a colorless oil (300 mg, 0.88 mmol, 88%).  [α]21D  20.9 (c 0.86, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 6.85 (d, J = 9.0 Hz, 5H), 3.76 (s, 3H), 3.50-3.46 (m, 1H), 2.77-2.65 (m, 
1H), 1.86 (s, 3H), 1.39-1.00 (m, 4H), 0.93 (d, J = 6.0 Hz, 3H), 0.90(s, 9H), 0.91-0.88 (m 
3H), 0.87 (t, J = 9.0 Hz, 3H);  13C NMR (75 MHz, CDCl3) δ 169.1, 146.6, 126.3, 79.7, 
51.9, 37.5, 37.5, 36.2, 26.3, 21.0, 18.1, 15.0, 14.5, 12.8, -3.5, -3.7.  HRMS (ESI): Exact 
mass calcd for C19H39O3Si[M+H]
+ 343.2668. Found 343.2679. 
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(i) 80 Bar H2
1 mol% (S)-Cat.
CH2Cl2, 25 
oC, 24 h
(ii) 10% HCl, MeOH
40 oC, 12 h
19  90%
(-)-Invictolide
O
OOTBS
MeO
O
18
 
Hydrogenation of 18 (200 mg, 0.58 mmol) was carried out according to the general 
procedure using (S)-Cat. (1 mol%, 10 mg) in CH2Cl2 (1.0 mL).  NMR of the crude 
product showed 100% reduction.  1H NMR analysis of the crude material showed >19:1.0 
diastereoselectivity for the hydrogenation.  After hydrogenation the solvent was 
evaporated.  Then the crude oil was dissolved in MeOH (4 mL) followed by addition of 
10% HCl(aq) (0.2 mL).  The resulting solution was stirred at 40 oC for 12 h, and then the 
reaction was cooled to 25 oC and quenched by addition of NaHCO3(s) (5 mL).  The 
solution was diluted by addition of Et2O (20 mL) and the layers were separated.  The 
aqueous layer was extracted with Et2O (3 x 10 mL).  The organic extract was dried 
(Na2SO4) and concentrated in vacuo.  Purification by flash column chromatography, 
eluting with Et2O/pentane (10:90) gave (-)-invictolide 193 (104 mg, 0.52 mmol, 90%) as 
a colorless oil. [α]21D  -99.7 (c 0.77, CHCl3) {lit4 [α]D  -99.2 (c 0.7, CHC13)}; 1H NMR 
(500 MHz, CDCl3) δ 3.92 (d, J = 10.0 Hz, 1H), 2.69-2.62 (m, 1H), 2.05-1.95 (m, 1H), 
1.69 (t, J = 10.0 Hz, 2H), 1.38-1.27 (m, 5H), 1.23 (d, J = 10.0 Hz, 3H), 0.99 (d, J = 5.0 
Hz, 3H), 0.92 (t, J = 5.0 Hz, 3H), 0.88 (d, J = 12.0 Hz, 3H);  13C NMR (75 MHz, CDCl3) 
δ 176.7, 85.7, 36.1, 35.4, 33.6, 32.5, 28.4, 20.4, 16.6, 14.1, 12.3.  HRMS (ESI): Exact 
mass calcd for C12H23O2[M+H]
+ 199.1698. Found 199.1691. 
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Table S-1. Comparison of 13C NMR of (-)-invictolide 
atom number previous synthesis3 of  
(-)-invictolide (δc ppm) 
this work: (-)-invictolide 
(δc ppm) 
C1 12.2 12.3 
C2 14.1 14.1 
C3 16.5 16.5 
C4 17.6 17.6 
C5 20.4 20.4 
C6 28.3 28.4 
C7 32.5 32.5 
C8 33.5 33.6 
C9 35.3 35.4 
C10 36.0 36.1 
C11 85.6 85.7 
C12 176.8 176.7 
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Relative and absolute configuration determination 
 
All the alkene substrates were made from enantiomer enriched (R)-Roche ester (98% ee).  
So the absolute stereochemistry was determined by the chirality from the starting 
material.  Hydrogenation of 2 with (S)-Cat provided the triad 8 with high 
diastereoselectivity (syn:anti, dr 1.0:48).  Starting from 8, an acetonide derivative 8’ can 
be synthesized in two steps (Reaction S1).  8’ was a known compound with reported 1H 
NMR and 13C NMR.2  Thus 8, the hydrogenation product of 2, was determined to be an 
anti,anti stereotriad.  Hydrogenation of 3 with (R)-Cat provided the triad 9 with high 
diastereoselectivity (syn:anti, dr 21:1.0).  The isolated product 9 was also a known 
compound with reported 1H NMR and 13C NMR data.2  Hence 9 was determined to the 
the anti,syn stereotriad undoubtedly. 
TBDPSO
OH
OBn
8
(i) TBAF, THF, 25 oC, 1 h
(ii) TsOH H2O, (MeO)2CMe2
CH2Cl2, 25 
oC, 1 h
O
OBn
O
8'
(S1)
 
 
Hydrogenation of 6 with (S)-Cat provided the triad 10 with high diastereoselectivity 
(syn:anti, dr >99:1.0).  Starting from 10, the diol 10’ can be synthesized in one step 
(Reaction S2).  10’ was a known compound with reported 1H NMR and 13C NMR data.5  
Thus 10, the hydrogenation product of 6, was determined to be an syn,syn stereotriad.  
Hydrogenation of 7 with (R)-Cat provided the triad 11 with high diastereoselectivity 
(syn:anti, dr 1.0:18).  The 1H NMR and 13C NMR of the isolated product 11 was 
compared carefully with those of 8 and 10.2 Hence 11 was determined to the the syn,anti 
stereotriad certainly. 
 
TBDPSO
OH
OBn
10
(i) TBAF, THF, 25 oC, 1 h
OH
OBn
OH
10'
(S2)
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 1  
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 2 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 3 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 4 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 5 
 
 
 293 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 6 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 7 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 8 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 9 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 10 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 11 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 12 
 
 
 300 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 13 
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1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 14 
 
 
 302 
1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 15 
 
 
 303 
1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 16 
 
 
 304 
1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of 18 
 
 
 305 
1H NMR (500 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3) of (-)-invictolide 
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